U.S. patent application number 11/398357 was filed with the patent office on 2007-01-25 for purine and imidazopyridine derivatives for immunosuppression.
Invention is credited to Adolph C. Bohnstedt, Koc-Kan Ho, Celia Kingsbury, Yingchun Lu, Michael J. Ohlmeyer, Haengsoon Park, Jorge Gabriel Quintero, Ming You.
Application Number | 20070021443 11/398357 |
Document ID | / |
Family ID | 36699182 |
Filed Date | 2007-01-25 |
United States Patent
Application |
20070021443 |
Kind Code |
A1 |
Ohlmeyer; Michael J. ; et
al. |
January 25, 2007 |
Purine and imidazopyridine derivatives for immunosuppression
Abstract
The present invention provides novel purine and imidazopyridine
derivatives useful for the prevention and treatment of autoimmune
diseases, inflammatory disease, mast cell mediated disease and
transplant rejection. The compounds are of the general formulas:
##STR1##
Inventors: |
Ohlmeyer; Michael J.;
(Plainsboro, NJ) ; Bohnstedt; Adolph C.;
(Burlington, NJ) ; Kingsbury; Celia; (Cream Ridge,
NJ) ; Ho; Koc-Kan; (Monmouth Junction, NJ) ;
Quintero; Jorge Gabriel; (South Amboy, NJ) ; You;
Ming; (Plainsboro, NJ) ; Park; Haengsoon;
(Plainsboro, NJ) ; Lu; Yingchun; (Kendall Park,
NJ) |
Correspondence
Address: |
HESLIN ROTHENBERG FARLEY & MESITI PC
5 COLUMBIA CIRCLE
ALBANY
NY
12203
US
|
Family ID: |
36699182 |
Appl. No.: |
11/398357 |
Filed: |
April 5, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60668286 |
Apr 5, 2005 |
|
|
|
60736663 |
Nov 15, 2005 |
|
|
|
Current U.S.
Class: |
514/263.22 ;
514/303; 544/276; 546/117 |
Current CPC
Class: |
A61P 43/00 20180101;
A61P 35/00 20180101; C07D 471/04 20130101; C07D 473/32 20130101;
A61P 9/10 20180101; A61P 37/02 20180101; A61P 37/06 20180101; C07D
473/00 20130101; A61P 17/06 20180101; A61P 11/06 20180101; A61P
9/00 20180101; A61P 27/02 20180101; C07D 487/04 20130101; A61P
19/02 20180101; A61P 29/00 20180101 |
Class at
Publication: |
514/263.22 ;
514/303; 544/276; 546/117 |
International
Class: |
A61K 31/522 20070101
A61K031/522; A61K 31/4745 20070101 A61K031/4745; C07D 473/02
20070101 C07D473/02; C07D 471/02 20060101 C07D471/02 |
Claims
1. A compound of formula I ##STR441## wherein Q.sub.1 and Q.sub.2
are independently selected from the group consisting of CX.sub.1,
CX.sub.2, and nitrogen; Q.sub.3 is N or CH; X.sub.1 and X.sub.2 are
independently selected from the group consisting of hydrogen,
(C.sub.1-C.sub.6)alkyl, cyano, halo, halo(C.sub.1-C.sub.6)alkyl,
hydroxyl, (C.sub.1-C.sub.6)alkoxy, halo(C.sub.1-C.sub.6)alkoxy,
nitro, carboxamido, and methylsulfonyl; V.sub.1 and V.sub.2 are
independently selected from CH and N; R.sub.1 is selected from the
group consisting of hydrogen and methyl; y is zero or an integer
selected from 1, 2 and 3; R.sub.2 and R.sub.3 are selected
independently for each occurrence of (CR.sub.2R.sub.3) from the
group consisting of hydrogen and (C.sub.1-C.sub.6)alkyl; and
R.sub.4 is selected from a group consisting of alkyl, heterocyclyl,
aryl, substituted alkyl, substituted heterocyclyl, and substituted
aryl.
2. A compound according to claim 1 of formula: ##STR442##
3. A compound according to claim 2 of formula: ##STR443##
4. A compound according to claim 2 of formula: ##STR444##
5. A compound according to claim 1 of formula: ##STR445##
6. A compound according to claim 5 of formula: ##STR446##
7. A compound according to claim 5 of formula: ##STR447##
8. A compound according to claim 1 of formula: ##STR448##
9. A compound according to claim 8 of formula: ##STR449##
10. A compound according to claim 1 of formula: ##STR450##
11. A compound according to claim 1 of formula: ##STR451##
12. A compound according to claim 11 of formula: ##STR452##
13. A compound according to claim 11 of formula: ##STR453##
14. A compound according to claim 1 of formula: ##STR454##
15. A compound according to claim 14 of formula: ##STR455##
16. A compound according to claim 14 of formula: ##STR456##
17. A compound according to claim 1 wherein X.sub.1 and X.sub.2 are
independently selected from hydrogen, cyano, chloro, fluoro,
methyl, trifluoromethyl and trifluoromethoxy, carboxamido.
18. A compound according to claim 8 wherein X.sub.1 is hydrogen and
X.sub.2 is chosen from hydrogen, cyano, chloro, fluoro, methyl,
carboxamido, and trifluoromethyl.
19. A compound according to claim 1 wherein R.sub.1 is H.
20. A compound according to claim 1 wherein, y is 1 or 2 and
R.sub.2 and R.sub.3 are hydrogen or methyl.
21. A compound according to claim 20, wherein R.sub.4 is selected
from phenyl, quinoline, pyridine, pyrazine and their substituted
counterparts.
22. A compound according to claim 1 wherein y is zero.
23. A compound according to claim 22, wherein R.sub.4 is selected
from a monocycle, bicycle, or substituted monocycle or substituted
bicycle containing at least one oxygen atom or nitrogen atom.
24. A compound according to claim 22, wherein R.sub.4 is chosen
from cyclopentyl, cyclohexyl, phenyl, tetralin, piperidine,
oxepane, benzoxepane, tetrahydropyran, tetrahydrofuran,
tetrahydroindole, tetrahydroisoquinoline, quinoline,
tetrahydroquinoline, chroman, pyridine,
dihydrocyclopenta[b]pyridine, dihydrobenzofuran,
tetrahydrobenzofuran, tetrahydrobenzothiophene,
dihydrobenzothiophene, dihydropyrano[2,3-b]pyridine,
tetrahydroquinoxaline, tetrahydrothiopyran (thiane), thiochroman
(dihydrobenzothiin), thiochroman-1,1-dioxide,
tetrahydronaphthalene, oxa-bicyclooctane, oxocane,
tetrathiohydropryan-1,1-dioxide, tetrathiohydropryanoxide, and
their substituted counterparts.
25. A compound according to claim 22, wherein R.sub.4 is cycloalkyl
substituted with OH, alkoxy, hydroxyalkyl, oxo, carboxamido,
carboxy, or alkoxycarbonyl.
26. A compound according to claim 22 wherein R.sub.4 is selected
from cyclopentyl, cyclohexyl, phenyl, indane, tetralin, piperidine,
oxepane, benzoxepane, dihydrocyclopentapyridine, tetrahydropyran,
tetrahydrofuran, tetrahydroindole, isoquinoline,
tetrahydroisoquinoline, quinoline, tetrahydroquinoline, chroman,
isochroman, pyridine, dihydrocyclopental[b]pyridine, pyrimidine,
dihydropyran, dihydrobenzofuran, tetrahydrobenzofuran,
tetrahydrobenzothiophene, dihydrobenzothiophene, furan,
dihydropyrano[2,3-b]pyridine, tetrahydroquinoxaline,
tetrahydrothiopyran (thiane), thiochroman (dihydrobenzothiin),
thiochroman-1,1-dioxide, tetrahydronaphthalene, oxa-bicyclooctane,
oxocane, tetrahydrothiopyran-1,1-dioxide, tetrahydrothiopyran
oxide, and their substituted counterparts.
27. A compound according to claim 1 wherein, (a) y is zero and
R.sub.4 is selected from cyclohexyl, tetralin, indane, oxepane,
benzoxepane, dihydrocyclopentapyridine, tetrahydropyran,
tetrahydroquinoline, chroman, dihydrobenzofuran,
tetrahydrobenzofuran, dihydropyrano[2,3-b]pyridine and
tetrahydroquinoxaline, each optionally substituted with hydroxy,
oxo, or halogen; or (b) y is 1 or 2, R.sub.2 and R.sub.3 are
hydrogen or methyl and R.sub.4 is selected from phenyl, pyridine
and pyrazine, each optionally substituted with halogen.
28. A compound according to claim 27 wherein y is 0 and R.sub.4 is
chosen from chroman-4-yl; 3,4-dihydronaphthalen-1(2H)-on-4-yl;
2,3-dihydroinden-1-on-4-yl and their fluoro substituted
counterparts.
29. A compound according to claim 28 wherein R.sub.4 is
chroman-4-yl and the carbon at 4 of the chroman is of the (R)
configuration.
30. A compound according to claim 27 wherein y is 0 and R.sub.4 is
##STR457## wherein W is CH.sub.2, C.dbd.O, O, and CHOH; p is 1, 2
or 3; A is a six-membered heteroaromatic ring containing 1 or 2
nitrogens, a benzene ring optionally substituted with one or two
fluorines, or a five-membered heterocyclic ring; and the wavy line
is the point of attachment to the purinone.
31. A compound according to claim 30 wherein the carbon marked with
an asterisk ##STR458## is of the (R) configuration.
32. A compound according to claim 1, wherein Y is 0 and R.sub.4 is
a monocyclic carbocycle or bridged bicyclic carbocycle optionally
substituted with one or more OH, alkoxy, hydroxyalkyl, oxo,
carboxamido, carboxy, and alkoxycarbonyl.
33. A compound according to claim 1, wherein Y is 0 and R.sub.4 is
a heterocycle containing at least one nitrogen atom and optionally
substituted with OH, alkoxy, hydroxyalkyl, oxo, acyl, carboxamido,
carboxy, and alkoxycarbonyl.
34. A compound according to claim 33, wherein R.sub.4 is a
monocyclic heterocycle.
35. A compound according to claim 27 wherein y is 1 and R.sub.4 is
selected from difluorophenyl, fluorophenyl, chlorophenyl,
chlorofluorophenyl, pyridin-3-yl and pyrazin-3-yl.
36. A compound according to claim 27 wherein y is zero and R.sub.4
is selected from tetrahydropyran-4-yl, 4-hydroxycyclohexyl,
4-loweralkoxycyclohexyl, 4-oxocyclohexyl and oxepan-4-yl.
37-63. (canceled)
64. A pharmaceutical composition comprising a pharmaceutically
acceptable carrier and a therapeutically effective amount of at
least one compound according to claim 1.
65. (canceled)
66. A method of treating a disorder selected from an autoimmune
disease, an inflammatory disease, a mast cell mediated disease,
cancer, hematological malignancy, organ transplant rejection, and
cardiovascular disease which is dependent upon inhibition of Janus
kinase 3, which comprises administering to a subject in need of
such treatment a therapeutically effective amount of a compound
according to claim 1.
67. (canceled)
68. The method according to claim 66 wherein said disorder is organ
transplant rejection.
69-76. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional
Application Ser. No. 60/668,286, filed Apr. 5, 2005, and U.S.
Provisional Application Ser. No. 60/736,663, filed Nov. 15, 2005,
the entire contents of both which are incorporated herein by
reference.
FIELD OF THE INVENTION
[0002] The invention relates to purine and imidazopyridine
derivatives useful as immunosuppressants.
BACKGROUND OF THE INVENTION
[0003] Immunosuppression is an important clinical approach in
treating autoimmune disease and in preventing organ and tissue
rejection. The clinically available immunosuppressants, including
azathioprine, cyclosporine and tacrolimus, although effective,
often cause undesirable side effects including nephrotoxicity,
hypertension, gastrointestinal disturbances and gum inflammation.
Inhibitors of the tyrosine kinase Jak3 are known to be useful as
immunosuppressants (see U.S. Pat. No. 6,313,129).
[0004] The members of the Janus kinase (Jak) family of non-receptor
intracellular tyrosine kinases are components of cytokine signal
transduction. Four family members have been identified to date:
Jak1, Jak2, Jak3 and Tyk2. The Jaks play a key role in the
intracellular signaling mediated through cytokine receptors. Upon
binding of cytokines to their receptors, Jaks are activated and
phosphorylate the receptors, creating docking sites for other
signaling molecules, in particular members of the signal transducer
and activator of transcription (STAT) family. While expression of
Jak1, Jak2 and Tyk2 is relatively ubiquitous, Jak3 expression is
temporally and spatially regulated. Jak3 is predominantly expressed
in cells of hematopoietic lineage; it is constitutively expressed
in natural killer (NK) cells and thymocytes and is inducible in T
cells, B cells and myeloid cells (reviewed in Ortmann, et al., 1999
and Yamaoka, et al., 2004). Jak3 is also is expressed in mast
cells, and its enzymatic activity is enhanced by IgE receptor/FccRI
cross-linking (Malaviya and Uckun, 1999).
[0005] A specific, orally active Jak3 inhibitor, CP-690,550, has
been shown to act as an effective immunosuppressant and prolong
animal survival in a murine model of heart transplantation and a
primate model of kidney transplantation (Changelian, et al.,
2003).
[0006] Furthermore, aberrant Jak3 activity has been linked to a
leukemic form of cutaneous T-cell lymphoma (Sezary's syndrome) and
acute lymphoblastic leukemia (ALL), the most common form of
childhood cancer. The identification of Jak3 inhibitors has
provided the basis for new clinical approaches in treating
leukemias and lymphomas (Cetkovic-Cvrlje, Marina; Uckun, Faith M.,
Targeting Janus Kinase 3 in the treatment of Leukemia and
Inflammatory Diseases. Archivum Immunologiae et Therapie
Experimentalis (2004) and/or Uckun, Faith M.; Mao, Chen. Tyrosine
kinases as new molecular targets in treatment treatment of
inflammatory disorders and leukemia. Current Parmaceutical
Design(2004)). Two dimethoxyquinazoline derivatives, WHI-P131
(JANEX-1) and WHI-P154 (JANEX-2), have been reported to be
selective inhibitors of Jak3 in leukemia cells (Sudbeck et al.,
1999).
[0007] Jak3 has also been shown to play a role in mast-cell
mediated allergic reactions and inflammatory diseases and serves as
a target in indications such as asthma and anaphylaxis.
[0008] Therefore, compounds that inhibit Jak3 are useful for
indications such as leukemias and lymphomas, organ and bone marrow
transplant rejection, mast cell-mediated allergic reactions and
inflammatory diseases and disorders.
SUMMARY OF THE INVENTION
[0009] It has now been found that compounds of general formula I
and II are potent and selective inhibitors of Jak3: ##STR2##
[0010] In these compounds, [0011] Q.sub.1 and Q.sub.2 are
independently selected from the group consisting of CX.sub.1,
CX.sub.2, and nitrogen; [0012] Q.sub.3 is N or CH; [0013] X.sub.1
and X.sub.2 are independently selected from the group consisting of
hydrogen, (C.sub.1-C.sub.6)alkyl, cyano, halo,
halo(C.sub.1-C.sub.6)alkyl, hydroxyl, (C.sub.1-C.sub.6)alkoxy,
halo(C.sub.1-C.sub.6)alkoxy, nitro, carboxamido, and
methylsulfonyl; [0014] V.sub.1 and V.sub.2 are independently
selected from CH and N; [0015] R.sub.1 is selected from the group
consisting of hydrogen and methyl; [0016] y is zero or an integer
selected from 1, 2 and 3; [0017] R.sub.2 and R.sub.3 are selected
independently for each occurrence of (CR.sub.2R.sub.3) from the
group consisting of hydrogen and (C.sub.1-C.sub.6)alkyl; and [0018]
R.sub.4 is selected from a group consisting of alkyl, heterocyclyl,
aryl, substituted alkyl, substituted heterocyclyl, and substituted
aryl.
[0019] The members of these genera are useful in inhibiting Jak3
activity and as such are useful in indications where clinical
immunosuppression is desired and in the treatment of hematological
cancers.
[0020] In another aspect, the invention relates to pharmaceutical
compositions comprising a therapeutically effective amount of at
least one compound of general formula I or general formula II, or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier.
[0021] In another aspect, the invention relates to a method for
treating a disease by altering a response mediated by Jak3 tyrosine
kinase. The method comprises bringing into contact with Jak3 at
least one compound of general formula I or II.
[0022] In yet another aspect the present invention relates to a
method of suppressing the immune system in a subject in need
thereof comprising administering to the subject a therapeutically
effective amount of at least one compound of general formula I or
II.
[0023] Suppression of immune system activity is desirable for
preventing or treating tissue or organ rejection following
transplant surgery and for preventing and treating diseases and
disorders arising from aberrant activity of the immune system, in
particular autoimmune disorders and diseases. Exemplary autoimmune
disorders include graft versus host disease (GVHD),
insulin-dependent diabetes (Type I), Hashimoto's thyroiditis and
Graves' disease, pernicious anemia, Addison's disease, chronic
active hepatitis, Crohn's disease, ulcerative colitis, rheumatoid
arthritis, multiple sclerosis, systemic lupus erythematosus,
psoriasis, scleroderma and myasthenia gravis.
[0024] The compounds of the present invention are useful in
preventing and treating diseases and disorders related to mast
cell-mediated allergic reactions and inflammation.
[0025] Other indications in which the Jak3 inhibitors are useful
include leukemias and lymphomas.
DETAILED DESCRIPTION OF THE INVENTION
[0026] Throughout this specification the substituents are defined
when introduced and retain their definitions.
[0027] In a first aspect the invention relates to purinones and
imidazopyridinones having general formula I: ##STR3##
[0028] The members of the genus I may be conveniently divided into
subgenera based on the values of Q and V. When Q.sub.1 is carbon,
Q.sub.2 is nitrogen, V.sub.1 is nitrogen, and V.sub.2 is carbon a
subgenus of purinones and imidazo[4,5-b]pyridinones having an
attached purine arises. When Q.sub.1 is carbon, Q.sub.2 is
nitrogen, and both V.sub.1 and V.sub.2 are carbon, a subgenus of
purinones and imidazo[4,5-b]pyridinones having an attached
imidazo[5,4-c]pyridine arises. When Q.sub.1 and Q.sub.2 are carbon,
and both V.sub.1 and V.sub.2 are carbon, a subgenus of purinones
and imidazo[4,5-b]pyridinones having an attached benzimidazole
arises. When Q.sub.1 and Q.sub.2 are carbon, V.sub.1 is carbon, and
V.sub.2 is nitrogen, a subgenus of purinones and
imidazo[4,5-b]pyridinones having an attached benzotriazole arises.
The genus could similarly be divided on the basis of Q.sub.3. When
Q.sub.3 is nitrogen, a subgenus of purinones having an attached
purine, imidazo[5,4-c]pyridine, benzimidazole or benzotriazole
arises. When Q.sub.3 is carbon, a subgenus of
imidazo[4,5-b]pyridinones having an attached purine,
imidazo[5,4-c]pyridine, benzimidazole or benzotriazole arises. The
structures of these subgenera are shown below: ##STR4##
[0029] When Q.sub.3 is nitrogen, a subgenus of purinones having an
attached purine, imidazo[5,4-c]pyridine, benzimidazole or
benzotriazole arises. The structures of these subgenera are shown
below ##STR5##
[0030] In another aspect the invention relates to purines and
imidazopyridines having general formula II: ##STR6##
[0031] The members of the genus II may be similarly divided into
subgenera based on the values of Q and V. When Q.sub.1 is carbon,
Q.sub.2 is nitrogen, V.sub.1 is nitrogen, and V.sub.2 is carbon, a
subgenus of purines and imidazo[4,5-b]pyridines having an attached
purine arises. When Q.sub.1 is carbon, Q.sub.2 is nitrogen, and
both V.sub.1 and V.sub.2 are carbon, a subgenus of purines and
imidazo[4,5-b]pyridines having an attached imidazo[5,4-c]pyridine
arises. When all of Q.sub.1, Q.sub.2, V.sub.1 and V.sub.2 are
carbon, a subgenus of purines and imidazo[4,5-b]pyridines having an
attached benzimidazole arises. When Q.sub.1, Q.sub.2 and V.sub.1
are carbon, and V.sub.2 is nitrogen, a subgenus of purines and
imidazo[4,5-b]pyridines having an attached benzotriazole arises.
The genus could similarly be divided on the basis of Q.sub.3. When
Q.sub.3 is nitrogen, a subgenus of purines having an attached
purine, imidazo[5,4-c]pyridine, benzimidazole or benzotriazole
arises. When Q.sub.3 is carbon, a subgenus of
imidazo[4,5-b]pyridines having an attached purine,
imidazo[5,4-c]pyridine, benzimidazole or benzotriazole arises. The
structures of these subgenera are shown below: ##STR7##
##STR8##
[0032] In certain embodiments, X.sub.1 and X.sub.2 are selected
from hydrogen, cyano, chloro, fluoro, trifluoromethyl,
trifluoromethoxy, carboxamido, and methyl; in other embodiments
R.sub.1 is H. In one subdivision, y is zero; in another y is 1 or 2
and R.sub.2 and R.sub.3 are hydrogen or methyl. Examples of R.sub.4
include: cyclopentyl, cyclohexyl, piperidine, oxepane, benzoxepane,
dihydrocyclopentapyridine, phenyl, tetralin, indane,
tetrahydropyran, tetrahydrofuran, tetrahydroindole, isoquinoline,
tetrahydroisoquinoline, quinoline, tetrahydroquinoline, chroman,
isochroman, pyridine, pyrazine, pyrimidine, dihydropyran,
dihydrobenzofuran, tetrahydrobenzofuran, tetrahydrobenzothiophene,
furan, dihydropyrano[2,3-b]pyridine (see example below),
tetrahydroquinoxaline, tetrahydrothiopyran (thiane), thiochroman
(dihydrobenzothiin), thiochroman-1,1-dioxide,
tetrahydronaphthalene, oxabicyclooctane, oxocane,
tetrathiohydropyran-1,1-dioxide, tetrathiohydropyranoxide, or any
of the foregoing rings carrying from 1-3 additional substituents,
such as halogen, methyl, methoxy, trifluoromethyl, cyano, hydroxy,
oxo, oxide and acetyl. Additional examples in which R.sub.4 is
alkyl or substituted alkyl include subgenera in which R.sub.4 is
oxaalkyl (alkoxyalkyl).
[0033] In certain embodiments of genus I, y is 1 or 2; R.sub.2 and
R.sub.3 are hydrogen or methyl and R.sub.4 is phenyl, quinoline,
pyridine, pyrazine or substituted phenyl, quinoline, pyridine or
pyrazine. In other embodiments of genus I, y is zero and R.sub.4 is
cyclopentyl, cyclohexyl, phenyl, piperidine, oxepane, benzoxepane,
dihydrocyclopentapyridine, tetralin, indane, tetrahydropyran,
tetrahydrofuran, tetrahydroindole, isoquinoline,
tetrahydroisoquinoline, quinoline, tetrahydroquinoline, chroman,
pyridine, pyrimidine, dihydropyran, dihydrobenzofuran,
tetrahydrobenzofuran, tetrahydrobenzothiophene,
dihydrobenzothiophene, furan, dihydropyrano[2,3-b]pyridine,
tetrahydroquinoxaline, tetrahydrothiopyran (thiane), thiochroman
(dihydrobenzothiin), thiochroman-1,1-dioxide,
tetrahydronaphthalene, oxabicyclooctane, oxocane,
tetrathiohydropyran-1,1-dioxide, tetrathiohydropyranoxide, or a
substituted ring from the foregoing list. In further embodiments,
(a) y is zero and R.sub.4 is selected from cyclopentyl, cyclohexyl,
oxepane, dihydrocyclopentapyridine, tetrahydropyran,
tetrahydroquinoline, chroman, dihydrobenzofuran,
tetrahydrobenzofuran, dihydropyrano[2,3-b]pyridine and
tetrahydroquinoxaline, each optionally substituted with hydroxy,
oxo, or halogen; or (b) y is 1 or 2, R.sub.2 and R.sub.3 are
hydrogen or methyl and R.sub.4 is selected from phenyl, pyridine
and pyrazine, each optionally substituted with halogen. When y is
zero, R.sub.4 may be tetrahydropyran-4-yl, 4-hydroxycyclohexyl,
4-oxocyclohexyl, oxepan-4-yl, chroman-4-yl or fluoro substituted
chroman-4-yl. It appears that, although both enantiomers are
active, compounds in which the carbon at 4 of the chroman is of the
(R) configuration have higher potency. Certain of the foregoing
subgenera in which y is zero may also be described by a
representation in which R.sub.4 is ##STR9##
[0034] According to this representation, W is CH.sub.2, C.dbd.O,
CHOH, or O; p is 1, 2 or 3; and A is a six-membered heteroaromatic
ring containing 1 or 2 nitrogens, a benzene ring optionally
substituted with one or two fluorines, or a five-membered
heterocyclic ring. The wavy line denotes the point of attachment to
the purinone. Examples in which W is C.dbd.O include indanones,
tetralones and benzosuberones. Examples in which W is CH.sub.2
include indanes, tetralins and benzocycloheptanes. Examples in
which W is CHOH include substituted tetralins. Examples in which W
is O include dihydrobenzofuran, chroman, benzopyrans and
benzoxepanes. As before, compounds in which the carbon marked with
an asterisk ##STR10## is of the (R) configuration appear to be more
potent than their corresponding (S) enantiomers. An example of such
a compound is ##STR11## which is more potent than its corresponding
(S) enantiomer ##STR12## but both exhibit Jak3 kinase IC.sub.50
below 1 micromolar. Examples below also include compounds in which
y is 1 and R.sub.4 is selected from difluorophenyl, fluorophenyl,
chlorophenyl, chlorofluorophenyl, pyridin-3-yl and
pyrazin-3-yl.
[0035] In certain embodiments of genus II, nitrogen is present at
the 7 and 9 position on the 6,5 bicyclic heterocycle; X.sub.1 is
selected from hydrogen, cyano and fluoro; Q.sub.1 is N and R.sub.1
is H. In some embodiments, y is zero and R.sub.4 is selected from
phenyl, tetrahydropyran (e.g. tetrahydropyran-4-yl), isoquinoline
(e.g. isoquinolin-8-yl), tetrahydroquinoline (e.g.
1,2,3,4-tetrahydroquinolin-5-yl), and their substituted
counterparts. In other embodiments, y is 1 and R.sub.4 is selected
from difluorophenyl, fluorophenyl, chlorophenyl,
chlorofluorophenyl, pyridin-3-yl and pyrazin-3-yl.
[0036] All of the compounds falling within the foregoing parent
genera and their subgenera are useful as Jak3 inhibitors.
Definitions
[0037] For convenience and clarity certain terms employed in the
specification, examples and claims are described herein.
[0038] Alkyl is intended to include linear, branched, or cyclic
hydrocarbon structures and combinations thereof. Lower alkyl refers
to alkyl groups of from 1 to 6 carbon atoms. Examples of lower
alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-
and t-butyl and the like. Preferred alkyl groups are those of
C.sub.20 or below; more preferred are C.sub.1-C.sub.8 alkyl.
Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon
groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomyl,
or other bridged systems and the like.
[0039] C.sub.1 to C.sub.20 hydrocarbon includes alkyl, cycloalkyl,
alkenyl, alkynyl, aryl and combinations thereof. Examples include
phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl.
[0040] Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon
atoms of a straight, branched, cyclic configuration and
combinations thereof attached to the parent structure through an
oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy,
cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to
groups containing one to four carbons. Oxaalkyl refers to alkyl
residues in which one or more carbons (and their associated
hydrogens) have been replaced by oxygen. Examples include
methoxypropoxy, 3,6,9-trioxadecyl and the like. The term oxaalkyl
is intended as it is understood in the art [see Naming and Indexing
of Chemical Substances for Chemical Abstracts, published by the
American Chemical Society, 196, but without the restriction of
127(a)], i.e. it refers to compounds in which the oxygen is bonded
via a single bond to its adjacent atoms (forming ether bonds); it
does not refer to doubly bonded oxygen, as would be found in
carbonyl groups.
[0041] Acyl refers to groups of from 1 to 8 carbon atoms of a
straight, branched, cyclic configuration, saturated, unsaturated
and aromatic and combinations thereof, attached to the parent
structure through a carbonyl functionality. One or more carbons in
the acyl residue may be replaced by nitrogen, oxygen or sulfur as
long as the point of attachment to the parent remains at the
carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl,
t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers
to groups containing one to four carbons.
[0042] Aryl and heteroaryl mean a 5- or 6-membered aromatic or
heteroaromatic ring containing 0-3 heteroatoms selected from O, N,
or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring
system containing 0-3 heteroatoms selected from O, N, or S; or a
tricyclic 13- or 14-membered aromatic or heteroaromatic ring system
containing 0-3 heteroatoms selected from O, N, or S. The aromatic
6- to 14-membered carbocyclic rings include, e.g., benzene and
naphthalene, and for the purposes of the present invention, fused
moieties such as tetrahydronaphthalene (tetralin), and indane, in
which one or more rings are aromatic, but not all need be. The 5-
to 10-membered aromatic heterocyclic rings include, e.g.,
imidazole, pyridine, indole, thiophene, benzopyranone, thiazole,
furan, benzimidazole, quinoline, isoquinoline, quinoxaline,
pyrimidine, pyrazine, tetrazole and pyrazole.
[0043] Arylalkyl refers to a substituent in which an aryl residue
is attached to the parent structure through alkyl. Examples are
benzyl, phenethyl and the like. Heteroarylalkyl refers to a
substituent in which a heteroaryl residue is attached to the parent
structure through alkyl. Examples include, e.g., pyridinylmethyl,
pyrimidinylethyl and the like.
[0044] Heterocycle means a cycloalkyl or aryl residue in which from
one to three carbons is replaced by a heteroatom selected from the
group consisting of N, O and S. The nitrogen and sulfur heteroatoms
may optionally be oxidized, and the nitrogen heteroatom may
optionally be quatemized. Examples of heterocycles include
pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline,
tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole
(commonly referred to as methylenedioxyphenyl, when occurring as a
substituent), tetrazole, morpholine, thiazole, pyrazine, pyridine,
pyridazine, pyrimidine, thiophene, ftiran, oxazole, oxazoline,
isoxazole, dioxane, tetrahydrofuran and the like. Further examples
include cyclic ethers (including bridged cyclic ethers), lactones,
lactams, cyclic ureas, and the like. It is to be noted that
heteroaryl is a subset of heterocycle in which the heterocycle is
aromatic. Examples of heterocyclyl residues additionally include
piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxo-pyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidinyl,
pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl,
oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl,
quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl,
benzopyranyl, benzothiazolyl, tetrahydrofuryl, tetrahydropyranyl,
thienyl, benzothienyl, thiamorpholinyl, thiamorpholinylsulfoxide,
thiamorpholinylsulfone, oxadiazolyl, triazolyl and
tetrahydroquinolinyl. A nitrogenous heterocycle is a heterocycle
containing at least one nitrogen in the ring; it may contain
additional nitrogens, as well as other heteroatoms. The nitrogenous
heterocycle may be monocyclic, bicyclic, or multi-cyclic.
[0045] Substituted alkyl, aryl, cycloalkyl, heterocyclyl etc. refer
to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H
atoms in each residue are replaced with halogen, haloalkyl,
hydroxy, loweralkoxy, hydroxyloweralkyl, carboxy, carboalkoxy (also
referred to as alkoxycarbonyl), carboxamido (also referred to as
alkylaminocarbonyl), cyano, carbonyl, nitro, amino, alkylamino,
dialkylamino, mercapto, alkylthio, sulfoxide, sulfone, acylamino,
amidino, phenyl, benzyl, heteroaryl, phenoxy, benzenesulfonyl,
benzyloxy, or heteroaryloxy. When the parent is a heterocycle that
allows such substitution, the term also includes oxides, for
example pyridine-N-oxide, thiopyran sulfoxide and
thiopyran-S,S-dioxide. As mentioned above, two hydrogens on a
single carbon may be replaced by a carbonyl to form an oxo
derivative. Noteworthy oxo-substituted aryl residues include
tetralone (3,4-dihydronaphthalen-1(2H)-one) and indanone
(2,3-dihydroinden-1-one).
[0046] The terms "halogen" and "halo" refer to fluorine, chlorine,
bromine or iodine.
[0047] Some of the compounds described herein may contain one or
more asymmetric centers and may thus give rise to enantiomers,
diastereomers, and other stereoisomeric forms that may be defined,
in terms of absolute stereochemistry, as (R)- or (S)-. The present
invention is meant to include all such possible isomers, as well
as, their racemic and optically pure forms. Optically active (R)-
and (S)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques. When the
compounds described herein contain olefinic double bonds or other
centers of geometric asymmetry, and unless specified otherwise, it
is intended that the compounds include both E and Z geometric
isomers. Likewise, all tautomeric forms are also intended to be
included. The configuration of any carbon-carbon double bond
appearing herein is selected for convenience only and is not
intended to designate a particular configuration; thus a
carbon-carbon double bond depicted arbitrarily herein as trans may
be Z, E or a mixture of the two in any proportion.
[0048] It will be recognized that the compounds of this invention
can exist in radiolabeled form, i.e., the compounds may contain one
or more atoms containing an atomic mass or mass number different
from the atomic mass or mass number usually found in nature.
Radioisotopes of hydrogen, carbon, phosphorous, fluorine, chlorine
and iodine include .sup.3H, .sup.14C, .sup.35S, .sup.18F, .sup.36Cl
and .sup.125I, respectively. Compounds that contain those
radioisotopes and/or other radioisotopes of other atoms are within
the scope of this invention. Tritiated, i.e. .sup.3H, and
carbon-14, i.e., .sup.14C, radioisotopes are particularly preferred
for their ease in preparation and detectability. Radiolabeled
compounds of this invention can generally be prepared by methods
well known to those skilled in the art. Conveniently, such
radiolabeled compounds can be prepared by carrying out the
procedures disclosed in the Examples by substituting a readily
available radiolabeled reagent for a non-radiolabeled reagent.
Because of the high affinity for the JAK3 enzyme active site,
radiolabeled compounds of the invention are useful for JAK3
assays.
[0049] In one embodiment, R.sub.4 is a heterocycle selected from a
nitrogenous heterocycle and an oxygenous heterocycle. Nitrogenous
heterocycles that appear in the examples are monocyclic and
bicyclic heterocycles or monocyclic and bicyclic heterocycles
substituted with one or two substitutions. When y is not zero,
heteroaryl is a preferred subset of heterocyclyl for R.sub.4.
Exemplary nitrogenous heterocycles include piperidine, pyridine,
pyrazine, pyrimidine, pyridine, quinoline, isoquinoline,
tetrahydroquinoline, tetrahydroisoquinoline, and their variously
substituted derivatives, such as ##STR13##
[0050] In another embodiment, R.sub.4 is a substituted cycloalkyl.
Substituents include hydroxyl, alkoxy, hydroxyalkyl, oxo,
carboxamido (aminocarbonyl), carboxy, and carboalkoxy. Substituted
cycloalkyls include: ##STR14##
[0051] An oxygenous heterocycle is a heterocycle containing at
least one oxygen in the ring; it may contain additional oxygens, as
well as other heteroatoms. Exemplary oxygenous heterocycles include
tetrahydropyran, chroman, pyran, oxocane and their variously
substituted derivatives, such as: ##STR15## Chemical Synthesis
[0052] Terminology related to "protecting", "deprotecting" and
"protected" functionalities occurs throughout this application.
Such terminology is well understood by persons of skill in the art
and is used in the context of processes that involve sequential
treatment with a series of reagents. In that context, a protecting
group refers to a group which is used to mask a functionality
during a process step in which it would otherwise react, but in
which reaction is undesirable. The protecting group prevents
reaction at that step, but may be subsequently removed to expose
the original functionality. The removal or "deprotection" occurs
after the completion of the reaction or reactions in which the
functionality would interfere. Thus, when a sequence of reagents is
specified, as it is in the processes of the invention, the person
of ordinary skill can readily envision those groups that would be
suitable as "protecting groups". Suitable groups for that purpose
are discussed in standard textbooks in the field of chemistry, such
as Protective Groups in Organic Synthesis by T. W. Greene [John
Wiley & Sons, New York, 1991], which is incorporated herein by
reference.
[0053] A comprehensive list of abbreviations utilized by organic
chemists appears in the first issue of each volume of the Journal
of Organic Chemistry. The list, which is typically presented in a
table entitled "Standard List of Abbreviations", is incorporated
herein by reference.
[0054] In general, the compounds of the present invention may be
prepared by the methods illustrated in the general reaction schemes
as, for example, described below, or by modifications thereof,
using readily available starting materials, reagents and
conventional synthesis procedures. In these reactions, it is also
possible to make use of variants that are in themselves known, but
are not mentioned here. The starting materials, for example in the
case of suitably substituted benzimidazole ring compounds, are
either commercially available, synthesized as described in the
examples or may be obtained by the methods well known to persons of
skill in the art
[0055] The present invention further provides pharmaceutical
compositions comprising as active agents, the compounds described
herein.
[0056] As used herein a "pharmaceutical composition" refers to a
preparation of one or more of the compounds described herein, or
physiologically acceptable salts or solvents thereof, with other
chemical components such as physiologically suitable carriers and
excipients.
[0057] Pharmaceutical compositions for use in accordance with the
present invention thus may be formulated in conventional manner
using one or more physiologically acceptable carriers comprising
excipients and auxiliaries, which facilitate processing of the
active compounds into preparations which, can be used
pharmaceutically. Proper formulation is dependent upon the route of
administration chosen.
[0058] Compounds that inhibit Jak-3 can be formulated as
pharmaceutical compositions and administered to a mammalian
subject, such as a human patient in a variety of forms adapted to
the chosen route of administration, i.e., orally or parenterally,
by intravenous, intramuscular, topical, transdermal or subcutaneous
routes.
[0059] For oral administration, the compounds can be formulated
readily by combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the invention to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions,
and the like, for oral ingestion by a patient. Pharmacological
preparations for oral use can be made using a solid excipient,
optionally grinding the resulting mixture, and processing the
mixture of granules, after adding suitable auxiliaries if desired,
to obtain tablets or dragee cores. Suitable excipients are, in
particular, fillers such as sugars, including lactose, sucrose,
mannitol, or sorbitol; cellulose preparations such as, for example,
maize starch, wheat starch, rice starch, potato starch, gelatin,
gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose,
sodium carbomethylcellulose; and/or physiologically acceptable
polymers such as polyvinylpyrrolidone (PVP). If desired,
disintegrating agents may be added, such as cross-linked polyvinyl
pyrrolidone, agar or alginic acid or a salt thereof such as sodium
alginate.
[0060] In addition, enteric coating may be useful as it is may be
desirable to prevent exposure of the compounds of the invention to
the gastric environment.
[0061] Pharmaceutical compositions, which can be used orally,
include push-fit capsules made of gelatin as well as soft, sealed
capsules made of gelatin and a plasticizer, such as glycerol or
sorbitol. The push-fit capsules may contain the active ingredients
in admixture with filler such as lactose, binders such as starches,
lubricants such as talc or magnesium stearate and, optionally,
stabilizers.
[0062] In soft capsules, the active compounds may be dissolved or
suspended in suitable liquids, such as fatty oils, liquid paraffin,
or liquid polyethylene glycols. In addition, stabilizers may be
added. All formulations for oral administration should be in
dosages suitable for the chosen route of administration.
[0063] For injection, the compounds of the invention may be
formulated in aqueous solutions, preferably in physiologically
compatible buffers such as Hank's or Ringer's solution or
physiological saline buffer. For transmucosal and transdermal
administration, penetrants appropriate to the barrier to be
permeated may be used in the composition. Such penetrants,
including for example DMSO or polyethylene glycol, are known in the
art.
[0064] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from a pressurized pack
or a nebulizer with the use of a suitable propellant, e. g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichloro-tetrafluoroethane or carbon dioxide. In the case of a
pressurized aerosol, the dosage unit may be determined by providing
a valve to deliver a metered amount. Capsules and cartridges of, e.
g., gelatin for use in an inhaler or insufflator may be formulated
containing a powder mix of the compound and a suitable powder base
such as lactose or starch.
[0065] Pharmaceutical compositions for parenteral administration
include aqueous solutions of the active ingredients in
water-soluble form. Additionally, suspensions of the active
compounds may be prepared as appropriate oily injection
suspensions. Suitable lipophilic solvents or vehicles include fatty
oils such as sesame oil, or synthetic fatty acids esters such as
ethyl oleate, triglycerides or liposomes. Aqueous injection
suspensions may contain substances, which increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol or
dextran. Optionally, the suspension may also contain suitable
stabilizers or agents, which increase the solubility of the
compounds, to allow for the preparation of highly concentrated
solutions.
[0066] The compounds of the present invention may also be
formulated in rectal compositions such as suppositories or
retention enemas, using, e.g., conventional suppository bases such
as cocoa butter or other glycerides.
[0067] Depending on the severity and responsiveness of the
condition to be treated, dosing can also be a single administration
of a slow release composition, with course of treatment lasting
from several days to several weeks or until cure is effected or
diminution of the disease state is achieved. The amount of a
composition to be administered will, of course, be dependent on
many factors including the subject being treated, the severity of
the affliction, the manner of administration, the judgment of the
prescribing physician. The compounds of the invention may be
administered orally or via injection at a dose from 0.001 to 2500
mg/kg per day. The dose range for adult humans is generally from
0.005 mg to 10 g/day. Tablets or other forms of presentation
provided in discrete units may conveniently contain an amount of
compound of the invention which is effective at such dosage or as a
multiple of the same, for instance, units containing 5 mg to 500
mg, usually around 10 mg to 200 mg. The precise amount of compound
administered to a patient will be the responsibility of the
attendant physician. However, the dose employed will depend on a
number of factors, including the age and sex of the patient, the
precise disorder being treated, and its severity. Also, the route
of administration may vary depending on the condition and its
severity.
[0068] As used herein, and as would be understood by the person of
skill in the art, the recitation of "a compound" is intended to
include salts, solvates and inclusion complexes of that compound.
The term "solvate" refers to a compound of Formula I or II in the
solid state, wherein molecules of a suitable solvent are
incorporated in the crystal lattice. A suitable solvent for
therapeutic administration is physiologically tolerable at the
dosage administered. Examples of suitable solvents for therapeutic
administration are ethanol and water. When water is the solvent,
the solvate is referred to as a hydrate. In general, solvates are
formed by dissolving the compound in the appropriate solvent and
isolating the solvate by cooling or using an antisolvent. The
solvate is typically dried or azeotroped under ambient conditions.
Inclusion complexes are described in Remington: The Science and
Practice of Pharmacy 19th Ed. (1995) volume 1, page 176-177, which
is incorporated herein by reference. The most commonly employed
inclusion complexes are those with cyclodextrins, and all
cyclodextrin complexes, natural and synthetic, are specifically
encompassed within the claims.
[0069] The term "pharmaceutically acceptable salt" refers to salts
prepared from pharmaceutically acceptable non-toxic acids or bases
including inorganic acids and bases and organic acids and bases.
When the compounds of the present invention are basic, salts may be
prepared from pharmaceutically acceptable non-toxic acids including
inorganic and organic acids. Suitable pharmaceutically acceptable
acid addition salts for the compounds of the present invention
include acetic, benzenesulfonic (besylate), benzoic,
camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic,
glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic,
malic, mandelic, methanesulfonic, mucic, nitric, pamoic,
pantothenic, phosphoric, succinic, sulfuric, tartaric acid,
p-toluenesulfonic, and the like. When the compounds contain an
acidic side chain, suitable pharmaceutically acceptable base
addition salts for the compounds of the present invention include
metallic salts made from aluminum, calcium, lithium, magnesium,
potassium, sodium and zinc or organic salts made from lysine,
N,N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and
procaine.
[0070] The term "preventing" as used herein refers to administering
a medicament beforehand to forestall or obtund an attack. The
person of ordinary skill in the medical art (to which the present
method claims are directed) recognizes that the term "prevent" is
not an absolute term. In the medical art it is understood to refer
to the prophylactic administration of a drug to substantially
diminish the likelihood or seriousness of a condition, and this is
the sense intended herein.
[0071] It should be understood that in addition to the ingredients
particularly mentioned above, the formulations of this invention
may include other agents conventional in the art having regard to
the type of formulation in question, for example those suitable for
oral administration may include flavoring agents.
[0072] The compositions may be presented in a packaging device or
dispenser, which may contain one or more unit dosage forms
containing the active ingredient. Examples of a packaging device
include metal or plastic foil, such as a blister pack and a
nebulizer for inhalation. The packaging device or dispenser may be
accompanied by instructions for administration. Compositions
comprising a compound of the present invention formulated in a
compatible pharmaceutical carrier may also be placed in an
appropriate container and labeled for treatment of an indicated
condition.
Indications
[0073] The compounds of the present invention are useful in
inhibiting the activity if Jak3 or in inhibiting Jak3 mediated
activity and are useful as immunosuppressive agents for tissue and
organ transplants, including bone marrow and kidney transplant, and
in the treatment of autoimmune and inflammatory diseases and of
complications arising therefrom.
[0074] Hyperacute, acute and chronic organ transplant rejection may
be treated. Hyperacute rejection occurs within minutes of
transplantation. Acute rejection generally occurs within six to
twelve months of the transplant. Hyperacute and acute rejections
are typically reversible where treated with immunosuppressant
agents. Chronic rejection, characterized by gradual loss of organ
function, is an ongoing concern for transplant recipients because
it can occur anytime after transplantation.
[0075] There are about 75 different autoimmune disorders known that
may be classified into two types, organ-specific (directed mainly
at one organ) and non-organ-specific (affecting multiple
organs).
[0076] Examples of organ-specific autoimmune disorders are
insulin-dependent diabetes (Type I) which affects the pancreas,
Hashimoto's thyroiditis and Graves' disease which affect the
thyroid gland, pernicious anemia which affects the stomach,
Cushing's disease and Addison's disease which affect the adrenal
glands, chronic active hepatitis which affects the liver;
polycystic ovary syndrome (PCOS), celiac disease, psoriasis,
inflammatory bowel disease (IBD) and ankylosing spondylitis.
[0077] Examples of non-organ-specific autoimmune disorders are
rheumatoid arthritis, multiple sclerosis, systemic lupus and
myasthenia gravis.
[0078] Type I diabetes ensues from the selective aggression of
autoreactive T-cells against insulin secreting .beta. cells of the
islets of Langerhans. Targeting Jak3 in this disease is based on
the observation that multiple cytokines that signal through the Jak
pathway are known to participate in the T-cell mediated autoimmune
destruction of .beta. cells. Indeed, a Jak3 inhibitor, JANEX-1 was
shown to prevent spontaneous autoimmune diabetes development in the
NOD mouse model of type I diabetes.
[0079] Graft-versus-host disease (GVHD) is a donor T-cell initiated
pathological condition that frequently follows allogeneic bone
marrow transplantation (BMT). Substantial experimental and clinical
research have demonstrated that donor T-cells are the principal
mediators and effectors of GVHD. Jak3 plays a key role in the
induction of GVHD and treatment with a Jak3 inhibitor, JANEX-1, was
shown to attenuate the severity of GVHD (reviewed in
Cetkovic-Cvrlje and Ucken, 2004).
[0080] Mast cells express Jak3 and Jak3 is a key regulator of the
IgE mediated mast cell responses including the release of
inflammatory mediators. Jak3 was shown to be a valid target in the
treatment of mast cell mediated allergic reaction.
[0081] Allergic disorders associated with mast cell activation
include Type I immediate hypersensitivity reactions such as
allergic rhinitis (hay fever), allergic urticaria (hives),
angioedema, allergic asthma and anaphylaxis, i.e., "anaphylatic
shock." These disorders are treated or prevented by inhibition of
Jak3 activity, for example, by administration of a Jak3 inhibitor
according to the present invention.
[0082] According to the present invention, the Jak3 inhibitors may
be administered prophylactically, i.e., prior to onset of acute
allergic reaction, or they may be administered after onset of the
reaction, or at both times.
[0083] Inflammation of tissues and organs occurs in a wide range of
disorders and diseases and in certain variations, results from
activation of the cytokine family of receptors. Exemplary
inflammatory disorders associated with activation of Jak3 include,
in a non-limiting manner, skin inflammation due radiation exposure,
asthma, allergic inflammation and chronic inflammation such as
keratoconjunctivitis sicca.
[0084] The compounds of the present invention are also useful in
treating certain malignancies, including skin cancer and
hematological malignancy such as lymphomas and leukemias. An
example of the lymphoma is anaplastic large cell lymphoma (ALCL).
The utility of the Jak3 inhibitors of the present invention for
treating ALCL have been demonstrated by the studies presented by
Lai, R. et al. Jak3 activation is significantly associated with ALK
expression in anaplastic large cell lymphoma. Human Pathology
(2005) 36, 939-944 and Harrington et al. VX-680, a potent and
selective small-molecule inhibitor of the Aurora kinases,
suppresses tumor growth in vivo. Nature Medicince (2004) 3, 262-267
which are both incorporated in there entirety herein by
reference.
[0085] An example of the leukemia is chronic myelogenous leukemia
(CML). The utility of the Jak3 inhibitors of the present invention
for treating CML have been demonstrated by the studies presented by
Harrington et al. referenced above. The aforementioned study
further has demonstrated the treatement of acute myelogenous
leukemia (AML) via in vivo experiments.
[0086] The comounds of the present invention are also useful in
treating non-hemotological malignancies, including pancreatic and
colon cancer. [See Harrington et al., op. cit. for in vivo
tests.]
[0087] The Jak3 inhibitors of the present invention are
additionally useful in treating cardiovascular disease.
[0088] The following examples will further describe the invention,
and are used for the purposes of illustration only, and should not
be considered as limiting the invention being disclosed.
EXAMPLES
[0089] The following abbreviations and terms have the indicated
meaning throughout: TABLE-US-00001 Ac = acetyl Bu = butyl DCM =
dichloromethane = methylene chloride = CH.sub.2Cl.sub.2 DEAD =
diethyl azodicarboxylate DIC = diisopropylcarbodiimide DIEA =
N,N-diisopropylethyl amine DMF = N,N-dimethylformamide DMSO =
dimethyl sulfoxide EA (EtOAc) = Ethyl Acetate GC = gas
chromatography h = hours HOAc = acetic acid HOBt =
hydroxybenzotriazole Me = methyl Pd(dppf).sub.2Cl.sub.2 =
dichloro[1,1'-bis(diphenyl- phosphinoferrocene]palladium Ph =
phenyl PhOH = phenol RT = room temperature sat'd = saturated s- =
secondary t- = tertiary TBDMS = t-butyldimethylsilyl TFA =
trifluoroacetic acid THF = tetrahydrofuran TMOF = trimethyl
orthoformate TMS = trimethylsilyl tosyl = p-toluenesulfonyl Trt =
triphenylmethyl
Examples 1-15 describe syntheses of certain precursors and
intermediates of the invention.
Example 1
Synthesis of 3,4-Diaminobenzonitrile
[0090] ##STR16##
[0091] A solution of 4-amino-3-nitrobenzonitrile (1) (3.0 g) in
ethanol (80 mL) was sparged for 5 minutes with nitrogen. Palladium
on carbon (10%, 300 mg) was added and the mixture was saturated
with hydrogen. The mixture was stirred under a hydrogen balloon for
seven hours. The mixture was sparged with nitrogen and filtered
through celite. The filtrate was concentrated in vacuo to provide
the title compound, 3,4-diaminobenzonitrile (2).
Example 2
Synthesis of 3H-Benzo[d]imidazole-5-carbonitrile
[0092] A mixture of 3,4-diaminobenzonitrile (2) (1.0 g) and
(ethoxymethylene)malononitrile (1.4 g) was refluxed in 50 mL of
isopropyl alcohol for 16 h. The mixture was concentrated in vacuo
to provide the title compound, 3H-benzo[d]imidazole-5-carbonitrile
(3).
Example 3
Synthesis of 6-(Trifluoromethoxy)-1H-benzo[d]imidazole
[0093] ##STR17##
[0094] 6-(trifluoromethoxy)-1H-benzo[d]imidazole (4) was prepared
in two steps from 2-nitro-4-(trifluoromethoxy)aniline (5) using
procedures identical to those used to make
3H-benzo[d]imidazole-5-carbonitrile (3) from
4-amino-3-nitrobenzonitrile (1, examples 1,2).
Example 4
Synthesis of 5,6-Difluoro-1H-benzo[d]imidazole
[0095] ##STR18##
[0096] A solution of 4,5-difluoro-2-nitroaniline (6)(1.0 g) in 30
mL of THF was treated with a solution comprised of 6 g of
Na.sub.2S.sub.2O.sub.4 and 3 g NaHCO.sub.3 in 30 mL of water.
Methanol (10 mL) was added after the addition of the aqueous
solution so that the mixture remained homogeneous. The mixture was
stirred for two hours and then diluted with 100 mL of ethyl acetate
and 100 mL of water. The organic layer was separated and the
aqueous layer was extracted again with 100 mL of methylene
chloride. The combined organic layers were dried over sodium
sulfate, filtered, and concentrated to provide the crude
intermediate 4,5-difluorobenzene-1,2-diamine (7). The intermediate
was refluxed with (ethoxymethylene)malononitrile (1.1 g) in 25 mL
of isopropyl alcohol for 16 h. The mixture was concentrated in
vacuo and the resulting crude product was suspended in water and
filtered. The precipitate was washed with water and air-dried to
provide 380 mg of 5,6-difluoro-1H-benzo[d]imidazole (8).
Example 5
Synthesis of 5,6-Dimethoxy-1H-benzo[d]imidazole
[0097] ##STR19##
[0098] The title compound 5,6-dimethoxy-1H-benzo[d]imidazole (10)
was made by heating 4,5-dimethoxy-1,2-phenylenediamine
dihydrochloride (9) in formic acid at 220.degree. C. in a microwave
followed by concentration in vacuo.
Example 6
Synthesis of 6-Fluoro-1H-benzo[d]imidazole (11) and
6-(trifluoromethyl)-1H-benzo[d]imidazole (12)
[0099] The title compounds were by made as described in U.S.
Application Publication No. 2004/0087601, of some of the present
inventors. ##STR20##
Example 7
Benzimidazole (13), 5-azabenzimidazole (14),
6-chloro-5-fluorobenzimidazole (15), and 5-methylbenzimidazole
(16)
[0100] The title compounds were commercially available.
##STR21##
Example 8
Synthesis of the primary amine, pyrazin-2-ylmethanamine
[0101] ##STR22##
[0102] Raney nickel catalyst was carefully washed with THF and
methanol making sure that the catalyst remained moist. The weight
of the moist catalyst was 2.5 g after washing. This material was
added to a solution of pyrazinecarbonitrile (17) (3.0 g) in 7N
methanolic ammonia (120 mL). The mixture was shaken under a 50
p.s.i. atmosphere of hydrogen for 1.5 hours. The mixture was
filtered and the filtrate was concentrated in vacuo to provide the
crude title compound. Purification was accomplished by conversion
of the crude amine to the tert-butyl carbamate with excess
di-tert-butyl dicarbonate in methylene chloride. Column
chromatography (70:27:3 hexanes:ethyl acetate:methanol) provided
0.50 g of pure tert-butyl pyrazin-2-ylmethylcarbamate. Pure
pyrazin-2-ylmethanamine (18) was obtained as the TFA salt from
deprotection of the carbamate with 1:1 TFA/CH.sub.2Cl.sub.2.
Example 9
Synthesis of 3-Aminomethyl-2-fluoropyridine
[0103] ##STR23##
[0104] A round bottom flask was charged with 0.3 g (2.46 mM) of
3-cyano-2-fluoropyridine (19), which was then diluted in 20 mL
EtOH. The solution was flushed with argon, and then while under a
blanket of argon, 60 mg of 10% Pd/C (20% by weight), was added. The
system was then sealed by septum and put under vacuum. A hydrogen
balloon was then added, and the reaction was stirred for three
hours (followed by TLC). The reaction was then put under vacuum
again, then exposed to air, and filtered (keeping catalyst wet).
The resulting solution was dried and evaporated to give 0.28 g
(90%) of the title compound, 3-aminomethyl-2-fluoropyridine
(20).
Example 10
Synthesis of 3-Aminomethyl-6-methoxypyridine (21),
3-Aminomethyl-6-methylpyridine (22), and 3-Aminomethylquinoline
(23)
[0105] The title amines were obtained from the corresponding
nitrites using the same procedure that was used to obtain
3-aminomethyl-2-fluoropyridine (20) from 3-cyano-2-fluoropyridine
(see Example 9). ##STR24##
Example 11
Synthesis of 3-aminomethyl-2-methoxypyridine
[0106] ##STR25##
[0107] A round bottom flask was charged with 0.44 g (3.23 mM) of
2-methoxy-3-pyridine carboxaldehyde (24), 1.24 g (16.15 mM) of
ammonium acetate, and 0.61 g (19.69 mM) of sodium cyanoborohydride.
The flask was then flushed with argon, and then 50 mL of dry MeOH
was added by syringe. The reaction was stirred for 2 days, at which
point the MeOH was evaporated off. 25 mL of water was added, and
the mixture was brought to pH 2 with conc. HCl. This was extracted
twice with EtOAc to remove the alcohol side product. The mixture
was brought to pH 10 using sodium hydroxide pellets, saturated with
NaCl, and extracted twice with DCM and once with EtOAc. The
combined organics were dried and evaporated to give 0.31 g (69%) of
3-aminomethyl-2-methoxypyridine (25).
Example 12
Synthesis of 3-(.alpha.-aminoethyl)-2-chloropyridine (26)
[0108] ##STR26##
[0109] The title amine was obtained from the corresponding ketone
using the same procedure that was used to obtain
3-aminomethyl-2-methoxypyridine from 2-methoxy-3-pyridine
carboxaldehyde (24; Example 11).
Example 13
Synthesis of 3-aminomethyl-4-methylpyridine
[0110] ##STR27##
[0111] A round bottom flask was charged with 0.45 g (3.30 mM) of
4-methylnicotinamide (27). The flask was flushed with argon, and 50
mL of dry THF was added by syringe. The resulting solution was
cooled to 0 dg C., and 2.5 mL (4.96 mM) of a 2M solution of
borane-dimethylsulfide complex (in THF) was added. A bubbler was
attached, and the solution was allowed to warm to RT overnight. The
solution was quenched with MeOH, and dried and evaporated to give
0.38 g (95%) of 3-aminomethyl-4-methylpyridine (28).
Example 14
Synthesis of 5-fluoro-1,2,3,4-tetrahydronaphthalen-1-amine
[0112] ##STR28##
[0113] Methyl 4-(2-fluorophenyl)butanoate
(2-(4-methylbutanoate)fluorobenzene, 30). A round bottom flask was
sealed with a rubber septum, flushed with argon, then charged with
5.32 mL of methyl 3-buteneoate (29) and 100 mL of a 0.5M solution
of 9-BBN in THF. The solution was stirred at RT for three hours. A
2-necked round bottom flask was equipped with a condenser and
flushed with argon, then charged with 7.36 g of sodium methoxide
and 1.11 g of Pd(dppf).sub.2Cl.sub.2. To this mixture were added 20
mL of dry THF and 5.22 mL of 1-fluoro-2-iodobenzene. The
hydroboration solution was added via canula and the resulting
mixture was refluxed for 16 hours. The solution was cooled to RT,
diluted with 150 mL of water, and extracted three times with ether.
The combined organic layers were washed with brine, dried, and
evaporated. Column chromatography (5% EtOAc/hexanes) gave 1.79 g
methyl 4-(2-fluorophenyl)butanoate (30).
[0114] 4-(2-Fluorophenyl)butanoic acid (31). A round bottom flask
was charged with 1.79 g of 2-(4-methylbutanoate)fluorobenzene,
which was dissolved in 17 mL of MeOH. To this solution was added a
solution of 1 g of sodium hydroxide. The resulting mixture was
stirred 20 hours at RT. The solvent was evaporated and the crude
material diluted with 15 mL of 0.5M HCl. Extraction with DCM three
times gave 1.17 g (92%) of 4-(2-fluorophenyl)butanoic acid
(31).
[0115] 5-Fluoro-3,4-dihydronaphthalen-1(2H)-one (32). A round
bottom flask was charged with 0.15 g of 4-(2-fluorophenyl)butanoic
acid, which was dissolved in 20 mL DCM and cooled to 0.degree. C.
Oxalyl chloride (0.15 mL) was added, followed by 1 drop of DMF. A
drying tube was attached, and the solution was stirred at 0.degree.
C. for two hours. Aluminum chloride (0.121 g) was added and the
solution was allowed to slowly warn to RT overnight. The mixture
was poured onto ice water, and extracted three times with DCM. The
combined organic layers were washed with 0.5 M NaOH and brine. The
organic phase was dried, evaporated, and purified by column
chromatography (eluting with 20% EtOAc/Hexanes), to give 0.07 g
(53%) of 5-fluoro-3,4-dihydronaphthalen-1(2H)-one (32).
[0116] 5-Fluoro-1,2,3,4-tetrahydronaphthalen-1-amine (34). A round
bottom flask was charged with 0.5 g of
5-fluoro-3,4-dihydronaphthalen-1(2H)-one, 0.28 g of hydroxylamine
hydrochloride, and 0.34 g of sodium acetate. A condenser was
attached, and the flask was purged with argon. 20 mL of dry EtOH
was added, and the mixture was stirred at reflux for 18 hours. The
solution was cooled to RT, diluted with EtOAc, and washed with
water. The organic phase was dried with sodium sulfate and
evaporated to give 0.5 g of the intermediate
5-fluoro-3,4-dihydronaphthalen-1(2H)-one oxime (33), which was
reduced with Pd/C in EtOH with hydrogen (50 psi), to give 0.43 g
(86%) of 5-fluoro-1,2,3,4-tetrahydronaphthalen-1-amine (34).
Example 15
Synthesis of
3-(9-((R)-6-fluorochroman-4-yl)-9H-purin-2-yl)-3H-benzo[d]imidazole-5-car-
bonitrile
[0117] ##STR29##
[0118] To a solution of
(R)-4-(2,4-dimethoxybenzylamino)-3-(4-(6-fluorochroman-4-ylamino)-5-nitro-
pyrimidin-2-ylamino)benzonitrile (prepared as described below in
example 26, paragraph [0157]) (12 mg) in THF (5 mL) was added a
premixed solution of sodium hydrosulfite (100 mg) and sodium
bicarbonate (50 mg) in water (10 mL). MeOH (1 mL) was also added to
aid solution of the mixture, which was stirred at room temperature
for 30 min, when sodium chloride was added to saturate the
solution. The resultant mixture was extracted with EtOAc
(2.times.), the combined organics were dried, filtered and
evaporated to yield
(R)-4-(2,4-dimethoxybenzylamino)-3-(5-amino-4-(6-fluorochroman-4-ylamino)-
pyrimidin-2-ylamino)benzonitrile that was used as such for the next
step, MH.sup.+=542.
[0119] To a microwave vial was added the above amine, a catalytic
amount of para-toluene sulfonic acid monohydrate, trimethyl
orthoformate (0.5 mL) and MeOH (1 mL). The vial was capped and
heated in an Emrys Optimizer microwave at 150.degree. C. for 5
minutes. The mixture was concentrated in vacuo, and purified by RP
HPLC to yield 4.6 mg of the titled product as the TFA salt, NMR
CDCl.sub.3 .sup.1H .delta. 9.5 (br s, 1H), 9.3 (s, 1H), 9.0 (s,
1H), 8.2 (br s, 1H), 8.0 (d, 1H), 7.7 (d, 1H), 7.1-7.0 (m, 2H), 6.6
(dd, 1H), 6.0 (t, 1H), 4.4 (m, 1H), 4.3 (m, 1H), 2.7 (m, 2H);
.sup.19F .delta. -121, -76 ppm; MH.sup.+=412.
Synthesis of
9-((R)-Chroman-4-yl)-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9H-purine
[0120] ##STR30##
[0121] The title compound as a TFA salt was synthesized from
(R)-tert-butyl
2-(4-(chroman-4-ylamino)-5-nitropyrimidin-2-ylamino)-4-fluorophenylcarbam-
ate via the procedure described in Example 15. .sup.1H NMR (300
MHz, CDCl.sub.3): .delta. 9.15 (s, 2H), 8.27 (dd, 1H), 7.89 (s,
1H), 7.78 (dd, 1H), 7.32 (td, 1H), 7.32 (td, 1H), 7.13 (td, 1H),
7.1-6.9 (m, 3H), 6.00 (t, 1H), 4.4-4.3 (m, 2H), 4.2-4.1 (m, 2H),
2.7-2.5 (m, 2H). .sup.19F NNMR: .delta. -116.4.
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-pur-
ine
[0122] ##STR31##
[0123] The title compound as a TFA salt was synthesized from
tert-butyl
4-fluoro-2-(5-nitro-4-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-ylamino)-
phenylcarbamate via the procedure described in Example 15. .sup.1H
NMR (300 MHz, CDCl.sub.3): .delta. 9.73 (s, 1H), 9.29 (s, 1H),
8.5-8.6 (m, 1H), 8.40 (s, 1H), 7.9-8.1 (m, 1H), 7.3-7.4 (m, 1H),
4.8-5.0 (m, 1H), 4.2-4.4 (m, 2H), 3.7-3.8 (m, 2H), 3.05 (d, 1H),
2.2-2.4 (m, 3H). .sup.19F NMR: .delta. -112.4.
Example 16
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-7H-purin-8(9H)--
one
[0124] ##STR32##
[0125]
2-(1H-Benzo[d]imidazol-1-yl)-N-((R)-8-fluorochroman-4-yl)-5-nitrop-
yrimidin-4-amine. (R)-8-fluorochroman-4-amine (60 mg, Example 29)
was added to a solution of 2,4-dichloro-5-nitropyrimidine (70 mg)
and DIEA (0.14 mL) in THF (5 mL) at -78.degree. C. The reaction
mixture was stirred for a further 15 min at -78.degree. C. then
removed from the cold bath and allowed to warm to RT. A one molar
solution of the sodium salt of benzimidazole (0.7 ml, stock
solution prepared via the addition of sodium hydride to a
benzimidazole solution in THF) was added to the reaction
intermediate
((R)-2-chloro-N-(8-fluorochroman-4-yl)-5-nitropyrimidin-4-amine)
and the resulting mixture was stirred at RT overnight. Purification
via column chromatography (elution with 1 MeOH/DCM) gave the titled
compound (120 mg), MH.sup.+=407.
[0126]
2-(1H-Benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-7H-purin-
-8(9H)-one. A freshly prepared solution of sodium hydrosulfite
(tech, 0.5 g) and sodium bicarbonate (0.25 g) in H.sub.2O (5 mL)
was added to a solution of the above nitro compound (120 mg) in THF
(10 mL). The mixture was stirred vigorously for 30 min then
extracted with EtOAc (2.times.) and DCM (2.times.), the combined
organics were washed with brine, dried, filtered and concentrated
to yield the intermediate
2-(1H-benzo[d]imidazol-1-yl)-N.sup.4-((R)-8-fluorochroman-4-yl)pyrimidine-
-4,5-diamine that was used as such in the next step.
[0127] Carbonyldiimidazole (0.2 g) was added to a solution of the
above amine in THF (10 mL). The resulting mixture was stirred at RT
overnight, silica gel was added, then the solvents were removed
under reduced pressure and purified via column chromatography,
elution with 5% MeOH/DCM, to yield the titled product (28 mg),
MH.sup.+=403, .sup.1H NMR (CDCl.sub.3) .delta. 10.6 (s, 1H), 8.9
(s, 1H), 8.3 (s, 1H), 7.8 (m, 2H), 7.3 (m, 2H), 7.0 (m, 1H), 6.7
(m, 1H), 5.9 (dd, 1H), 4.7 (m, 1H), 4.4 (t, 1H), 2.7 (m, 1H), 2.3
(m, 1H) ppm, .sup.19F NMR .delta. -135.7 (m). Chiral HPLC--no
evidence of other enantiomer, Method; Chiralcel OD-H (0.46.times.25
cm analytical column, Daicel Chemical Industries) isocratic 15%
(0.05% TFA/EtOH) 85% (0.05% TFA/Hex), Rt=19.5 min (R)-enantiomer,
Rt=22.4 min (S)-enantiomer.
Synthesis of
2-(1H-benzo[d]imidazol-1-yl)-9-((R)-6-fluorochroman-4-yl)-7H-purin-8(9H)--
one.
[0128] ##STR33##
[0129] The title compound was synthesized from
(R)-6-fluorochroman-4-amine using the procedures outline in Example
16. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 10.28 (s, 1H), 8.82
(s, 1H), 8.28 (s, 1H), 7.94 (d, 1H), 7.79 (d, 1H), 7.2-7.4 (m, 2H),
6.8-7.1 (m, 2H), 6.66 (dd, 1H), 5.92 (br t, 1H), 4.55 (m, 1H), 4.33
(m, 1H), 2.90 (m, 1H), 2.31 (m, 1H).
Synthesis of
2-(1H-benzo[d]imidazol-1-yl)-9-((R)-5,6-difluorochroman-4-yl)-7H-purin-8(-
9H)-one
[0130] ##STR34##
[0131] The title compound was synthesized from
(R)-5,6-difluorochroman-4-amine (obtained by resolution of
(+/-)-5,6-difluorochroman-4-amine using the resolution procedure
outlined in Example 29) using the procedures outline in Example 16.
.sup.1H NMR (300 MHz, CDCl.sub.3+5% CD.sub.3OD): .delta. 8.62 (s,
1H), 8.18 (s, 1H), 8.0-8.1 (m, 1H), 7.6-7.7 (m, 1H), 7.2-7.3 (m,
1H), 6.9-7.1 (m, 2H), 6.7-6.8 (m, 1H), 5.86 (br t, 1H), 4.4-4.5 (m,
1H), 4.2-4.3 (m, 1H), 2.5-2.6 (m, 1H), 2.3-2.4 (m, 1H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((2-fluoropyridin-3-yl)methyl)-7H-purin-8(-
9H)-one
[0132] ##STR35##
[0133] The title compound was synthesized from
3-aminomethyl-2-fluoropyridine via the procedure described in
Example 16. .sup.1H-NMR (CDCl.sub.3) .delta. 9.2 (s, 1H), 9.0 (d,
1H), 8.4 (m, 1H), 8.2 (d, 1H), 7.8 (m, 2H), 7.4 (m, 3H), 7.2 (t,
1H), 4.3 (s, 2H), ppm
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((2-methylpyridin-3-yl)methyl)-7H-purin-8(-
9H)-one
[0134] ##STR36##
[0135] The title compound was synthesized from
3-aminomethyl-2-methylpyridine via the procedure described in
Example 16. .sup.1H-NMR (CDCl.sub.3) .delta. 9.4 (s, 1H), 8.6 (d,
1H), 8.5 (d, 1H), 8.4 (d, 1H), 8.2 (s, 1H), 7.7 (d, 1H), 7.6 (t,
1H), 7.4 (m, 2H), 5.2 (s, 2H), 2.9 (s, 3H), ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((2-methoxypyridin-3-yl)methyl)-7H-purin-8-
(9H)-one
[0136] ##STR37##
[0137] The title compound was synthesized from
3-aminomethyl-2-methoxypyridine via the procedure described in
Example 16. .sup.1H-NMR (CDCl.sub.3) .delta. 9.1 (s, 1H), 8.6 (d,
1H), 8.2 (s, 1H), 8.0 (d, 1H), 7.7 (s, 1H), 7.7 (d, 1H), 7.5 (d,
1H), 7.3 (m, 2H), 6.80 (t, 1H), 5.1 (s, 2H), 3.9 (s, 3H), ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((4-methylpyridin-3-yl)methyl)-7H-purin-8(-
9H)-one
[0138] ##STR38##
[0139] The title compound was synthesized from
3-aminomethyl-4-methylpyridine via the procedure described in
Example 16. .sup.1H-NMR (CDCl.sub.3) .delta. 8.9 (s, 1H), 8.5 (s,
1H), 8.3 (m, 1H), 8.2 (m, 1H), 7.7 (m, 1H), 7.6 (m, 1H), 7.3 (m,
1H), 7.0 (m, 2H), 5.2 (s, 2H), 2.5 (s, 3H), ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)-
-7H-purin-8(9H)-one
[0140] ##STR39##
[0141] The title compound was synthesized from
6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (WO 2003/045924) via
the procedure described in Example 16. .sup.1H-NMR (CDCl.sub.3)
.delta. 8.8 (s, 1H), 8.6 (d, 1H), 8.3 (s, 1H), 7.8 (dd, 1H), 7.6
(dd, 1H), 7.4 (d, 1H), 7.3-7.1 (m, 3H), 6.3 (t, 1H), 3.6-3.5 (m,
1H), 3.4-3.2 (m, 1H), 2.9-2.6 (m, 2H) ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((6-methoxypyridin-3-yl)methyl)-7H-purin-8-
(9H)-one
[0142] ##STR40##
[0143] The title compound was synthesized from
3-aminomethyl-6-methoxypyridine via the procedure described in
Example 16. .sup.1H-NMR (CDCl.sub.3) .delta. 9.2 (s, 1H), 8.5 (d,
1H), 8.3 (s, 1H), 8.2 (s, 1H), 7.8 (m, 2H), 7.4 (t, 2H), 6.7 (d,
1H), 5.1 (s, 2H), 3.8 (s, 3H) ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-((6-methylpyridin-3-yl)methyl)-7H-purin-8(-
9H)-one
[0144] ##STR41##
[0145] The title compound was synthesized from
3-aminomethyl-6-methylpyridine via the procedure described in
Example 16. .sup.1H-NMR (CDCl.sub.3) .delta. 9.5 (s, 1H), 9.2 (s,
1H), 8.9 (s, 1H), 8.7 (d, 1H), 8.4 (s, 1H), 8.1 (d, 1H), 7.9 (d,
1H), 7.5 (m, 2H), 5.5 (s, 2H), 2.6 (s, 3H) ppm.
Example 17
Non-regiospecific synthesis of benzimidazole purinone derivatives:
Synthesis of
5-Nitro-N-(pyridin-3-ylmethyl)-2-(6-(trifluoromethoxy)-1H-benxo[d]imidazo-
l-1-yl)pyrimidin-4-amine (42) AND
5-nitro-N-(pyridin-3-ylmethyl)-2-(5-(trifluoromethoxy)-1H-benzo[d]imidazo-
l-1-yl)pyrimidin-4-amine (44)
[0146] ##STR42##
[0147] 2-Chloro-5-nitro-N-(pyridin-3-ylmethyl)pyrimidin-4-amine
(41). A solution of 2,4-dichloro-5-nitropyrimidine (40) (5 g) in
methylene chloride (60 mL) was cooled to -78.degree. C. and treated
with 3-(aminomethyl)pyridine (2.8 g). The mixture was stirred at
-78.degree. C. for six hours, and concentrated in vacuo at RT to
provide crude
2-chloro-5-nitro-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (41),
which was used without further purification.
[0148]
5-Nitro-N-(pyridin-3-ylmethyl)-2-(6-(trifluoromethoxy)-1H-benzo[d]-
imidazol-1-yl)pyrimidin-4-amine (42) and
5-nitro-N-(pyridin-3-ylmethyl)-2-(5-(trifluoromethoxy)-1H-benzo[d]imidazo-
l-1-yl)pyrimidin-4-amine (44). A suspension of crude
2-chloro-5-nitro-N-(pyridin-3-ylmethyl)pyrimidin-4-amine (52 mg) in
acetonitrile (10 mL) was treated with
6-(trifluoromethoxy)-1H-benzo[d]imidazole (40 mg), potassium
carbonate (0.5 g), and heated at 80.degree. C. for four hours. The
mixture was diluted with water and extracted with methylene
chloride. The organic layer was separated, dried with sodium
sulfate, filtered, and concentrated in vacuo. Column chromatography
(70:22:8 methylene chloride:ethyl acetate:methanol) provided 12 mg
of
5-nitro-N-(pyridin-3-ylmethyl)-2-(5-(trifluoromethoxy)-1H-benzo[d]imidazo-
l-1-yl)pyrimidin-4-amine as the first eluting isomer and 15 mg of
5-nitro-N-(pyridin-3-ylmethyl)-2-(6-(trifluoromethoxy)-1H-benzo[d]imidazo-
l-1-yl)pyrimidin-4-amine as the second eluting isomer.
[0149] High R.sub.f isomer: .sup.1H-NMR (CDCl.sub.3) .delta. 9.2
(s, 1H), 8.9 (s, 1H), 8.8 (m, 1H), 8.6 (s, 1H), 8.5 (d, 1H), 8.2
(d, 1H, assign: H-7 of benzimidazole ring), 7.6 (d, 1H), 7.6 (s,
1H, assign: H-4 of benzimidazole ring), 7.2 (dd, 1H), 4.9 (d,
2H).
[0150] Low R.sub.f isomer: .sup.1H-NMR (CDCl.sub.3) .delta. 9.2 (s,
1H), 8.9 (s, 1H), 8.8 (m, 1H), 8.6 (s, 1H), 8.5 (d, 1H), 8.2 (s,
1H, assign: H-7 of benzimidazole ring), 7.7 (d, 1H, assign: H-4 of
benzimidazole ring), 7.6 (d, 1H), 7.2 (dd, 1H), 7.1 (d, 1H), 4.9
(d, 2H).
Example 18
Non-regiospecific synthesis of benzimidazole purinone derivatives:
Synthesis of
9-(Pyridin-3-ylmethyl)-2-(6-(trifluoromethoxy)-1H-benzo[d]imidazol-1-yl)--
7H-purin-8(9H)-one (43) AND
9-(pyridin-3-ylmethyl)-2-(5-(trifluoromethoxy)-1H-benzo[d]imidazol-1-yl)--
7H-purin-8(9H)-one (45)
[0151] The title compounds were synthesized from
5-nitro-N-(pyridin-3-ylmethyl)-2-(6-(trifluoromethoxy)-1H-benzo[d]imidazo-
l-1-yl)pyrimidin-4-amine (42) and
5-nitro-N-(pyridin-3-ylmethyl)-2-(5-(trifluoromethoxy)-1H-benzo[d]imidazo-
l-1-yl)pyrimidin-4-amine (44) using the same procedures that were
used to convert (R)-tert-butyl
2,4-dimethoxybenzyl(5-nitro-6-(1-(pyridin-3-yl)ethylamino)pyridin-2-yl)ca-
rbamate to (R)-tert-butyl
2,4-dimethoxybenzyl(2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidaz-
o[4,5-b]pyridin-5-yl)carbamate (67; Example 22 below).
[0152] 6-Trifluoromethoxy isomer (non-salt): .sup.1H-NMR
(CD.sub.3OD) .delta. 9.3 (s, 1H), 8.8 (br s, 1H), 8.6 (s, 1H,
assign: H-7 of benzimdazole ring), 8.6 (m, 1H), 8.4 (s, 1H), 8.1
(d, 1H), 7.9 (d, 1H, assign: H-4 of benzimidazole ring), 7.5 (dd,
1H), 7.4 (dd, 1H), 5.4 (s, 2H).
[0153] 5-Trifluoromethoxy isomer (non-salt): .sup.1H-NMR
(CD.sub.3OD) .delta. 9.3 (s, 1H), 8.8 (s, 1H), 8.7 (d, 1H, assign:
H-7 of benzimdazole ring), 8.5 (d, 1H), 8.3 (s, 1H), 7.9 (d, 1H),
7.6 (s, 1H, assign: H-4 of benzimidazole ring), 7.4 (dd, 1H), 7.3
(dd, 1H), 5.3 (s, 2H).
Example 19
Non-regiospecific synthesis of an oxoimidazopyridine and an
imidazopyridine derivative: Synthesis of
5-(1H-Benzo[d]imidazol-1-yl)-3-(pyridin-3-ylmethyl)-1H-imidazo[4,5-b]pyri-
din-2(3H)-one (50) AND
5-(1H-benzo[d]imidazol-1-yl)3-(pyridin-3-ylmethyl)-3H-imidazo[4,5-b]pyrid-
ine (51)
[0154] ##STR43##
[0155]
6-(1H-Benzo[d]imidazol-1-yl)-3-nitro-N-(pyridin-3-ylmethyl)pyridin-
-2-amine (48). A solution of 2,6-dichloro-3-nitropyridine (46) (0.5
g) in acetonitrile (20 mL) was cooled to 0.degree. C. and treated
with triethylamine (0.36 mL) followed by 3-(aminomethyl)pyridine
(0.26 mL). The mixture was stirred for 30 minutes at 0.degree. C.
and eight hours at RT. The resulting solution, which contained the
intermediate 6-chloro-3-nitro-N-(pyridin-3-ylmethyl)pyridin-2-amine
(47), was transferred to a sealed tube containing benzimidazole
(0.84 g) and potassium carbonate (3 g) and heated at 70.degree. C.
for 16 h. The mixture was cooled and filtered. The precipitated was
washed with water and air-dried to provide 239 mg of the title
compound (48).
[0156]
5-(1H-Benzo[d]imidazol-1-yl)-3-(pyridin-3-ylmethyl)-1H-imidazo[4,5-
-b]pyridin-2(3H)-one (50) and
5-(1H-benzo[d]imidazol-1-yl)-3-(pyridin-3-ylmethyl)-3H-imidazo[4,5-b]pyri-
dine (51). A solution of
6-(1H-benzo[d]imidazol-1-yl)-3-nitro-N-(pyridin-3-ylmethyl)pyridin-2-amin-
e (48) (50 mg) in 1 mL of DMSO was treated with a solution of
Na.sub.2S.sub.2O.sub.4 (300 mg) in 1 mL of water. The mixture was
stirred for two hours and diluted with 50 mL of ethyl acetate. The
mixture was washed three times with 50 mL aliquots of saturated
sodium chloride solution, dried over sodium sulfate, filtered, and
concentrated in vacuo to provide the intermediate
6-(1H-benzo[d]imidazol-1-yl)-N2-(pyridin-3-ylmethyl)pyridine-2,3-diamine
(49). Half of the intermediate was dissolved in methylene chloride
(2 mL) and treated with 1,1'-carbonyldiimidazole (46 mg) at RT for
16 h. The resulting crude mixture was purified by preparative TLC
(1000 microns, 5% MeOH/CH.sub.2Cl.sub.2) to provide 7.1 mg of
5-(1H-benzo[d]imidazol-1-yl)-3-(pyridin-3-ylmethyl)-1H-imidazo[4,5-b]pyri-
din-2(3H)-one (50): .sup.1H-NMR (CDCl.sub.3) .delta. 10.0 (br s,
1H), 8.9 (s, 1H), 8.6 (d, 1H), 8.5 (s, 1H), 7.9 (m, 2H), 7.8 (m,
1H), 7.6 (d, 1H), 7.4 (m, 2H), 7.4 (m, 1H), 7.3 (d, 1H), 5.2 (s,
2H). The other half of the reduced intermediate was dissolved in 1
mL of formic acid and heated in a microwave at 220.degree. C. for
10 minutes. The mixture was concentrated in vacuo, diluted with
methylene chloride, and washed with saturated aqueous sodium
bicarbonate solution. The organic layer was separated, dried with
sodium sulfate, filtered, and concentrated in vacuo.
[0157] Purification by preparative TLC (1000 microns, 5%
MeOH/CH.sub.2Cl.sub.2) provided 3.5 mg of
5-(1H-benzo[d]imidazol-1-yl)-3-(pyridin-3-ylmethyl)-3H-imidazo[4,5-b]pyri-
dine (51): .sup.1H-NMR (CDCl.sub.3) .delta. 8.8 (s, 1H), 8.6 (d,
1H), 8.6 (s, 1H), 8.3 (d, 1H), 8.2 (s, 1H), 8.0 (m, 1H), 7.9 (m,
1H), 7.7 (dd, 1H), 7.6 (d, 1H), 7.4 (m, 2H), 7.3 (m, 1H).
Example 20
Regiospecific synthesis: Synthesis of
3-(9-(2,6-Difluorobenzyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo[d]imi-
dazole-5-carbonitrile
[0158] ##STR44## ##STR45##
[0159]
N.sup.2-(2,4-Dimethoxybenzyl)-N.sup.4-(2,6-diluorobenzyl)-5-nitrop-
yrimidine-2,4-diamine (53). 2,6-Difluorobenzylamine (0.24 mL) was
added dropwise over one min. to a solution of
2,4-dichloro-5-nitropyrimidine(40) (0.388 g) and DIEA (0.77 mL) in
THF in a cold bath set to -78.degree. C. The reaction mixture was
stirred for a further 15 min at -78.degree. C. then removed from
the cold bath and allowed to warm to RT. Additional DIEA (0.77 mL)
was added to the reaction intermediate
(N-(2,6-difluorobenzyl)-2-chloro-5-nitropyrimidin-4-amine) (52)
followed by the addition of 2,4-dimethoxybenzylamine (0.30 mL) and
the resulting mixture was stirred at RT overnight. Purification via
column chromatography (eluted with 1 and 2.5% MeOH/DCM) gave
N.sup.2-(2,4-dimethoxybenzyl)-N.sup.4-(2,6-difluorobenzyl)-5-nitropyrimid-
ine-2,4-diamine (53) (0.80 g), MH.sup.+=432.
[0160]
2-(2,4-Dimethoxybenzylamino)-9-(2,6-difluorobenzyl)-7H-purin-8(9H)-
-one (55). Raney Ni was added to a solution of
N.sup.2-(2,4-dimethoxybenzyl)-N.sup.4-(2,6-difluorobenzyl)-5-nitropyrimid-
ine-2,4-diamine (0.80 g) in THF (50 mL) under argon flush. The
suspension was evacuated, charged with hydrogen (balloon) and
stirred for 16 hr. The resulting mixture was filtered through a
celite plug that was thoroughly rinsed with THF and MeOH to yield
N.sup.2-(2,4-dimethoxybenzyl)-N.sup.4-(2,6-difluorobenzyl)pyrimidine-2,4,-
5-triamine (54) that was used as such in the next reaction.
[0161] Carbonyldiimidazole (0.93 g) was added to a solution of
N.sup.2-(2,4-dimethoxybenzyl)-N.sup.4-(2,6-difluorobenzyl)pyrimidine-2,4,-
5-triamine (54) in THF (20 mL) and the resultant mixture stirred at
RT overnight, then the solvents were removed under reduced pressure
and the taken up in EtOAc and washed trice with water. The organics
were dried, filtered and evaporated and purified via column
chromatography, elution with 2.5 and 4% MeOH/DCM, to yield
2-(2,4-Dimethoxybenzylamino)-9-(2,6-difluorobenzyl)-7H-purin-8(9H)-one
(55) (0.58 g), MH.sup.+=428.
[0162] tert-Butyl
9-(2,6-difluorobenzyl)-2-amino-8-oxo-8,9-dihydropurine-7-carboxylate
(57). A 1:1 solution of TFA/DCM (10 mL) was added to
2-(2,4-dimethoxybenzylamino)-9-(2,6-difluorobenzyl)-7H-purin-8(9H)-one
(55) (0.58 g) and stirred for 30 min, after which triethylsilane (2
mL) was added and the mixture was stirred an additional 4 hr. The
solvents were removed under in vacuo, the residue was taken up in
minimal MeOH and triturated with Et.sub.2O, to yield the TFA salt
of 9-(2,6-difluorobenzyl)-2-amino-7H-purin-8(9H)-one (56) (0.55 g),
MH.sup.+=278, as a salmon colored solid.
[0163] 9-(2,6-Difluorobenzyl)-2-amino-7H-purin-8(9H)-one (0.55 g)
was dissolved in a mixture of MeOH/ACN/DCM (40 mL), Et.sub.3N (2
mL) and di-tert-butyl dicarbonate (0.61 g) were added and the
mixture was stirred at RT overnight. The reaction solvents were
removed and the crude material was taken up in DCM and washed with
H.sub.2O, evaporated and purified via column chromatography,
elution with 2 and 3% MeOH/DCM gave the titled product (57) (0.36
g), MH.sup.+=378, MH.sup.+-Boc=278 (major), (M+Na).sup.+=400 and
(2M+Na).sup.+=777 were also observed.
[0164] tert-Butyl
9-(2,6-difluorobenzyl)-2-(5-cyano-2-nitrophenylamino)-8-oxo-8,9-dihydropu-
rine-7-carboxylate (58). Sodium hydride (88 mg, 95%) was added,
under argon flush, to a solution of tert-butyl
9-(2,6-difluorobenzyl)-2-amino-8-oxo-8,9-dihydropurine-7-carboxylate
(57) (191 mg) and 3-fluoro-4-nitrobenzonitrile (415 mg) in DMF (5
mL) at -40.degree. C. The reaction mixture was allowed to warm to
-20.degree. C. over 3 hr then quenched by the addition of sat. aq.
NH.sub.4Cl, once at RT the mixture was diluted with EtOAc and
separated. The organics were washed with brine (3.times.), dried,
filtered and evaporated, purified via column chromatography,
(eluted with DCM and 1 and 2.5% MeOH/DCM) to yield tert-Butyl
9-(2,6-difluorobenzyl)-2-(5-cyano-2-nitrophenylamino)-8-oxo-8,9-dihydropu-
rine-7-carboxylate (58) (288 mg), MH.sup.+=524.
[0165] tert-Butyl
9-(2,6-difluorobenzyl)-2-(6-cyano-1H-benzo[d]imidazol-1-yl)-8-oxo-8,9-dih-
ydropurine-7-carboxylate (60). A freshly prepared solution of
sodium hydrosulfite (tech, 1 g) and sodium bicarbonate (0.5 g) in
H.sub.2O (10 mL) was added to a solution of the above nitro
compound (58) (288 mg) in THF (10 mL). The mixture was stirred
vigorously for 5 min., extracted with DCM (3.times.), the combined
organics were washed with brine, dried, filtered and concentrated
to yield the intermediate tert-butyl
9-(2,6-difluorobenzyl)-2-(2-amino-5-cyanophenylamino)-8-oxo-8,9-dihydropu-
rine-7-carboxylate (59) that was used as such in the next step.
[0166] A catalytic amount of para-toluene sulfonic acid monohydrate
was added to a solution of the above amine intermediate and
trimethyl orthoformate (3 mL) in MeOH (10 mL). After 1 hr the crude
material was adsorbed onto silica gel and purified by column
chromatography (eluted with 1 and 2% MeOH/DCM) to yield tert-Butyl
9-(2,6-difluorobenzyl)-2-(6-cyano-1H-benzo[d]imidazol-1-yl)-8-oxo-8,9-dih-
ydropurine-7-carboxylate (60) (164 mg), MH.sup.+=504 and
MH.sup.+-BOC=404.
[0167]
3-(9-(2,6-Difluorobenzyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benz-
o[d]imidazole-5-carbonitrile (61). A 1:1 solution of TFA/DCM (10
mL) was added to tert-Butyl
9-(2,6-difluorobenzyl)-2-(6-cyano-1H-benzo[d]imidazol-1-yl)-8-oxo-8,9-dih-
ydropurine-7-carboxylate (60) and stirred for 1 hr. The solvents
were removed en vacuo and the resulting solid was triturated with
Et.sub.2O, and suspended in 6N HCl. Removal of solvents and
trituration with Et.sub.2O of the resulting solid gave the titled
compound (61) (68 mg) as a HCl salt, MH.sup.+=404, .sup.1H NMR
(d.sub.6-DMSO) .delta. 11.8 (s, 1H), 9.2 (s, 1H), 8.8 (s, 1H), 8.0
(s, 1H), 7.9 (d, 1H), 7.8 (broad s, 1H), 7.4 (d, 1H), 7.4 (quintet,
1H), 7.1 (m, 2H), 5.2 (s, 2H) ppm, .sup.19F NMR .delta. -114.3
(m).
Synthesis of
3-(8-Oxo-9-((R)-5,6,7,8-tetrahydroquinolin-5-yl)-8,9-dihydro-7H-purin-2-y-
l)-3H-benzo[d]imidazole-5-carbonitrile
[0168] ##STR46##
[0169] The title compound was synthesized from
(R)-5,6,7,8-tetrahydroquinolin-5-amine (obtained via Novozyme 435
resolution (J. Org. Chem., 2003, 68, 3546) in a manner similar to
that described in Example 29) via the procedure outlined in Example
20. .sup.1H-NMR (300 MHz, CDCl.sub.3+5% CD.sub.3OD) .delta. 8.9 (br
s, 1H), 8.7 (s, 1H), 8.6 (m, 1H), 8.3 (s, 1H), 7.8 (d, 1H), 7.7 (d,
2H), 7.6 (d, 1H), 7.5 (dd, 1H), 5.9 (dd, 1H), 3.3 (m 2H), 2.7-2.5
(m, 1H), 2.4-2.2 (m, 2H), 2.1-2.0 (m, 1H); MH.sup.+=386409.
Example 21
Synthesis of
3-(8-Oxo-9-(tetrahydro-2H-pyran-4-yl)-8,9-dihydro-7H-purin-2-yl)-3H-benzo-
[d]imidazole-5-carbonitrile (62)
[0170] ##STR47##
[0171] The title compound can be synthesized using the same
procedures as described for the synthesis of
3-(9-(2,6-difluorobenzyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo[d]imi-
dazole-5-carbonitrile (61, Example 20)
[0172] .sup.1H NMR (d.sub.6-DMSO) 11.71 (s, 1H), 9.34 (s, 1H), 8.94
(d, J=1.5 Hz, 1H), 8.38 (s, 1H), 8.00 (d, J=8.1 Hz, 1H), 7.79 (dd,
J=8.1, 1.5 Hz, 1H), 4.57 (m, 1H), 4.04 (m, 2H), 3.50 (m, 2H), 2.59
(m, 2H), 1.79 (m, 2H); Mass (MH+) 362.1.
Example 22
Regiospecific synthesis of an oxoimidazopyridine derivative:
Synthesis of
3-(2-oxo-3-((R)-1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrid-
in-5-yl)-3H-benzo[d]imidazole-5-carbonitrile
[0173] ##STR48## ##STR49##
[0174]
(R)-N6-(2,4-Dimethoxybenzyl)-3-nitro-N2-(1-(pyridin-3-yl)ethyl)pyr-
idine-2,6-diamine (64). A solution of 2,6-dichloro-5-nitropyridine
(46) (0.5 g) in THF (20 mL) was cooled to 0.degree. C. and treated
with 1.6 mL triethylarnine followed by (R)-l
-pyridin-3-yl-ethylamine (300 .mu.L). The mixture was stirred for
1.5 h, then warmed to RT and stirred another 20 h.
2,4-Dimethoxybenzylamine (0.8 mL) was added and the mixture was
heated at 50.degree. C. for four hours. The mixture was diluted
with ethyl acetate and washed twice with saturated sodium chloride
solution. The organic layer was separated, dried over sodium
sulfate, filtered, and concentrated. Column chromatography
(50.fwdarw.100% ethyl acetate in hexanes) provided 761 mg of
(R)-N6-(2,4-Dimethoxybenzyl)-3-nitro-N2-(1-(pyridin-3-yl)ethyl)pyridine-2-
,6-diamine (64).
[0175] (R)-tert-Butyl
2,4-dimethoxybenzyl(5-nitro-6-(1-(pyridin-3-yl)ethylamino)pyridin-2-yl)ca-
rbamate (65). A solution of
(R)-N6-(2,4-dimethoxybenzyl)-3-nitro-N2-(1-(pyridin-3-yl)ethyl)pyridine-2-
,6-diamine (64) (367 mg) in methylene chloride (20 mL) was treated
with di-tert-butyl dicarbonate (1.0 g) and 4-dimethylaminopyridine
(22 mg). The mixture was stirred for 16 h and concentrated in
vacuo. Column chromatography (50.fwdarw.100% ethyl acetate in
hexanes) provided 500 mg of (R)-tert-Butyl
2,4-dimethoxybenzyl(5-nitro-6-(1-(pyridin-3-yl)ethylamino)pyridin-2-yl)ca-
rbamate (65).
[0176] (R)-tert-Butyl
2,4-dimethoxybenzyl(2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidaz-
o[4,5-b]pyridin-5-yl)carbamate (67). A solution of (R)-tert-butyl
2,4-dimethoxybenzyl(5-nitro-6-(1-(pyridin-3-yl)ethylamino)pyridin-2-yl)ca-
rbamate (500 mg) in THF (25 mL) was treated with an aqueous
solution comprised of 2 g of Na.sub.2S.sub.2O.sub.4 and 1 g
NaHCO.sub.3 in 20 mL of water followed by 1 mL of methanol. The
mixture was stirred for 30 minutes, then diluted with ethyl acetate
and washed with saturated sodium chloride solution. The organic
layer was separated, dried over sodium sulfate, filtered, and
concentrated to provide the intermediate (R)-tert-butyl
2,4-dimethoxybenzyl(5-amino-6-(1-(pyridin-3-yl)ethylamino)pyridin-2-yl)ca-
rbamate (66). The intermediate was dissolved in THF (50 mL) and
treated with 1,1'-carbonyldiimidazole (0.5 g) at 50.degree. C. for
20 h. The mixture was concentrated and purified by column
chromatography (2.fwdarw.5% MeOH in methylene chloride) to provide
413 mg of (R)-tert-Butyl
2,4-dimethoxybenzyl(2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidaz-
o[4,5-b]pyridin-5-yl)carbamate (67).
[0177] (R)-tert-Butyl
5-amino-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydroimidazo[4,5-b]pyridine-
-1-carboxylate (69). A solution of (R)-tert-butyl
2,4-dimethoxybenzyl(2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidaz-
o[4,5-b]pyridin-5-yl)carbamate in methylene chloride (15 mL) was
treated with TFA (15 mL) and triethylsilane (1.0 mL) for one hour.
The mixture was concentrated to provide the intermediate
(R)-5-amino-3-(1-(pyridin-3-yl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
(68), which was dissolved in acetonitrile (50 mL) and stirred
vigorously with di-tert-butyl dicarbonate (1.0 g) and potassium
carbonate (3.0 g) for 2 h. Methylene chloride (200 mL) and water
(100 mL) was added and the organic layer was separated. The aqueous
layer was extracted with another 100 mL of methylene chloride. The
combined organic layers were separated, dried over sodium sulfate,
filtered, and concentrated. Column chromatography
(2.fwdarw.3.fwdarw.4% MeOH in methylene chloride) provided 235 mg
(R)-tert-Butyl
5-amino-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydroimidazo[4,5-b]pyridine-
-1-carboxylate (69).
[0178] (R)-tert-Butyl
5-(5-cyano-2-nitrophenylamino)-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydr-
oimidazo[4,5-b]pyridine-1-carboxylate (70). A solution of
(R)-tert-butyl
5-amino-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydroimidazo[4,5-b]pyridine-
-1-carboxylate (94 mg) and 3-fluoro-4-nitrobenzonitrile (225 mg) in
DMF (6 mL) was cooled to -25.degree. C. and treated with NaH (60%
w/w in mineral oil, 75 mg) and slowly allowed to warm to
-15.degree. C. The mixture was stirred for four hours between
-20.degree. C. and -15.degree. C., then diluted with EtOAc and
quenched with saturated ammonium chloride solution. The organic
phase was washed three times with brine, separated, dried over
sodium sulfate, filtered, and concentrated. Column chromatography
(2% MeOH in methylene chloride) provided 100 mg (R)-tert-Butyl
5-(5-cyano-2-nitrophenylamino)-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydr-
oimidazo[4,5-b]pyridine-1-carboxylate (70).
[0179] tert-Butyl
5-(6-cyano-1H-benzo[d]imidazol-1-yl)-2-oxo-3-((R)-1-(pyridin-3-yl)ethyl)--
2,3-dihydroimidazo[4,5-b]pyridine-1-carbo6xylate (72). A solution
of (R)-tert-butyl
5-(5-cyano-2-nitrophenylamino)-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydr-
oimidazo[4,5-b]pyridine-1-carboxylate (70) (100 mg) in THF (5 mL)
was treated with an aqueous solution comprised of 0.5 g of
Na.sub.2S.sub.2O.sub.4 and 0.25 g NaHCO.sub.3 in 5 mL of water. The
mixture went quickly from a red color to a slightly yellow color,
which indicated reduction of the nitro group. The mixture was
diluted with ethyl acetate and washed with saturated sodium
chloride solution. The organic layer was separated, dried over
sodium sulfate, filtered, and concentrated to provide the
intermediate (R)-tert-butyl
5-(2-amino-5-cyanophenylamino)-2-oxo-3-(1-(pyridin-3-yl)ethyl)-2,3-dihydr-
oimidazo[4,5-b]pyridine-1-carboxylate (71). The intermediate was
dissolved in THF (5 mL), DMF (1 mL), and trimethylorthoformate (2
mL). The mixture was treated with 10 mg of p-toluenesulfonic acid
and stirred for 20 h. The mixture was diluted with ethyl acetate
and washed once with saturated sodium bicarbonate and twice with
saturated NaCl solution. The organic layer was separated, dried
over sodium sulfate, filtered, and concentrated. Column
chromatography (2% MeOH in methylene chloride) provided 57 mg
tert-Butyl
5-(6-cyano-1H-benzo[d]imidazol-1-yl)-2-oxo-3-((R)-1-(pyridin-3-yl)ethyl)--
2,3-dihydroimidazo[4,5-b]pyridine-1-carboxylate (72).
[0180]
3-(2-oxo-3-((R)-1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidazo[4,5--
b]pyridin-5-yl)-3H-benzol[d]imidazole-5-carbonitrile (73). A
solution of tert-butyl
5-(6-cyano-1H-benzo[d]imidazol-1-yl)-2-oxo-3-((R)-1-(pyridin-3-yl)ethyl)--
2,3-dihydroimidazo[4,5-b]pyridine-1-carboxylate (72) (57 mg) in
methylene chloride (1 mL) was treated with TFA (1 mL) for one hour.
The mixture was concentrated and the resulting TFA salt was
converted to the HCl salt by dissolving it in 5 mL EtOH and adding
0.5 mL of conc. HCl, then concentrating the solution in vacuo. The
process was repeated and the resulting residue was dissolved in a
minimum amount of methanol and triturated with the addition of
ethyl ether. After 3 triturations,
3-(2-oxo-3-((R)-1-(pyridin-3-yl)ethyl)-2,3-dihydro-1H-imidazo[4,5-b]pyrid-
in-5-yl)-3H-benzo[d]imidazole-5-carbonitrile (73) HCl salt (39 mg)
was isolated as a tan colored solid: .sup.1H-NMR (CD.sub.3OD)
.delta. 9.9 (br s, 1H), 9.2 (s, 1H), 9.0 (m, 2H), 8.5 (s, 1H), 8.3
(m, 1H), 8.2 (m, 1H), 8.1 (d, 1H), 7.9 (d, 1H), 7.8 (d, 1H), 6.3
(q, 1H), 2.3 (d, 3H).
Example 23
Regiospecific synthesis: Synthesis of
9-(2,6-Difluorobenzyl)-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9H-purine
(78)
[0181] ##STR50##
[0182]
N.sup.4-(2,6-Difluorobenzyl)-N.sup.2-(5-fluoro-2-nitrophenyl)-5-ni-
tropyrimidine-2,4-diamine (75). Under an argon atmosphere, sodium
hydride (100 mg) was added to a solution of
N-(2,6-difluorobenzyl)-2-chloro-5-nitropyrimidin-4-amine (150 mg)
and 5-fluoro-2-nitroaniline (78 mg) in THF (10 mL) at RT. The
mixture was stirred for 30 min, quenched via the addition of sat.
aq. NH.sub.4Cl, extracted with DCM and purified by preparative HPLC
to give a low yield of
N.sup.4-(2,6-difluorobenzyl)-N.sup.2-(5-fluoro-2-nitrophenyl)-5-nitrop-
yrimidine-2,4-diamine (75) (24 mg), MH.sup.+=421.
[0183]
9-(2,6-Difluorobenzyl)-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9H-pu-
rine (78). A freshly prepared solution of sodium hydrosulfite
(tech, 100 mg) and sodium bicarbonate (50 mg) in H.sub.2O (5 mL)
was added to a solution of
N.sup.4-(2,6-difluorobenzyl)-N.sup.2-(5-fluoro-2-nitrophenyl)-5-nitropyri-
midine-2,4-diamine (75) (24 mg) in THF (5 mL). The mixture was
stirred vigorously for 30 min and extracted with DCM (3.times.).
The combined organics were washed with brine, dried, filtered and
concentrated to yield the intermediate
N.sup.4-(2,6-difluorobenzyl)-N.sup.2-(2-amino-5-fluorophenyl)pyrimidine-2-
,4,5-triamine (76) for use in the next step. A catalytic amount of
para-toluene sulfonic acid monohydrate was added to a solution of
the intermediate and trimethyl orthoformate (1 mL) in MeOH (2 mL),
after 2 hr conc. HCl (1 mL) was added and the mixture was heated at
50.degree. C. for 4 hr. The reaction solvents were removed and the
crude material was purified via preparative HPLC to give
9-(2,6-Difluorobenzyl)-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9H-purine
(78) as the TFA salt in low yield (0.8 mg) MH.sup.+=404, .sup.1H
NMR (5% CD.sub.3OD/CDCl.sub.3) .delta. 9.1 (s, 1H), 9.0 (s, 1H),
8.3 (d, 1H), 8.2 (s, 1H), 7.6 (m, 1H), 7.0 (t, 1H), 6.9 (m, 2H),
5.5 (s, 2H) ppm, .sup.19F NMR .delta.-76.6 (s, TFA), -114.5 (m),
-117.1 (m).
Example 24
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(cis-3-methyl-tetrahydro-2H-pyran-4-yl)-7H-
-purin-8(9H)-one
[0184] ##STR51##
[0185]
2-Chloro-N-(cis-3-methyl-tetrahydro-2H-pyran-4-yl)-5-nitropyrimidi-
n-4-amine. To a suspension of 0.24 g of the hydrochloride salt of
cis-3-methyl-tetrahydro-2H-pyran-4-amine (WO 2004/041161) and DIEA
(1.5 mL) in THF (10 mL) at -78.degree. C. was added
2,4-dichloro-5-nitropyrimidine (0.72 g). The mixture was allowed to
slowly reach room temperature and stirred for 16 hours. The mixture
was diluted with EtOAc and washed 3 times with brine. The organic
layer was separated, dried over sodium sulfate, and concentrated in
vacuo. Column chromatography (20.fwdarw.40% EtOAc/hexanes) provided
289 mg of the title compound.
[0186]
2-(1H-Benzo[d]imidazol-1-yl)-N-(cis-3-methyl-tetrahydro-2H-pyran-4-
-yl)-5-nitropyrimidin-4-amine. To a solution of
2-chloro-N-(cis-3-methyl-tetrahydro-2H-pyran-4-yl)-5-nitropyrimidin-4-ami-
ne (115 mg) in acetonitrile (5 mL) was added potassium carbonate
(300 mg) and benzimidazole (150 mg). The mixture was stirred at
70.degree. C. for 2.5 hours. After diluting with 70 mL EtOAc, the
mixture was washed with brine, dried over sodium sulfate, and
concentrated in vacuo. Column chromatography (50.fwdarw.100%
EtOAc/hexanes) provided 99 mg of the title compound.
[0187]
2-(1H-Benzo[d]imidazol-1-yl)-9-(cis-3-methyl-tetrahydro-2H-pyran-4-
-yl)-7H-purin-8(9H)-one. To a solution of
2-(1H-benzo[d]imidazol-1-yl)-N-(cis-3-methyl-tetrahydro-2H-pyran-4-yl)-5--
nitropyrimidin-4-amine (51 mg) in THF (10 mL) was added a solution
of sodium hydrosulfite (300 mg) and sodium bicarbonate (150 mg) in
water (10 mL). The mixture briefly became blue followed by
colorless. Methanol (1 mL) was added to maintain the homogeneity of
the solution. The mixture was diluted with 70 mL EtOAc and washed
twice with brine. The aqueous washes were extracted with another 50
mL of EtOAc and then the combined organic layers were dried over
sodium sulfate and concentrated in vacuo to provide
2-(1H-benzo[d]imidazol-1-yl)-N4-(cis-3-methyl-tetrahydro-2H-pyran-4-yl)py-
rimidine-4,5-diamine. The diamine intermediate was dissolved in THF
(5 mL) and treated with 1,1'-carbonyldiimidazole (80 mg) at
50.degree. C. for 16 hours. The mixture was diluted with 50 mL
EtOAc and washed 3 times with brine. The organic layer was
separated, dried over sodium sulfate, and concentrated in vacuo.
Column chromatography (2.fwdarw.4% MeOH/DCM) provided 19.3 mg of
the title compound. .sup.1H-NMR (300 MHz, 5% CD.sub.3OD in
CDCl.sub.3) .delta. 8.9 (s, 1H), 8.5 (d, 1H), 8.2 (s, 1H), 7.8 (d,
1H), 7.4 (t, 1H), 7.3 (t, 1H), 4.7 (m, 1H), 4.2 (d(br), 1H), 3.9
(d, 1H), 3.7 (d, 1H), 3.5 (m, 2H), 2.3 (t(br), 1H), 1.8 (d(br),
1H), 1.2 (d, 3H).
Synthesis of
4-(2-(1H-Benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)-1,2,3,4-tetr-
ahydronaphthalene-1-carbonitrile.
[0188] ##STR52##
[0189] The title compound was synthesized from
4-amino-3,4-dihydro-2H-chromene-8-carbonitrile via the procedure
described in Example 24. .sup.1H NMR (300 MHz, d.sub.6-DMSO)
.delta. 8.87 (s, 1H), 8.57 (s, 1H), 7.70 (m, 3H), 7.31 (m, 3H),
6.94 (t, J=7.8 Hz, 1H), 5.90 (m, 1H), 4.61 (m, 2H), 2.73 (m, 1H),
2.33 (m, I1H); Mass (MH+) 410.1.
Synthesis of
cis/trans-4-(2-(1H-Benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)-1,-
2,3,4-tetrahydronaphthalen-1-yl acetate
[0190] ##STR53##
[0191] The title compound was synthesized from
4-amino-1,2,3,4-tetrahydronaphthalen-1-yl acetate via the procedure
described in Example 24. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
10.56 (s, 0.66H), 10.48 (s, 0.34H), 8.87 (s, 0.66H), 8.83 (s,
0.34H), 8.30 (s, 0.66H), 8.27 (s, 0.34H), 7.76-7.02 (m, 8H), 6.35
(m, 0.34H), 6.17 (m, 0.66H), 5.93 (s, 0.34H), 5.79 (m, 0.66H),
2.90-2.01 (m, 7H); Mass (MH+) 441.0.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(1-methyl-4,5,6,7-tetrahydro-1H-indol-4-yl-
)-7H-purin-8(9H)-one
[0192] ##STR54##
[0193] The title compound was synthesized from
1-methyl-4,5,6,7-tetrahydro-1H-indol-4-amine via the procedure
described in Example 24. .sup.1H NMR (CD.sub.3OD) .delta. 8.90 (s,
1H), 8.25 (s, 1H), 7.88 (m, 1H), 7.68 (m, 1H), 7.32 (m, 2H), 6.51
(d, J=2.7 Hz, 1H), 5.66 (m, 2H), 3.65 (s, 3H), 2.80 (m, 2H), 2.46
(s, 1H), 2.19 (m, 2H), 1.96 (m, 1H); Mass (MH+) 386.0.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(oxepan-4-yl)-7H-purin-8(9H-one
[0194] ##STR55##
[0195] The title compound was synthesized from oxepan-4-amine via
the procedure described in Example 24. .sup.1H-NMR (CDCl.sub.3)
.delta. 9.0 (s, 1H), 8.5 (d, 1H), 8.1 (s, 1H), 7.7 (d, 1H), 7.3 (m,
2H), 4.6 (t, 1H), 3.9 (m, 2H), 3.8 (m, 2H), 2.7 (m, 2H), 2.0 (m,
4H), ppm.
Synthesis of
4-(2-(1H-Benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)chroman-6-car-
bonitrile
[0196] ##STR56##
[0197] The title compound was synthesized from
4-amino-3,4-dihydro-2H-chromene-6-carbonitrile via the procedure
described in Example 24. .sup.1H-NMR of TFA salt (300 MHz,
CDCl.sub.3) .delta. 9.4 (s, 1H), 9.2 (s, 1H), 8.4 (s, 1H), 8.0 (d,
1H), 7.9 (d, 1H), 7.4-7.6 (m, 3H), 7.1-7.2 (m, 2H), 5.8-6.0 (m,
1H), 4.6-4.7 (m, 1H), 4.4-4.5 (m, 1H), 2.8-3.0 (m, 1H), 2.2-2.4 (m,
1H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(4-fluoro-2,3-dihydrobenzofuran-3-yl)-7H-p-
urin-8(9H)-one
[0198] ##STR57##
[0199] The title compound was synthesized from
4-fluoro-2,3-dihydrobenzofuran-3-amine (prepared in example 37) via
the procedure described in Example 24. .sup.1H-NMR (300 MHz,
CDCl.sub.3+5% CD.sub.3OD) .delta. 8.7 (s, 1H), 8.1-8.2 (m, 1H), 8.1
(s, 1H), 7.6-7.7 (m, 1H), 7.1-7.3 (m, 3H), 6.7 (d, 1H), 6.5 (d,
1H), 6.3-6.4 (m, 1H), 4.8-4.9 (m, 2H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(2,3,4,5-tetrahydrobenzo[b]oxepin-
-5-yl)-7H-purin-8(9H)-one
[0200] ##STR58##
[0201] The title compound was synthesized from
2,3,4,5-tetrahydrobenzo[b]oxepin-5-amine (obtained from the
corresponding ketone (J. Med. Chem., 2004, 47, 5612) using the same
procedures outlined for the 4-aminochromanes) via the procedure
described in Example 24. .sup.1H-NMR (300 MHz, CDCl.sub.3+5%
CD.sub.3OD) .delta. 8.8 (s, 1H), 8.2 (s, 1H), 8.0 (dd, 1H), 7.6-7.7
(m, 1H), 6.95-7.2 (m, 3H), 6.9 (t, 1H), 6.6 (d, 1H), 5.9 (d, 1H),
4.4-4.5 (m, 1H), 3.7-3.9 (m, 1H), 2.8-3.0 (m, 1H), 2.0-2.3 (m,
3H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(1-(2-chloropyridin-3-yl)ethyl)-7H-purin-8-
(9H)-one
[0202] ##STR59##
[0203] The title compound was synthesized from
3-(.alpha.-aminoethyl)-2-chloropyridine via the procedure described
in Example 24. .sup.1H-NMR (CDCl.sub.3) .delta. 8.8 (s, 1H), 8.4
(d, 1H), 8.3 (d, 1H), 8.2 (d, 1H), 8.1 (s, 1H), 7.7 (d, 1H), 7.3
(m, 3H), 3.4 (m, 1H), 2.0 (d, 3H), ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(5-fluoro-1,2,3,4-tetrahydronaphthalen-1-y-
l)-7H-purin-8(9H)-one
[0204] ##STR60##
[0205] The title compound was synthesized from
5-fluoro-1,2,3,4-tetrahydronaphthalen-1-amine via the procedure
described in Example 24. .sup.1H-NMR (CDCl.sub.3) .delta. 8.7 (s,
1H), 8.1 (s, 1H), 7.6 (d, 1H), 7.5 (d, 1H), 7.2 (q, 2H), 6.9 (m,
2H), 6.7 (d, 1H), 5.7 (m, 1H), 3.3 (s, 2H), 2.8 (m, 2H), 2.4 (q,
1H), 2.1 (m, 1H), 1.8 (m, 1H), ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(quinolin-3-ylmethyl)-7H-purin-8(9H)-one
[0206] ##STR61##
[0207] The title compound was synthesized from
3-aminomethylquinoline via the procedure described in Example 24.
.sup.1H-NMR (CDCl.sub.3) .delta. 9.8 (s, 1H), 9.4 (s, 1H), 8.9 (s,
1H), 8.6 (d, 1H), 8.3 (m, 2H), 8.1 (d, 1H), 7.9 (m, 2H), 7.8 (d,
1H), 7.5 (t, 2H), 5.5 (s, 2H) ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(3-methoxypropyl)-7H-purin-8(9H)-one
[0208] ##STR62##
[0209] The title compound was synthesized from
3-methoxypropan-1-amine via the procedure described in Example 24.
.sup.1H NMR (CD.sub.3OD) .delta.9.71 (s, 1H), 8.81 (d, 1H), 8.30
(s, 1H), 7.83 (d, 1H), 7.57 (m, 2H), 4.15 (t, 2H), 3.50 (t, 2H),
3.28 (s, 3H), 2.13 (m, 2H); MS (MH.sup.+) 325.2.
Synthesis of
9-(Tetrahydro-2H-pyran-4-yl)-2-(6-(trifluoromethyl)-1H-benzo[d]imidazol-1-
-yl)-7H-purin-8(9H)-one
[0210] ##STR63##
[0211] The title compound was synthesized from
3-methoxypropan-1-amine via the procedure described in Example 24.
.sup.1H NMR (CD.sub.3OD+CHCl.sub.3) .delta.9.49 (s, 1H), 9.04 (s,
1H), 8.33 (s, 1H), 7.94 (d, 1H), 7.72 (m, 1H), 4.67 (m, 1H), 4.17
(m, 2H), 3.61 (m, 2H), 2.81 (m, 2H), 1.85 (m, 2H); MS (MH.sup.+)
405.1.
Synthesis of
2-(5,6-Difluoro-1H-benzo[d]imidazol-1-yl)-9-(pyridin-3-ylmethyl)-7H-purin-
-8(9H)-one
[0212] ##STR64##
[0213] The title compound was synthesized from
5,6-difluoro-1H-benzo[d]imidazole (Example 4) via the procedure
described in Example 24. .sup.1H-NMR (300 MHz, CD.sub.3OD) .delta.
9.2 (s, 1H), 9.0 (br, 1H), 8.7 (br, 1H), 8.6 (d, 1H), 8.4 (dd, 1H),
8.3 (s, 1H), 7.9 (dd, 1H), 7.6 (m, 2H), 5.4 (s, 2H).
Synthesis of
2-(6-Chloro-5-fluoro-1H-benzo[d]imidazol-1-yl)-9-(1-(pyridin-3-yl)ethyl)--
7H-purin-8(9H)-one
[0214] ##STR65##
[0215] The title compound was synthesized from
6-chloro-5-fluorobenzimidazole via the procedure described in
Example 24. .sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 9.2 (bs, 1H),
9.0 (m, 1H), 8.9-8.5 (m, 2H), 8.4 (m, 2H), 7.9 (m, 2H), 7.7 (m,
1H), 6.2 (q, 1H), 2.2 (d, 3H).
Synthesis of
2-(5,6-Dimethoxy-1H-benzo[d]imidazol-1-yl)-9-(pyridin-3-ylmethyl)-7H-puri-
n-8(9H)-one
[0216] ##STR66## The title compound was synthesized from
5,6-dimethoxy-1H-benzo[d]imidazole via the procedure described in
Example 24. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.6 (s, 1H),
8.5 (S, 1H), 8.4 (S, 1H), 8.0 (s, 1H), 7.9 (s, 1H), 7.5 (d, 1H),
7.3 (d, 1H), 6.9 (t, 1H), 4.8 (s, 2H), 3.7 (s, 6H).
[0217] Procedure for the synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(8-fluoroisochroman-4-yl)-7H-purin-8(9H)-o-
ne. ##STR67##
8-Fluoro-3,4-dihydro-1H-isochromen-4-amine
[0218] ##STR68##
[0219] (2-Fluoro-6-iodophenyl)methanol. To a stirred solution of
2-fluoro-6-iodobenzoic acid (10 mmol) in THF (6.5 mL) and
trimethylborate (3.25 mL) was added borane dimethylsulfide (12
mmol) slowly, maintaining the internal temperature at 20-25.degree.
C. Stirring was continued for an additional 16 h at room
temperature and then methanol (1.44 mL) was added cautiously. The
resulted solution was evaporated in vacuo to offer 2.5 g of the
title compound as a pale yellow oil.
[0220] 2-(Allyloxymethyl)-1-fluoro-3-iodobenzene. To a solution of
(2-fluoro-6-iodophenyl)methanol (10 mmol) in 50 mL of THF was added
NaH (12 mmol) in small portions at room temperature. After the
addition, allylbromide (12 mmol) was added slowly via syringe. The
reaction mixture was stirred 16 hours at room temperature. The
resulting white heterogeneous mixture was quenched with water and
then diluted with 100 mL of Et.sub.2O, followed by washing with
water and brine. The organic layer was dried over MgSO.sub.4 and
then concentrated to dryness in vacuo to offer 2.8 g of the title
compound.
[0221] 8-Fluoro-4-methylene-3,4-dihydro-1H-isochromene.
2-(Allyloxymethyl)-1-fluoro-3-iodobenzene (1 g) was dissolved in 20
mL of CH.sub.3CN and 2.4 mL of Et.sub.3N. The reaction solution was
vacuum degassed three times, followed by the addition of
Pd(OAc).sub.2 (37.6 mg) and PPh.sub.3 (89.8 mg). The resulting
mixture was heated at 80.degree. C. for 16 hours. The reaction
mixture was cooled to room temperature and diluted with Et.sub.2O.
The organic layer was washed with 1N HCl, 10% aqueous NaHCO.sub.3,
brine, and then dried over Na.sub.2SO.sub.4. After filtration, the
filtrate was concentrated to dryness to offer a brown oil, which
was purified by flash chromatography to offer 200 mg of the title
compound.
[0222] 8-Fluoro-1H-isochromen-4(3H)-one.
8-Fluoro-4-methylene-3,4-dihydro-1H-isochromene (400 mg) was
dissolved in a solution of 1:1 MeOH/DCM (50 mL) and 1 mL of
pyridine added. The mixture was chilled to -78.degree. C. and ozone
was bubbled through the mixture for 40 min. The reaction monitored
by TLC. The mixture was purged with nitrogen at -78.degree. C. for
10 min and then treated with PPh.sub.3. After concentration, the
resulting residue was purified by preparative TLC to offer 300 mg
of the title compound.
[0223] 8-Fluoro-3,4-dihydro-1H-isochromen-4-amine. The title
compound was prepared from 8-fluoro-1H-isochromen-4(3H)-one via the
procedure described in Example 29. .sup.1H-NMR (300 MHz,
CD.sub.3OD) .delta. 7.4 (m, 1H), 7.3 (d, 1), 7.2 (m, 1H), 5.0 (d,
1H), 4.7 (d, 1H), 4.4 (s, 1H), 4.2 (d, 1H) 3.9 (d, 1H) ppm.
[0224]
2-(1H-Benzo[d]imidazol-1-yl)-9-(8-fluoroisochroman-4-yl)-7H-purin--
8(9H)-one. The title compound was synthesized from
8-fluoroisochroman-4-amine via the procedure described in Example
24. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.7 (bs, 1H), 8.2 (s,
1H), 7.6 (m, 2H), 7.3-6.9 (m, 4H), 6.8 (d, 1H), 5.8 (t, 1H), 5.0
(s, 2H), 4.2 (m, 2H).
Example 25
[0225] ##STR69##
[0226]
2-(5,6-Dichloro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-
-yl)-7H-purin-8(9H)-one. A solution of
(R)-2-chloro-N-(8-fluorochroman-4-yl)-5-nitropyrimidin-4-amine in
acetonitrile was treated with 5,6-dichlorobenzimidazole and
potassium carbonate. The mixture was stirred at reflux for 6 hours,
cooled to room temperature, diluted with 150 mL of EtOAc, and
washed twice with 30 mL portions of water. The organic layer was
separated, dried with magnesium sulfate, filtered, and concentrated
in vacuo. Purification by column chromatography (2% MeOH/DCM) gave
the intermediate nitropyrimidinamine. The title compound was
synthesized from the intermediate nitropyrimidinamine via the
procedures described in Example 24. .sup.1H-NMR (300 MHz,
CDCl.sub.3) .delta. 8.7 (s, 1H), 8.3 (s, 1H), 8.2 (s, 1H), 7.8 (t,
1H), 7.0 (t, 1H), 6.6 (m, 2H), 5.9 (t, 1H), 4.6 (m, 1H), 4.4 (m,
1H), 3.0 (m, 1H), 2.3 (m, 1H), ##STR70##
[0227]
2-(5,6-Dimethyl-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-
-yl)-7H-purin-8(9H)-one. The title compound was synthesized from
5,6-dichlorobenzimidazole via the procedures described in Example
25. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.6 (s, 1H), 8.8 (s,
1H), 8.3 (s, 1H), 8.0 (s, 1H), 7.6 (s, 1H), 7.0 (t, 1H), 6.7 (m,
1H), 5.9 (t, 1H), 4.7 (m, 1H), 4.5 (m, 1H), 3.2 (m, 2H), 2.4 (d,
6H). ##STR71##
[0228]
9-((R)-8-Fluorochroman-4-yl)-2-(6-(trifluoromethyl)-1H-benzo[d]imi-
dazol-1-yl)-7H-purin-8(9H)-one and
9-((R)-8-fluorochroman-4-yl)-2-(5-(trifluoromethyl)-1H-benzo[d]imidazol-1-
-yl)-7H-purin-8(9H)-one. The title compound was synthesized from
5-trifluoromethylbenzimidazole (US 2004/0087601) via the procedures
described in Example 25. Purification by column chromatography (2%
MeOH/DCM) eluted the 6-trifluoromethyl isomer first (.sup.1H-NMR
(300 MHz, CDCl.sub.3) .delta. 8.8 (d, 2H), 8.4 (s, 1H), 7.9 (d,
1H), 7.6 (d, 2H), 7.0 (t, 1H), 6.7 (m, 2H), 5.9 (t, 1H), 4.7 (m,
1H), 4.4 (m, 1H), 3.0 (m, 1H), 2.4 (m, 1H).) followed by the
5-trifluoromethyl isomer (.sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.
9.0 (s, 1H), 8.4 (s, 1H), 8.1 (s, 1H), 8.0 (d, 1H), 7.6 (d, 2H),
7.0 (m, 1H), 6.8 (m, 2H), 5.9 (t, 1H), 4.7 (m, 1H), 4.4 (m, 1H),
2.9 (m, 1H), 2.4 (m, 1H). ##STR72##
[0229]
N-((R)-8-Fluorochroman-4-yl)-2-(3H-imidazo[4,5-c]pyridin-3-yl)-5-n-
itropyrimidin-4-amine and
N-((R)-8-fluorochroman-4-yl)-2-(1H-imidazo[4,5-c]pyridin-1-yl)-5-nitropyr-
imidin-4-amine. The title compound was synthesized from
5-azabenzimidazole via the procedure described in Example 25.
Purification by column chromatography (1% MeOH/DCM) provided
N-((R)-8-fluorochroman-4-yl)-2-(3H-imidazo[4,5-c]pyridin-3-yl)-5-nitropyr-
imidin-4-amine as the first eluting isomer: (.sup.1H-NMR (300 MHz,
CDCl.sub.3) .delta. 9.8 (s, 1H), 9.4 (s, 1H), 9.2 (s, 1H), 8.9 (d,
1H), 8.6 (d, 1H), 7.8 (d, 1H), 7.1 (m, 2H), 6.9 (m, 1H), 5.8 (q,
1H), 4.6 (m, 1H), 4.4 (m, 1H), 2.6 (m, 1H), 2.4 (m, 1H).).
N-((R)-8-Fluorochroman-4-yl)-2-(1H-imidazo[4,5-c]pyridin-1-yl)-5-nitropyr-
imidin-4-amine eluted second: (.sup.1H-NMR (300 MHz, CDCl.sub.3)
.delta. 9.4 (s, 1H), 9.2 (s, 1H), 9.1 (s, 1H), 8.9 (d, 1H), 8.6 (d,
1H), 8.4 (d, 1H), 7.1 (m, 2H), 6.9 (m, 1H), 5.7 (q, 1H), 4.5 (m,
1H), 4.4 (m, 1H), 2.6 (m, 1H), 2.4 (m, 1H).). ##STR73##
[0230]
9-((R)-8-fluorochroman-4-yl)-2-(3H-imidazo[4,5-c]pyridin-3-yl)-7H--
purin-8(9H)-one. The title compound was synthesized from
N-((R)-8-fluorochroman-4-yl)-2-(3H-imidazo[4,5-c]pyridin-3-yl)-5-nitropyr-
imidin-4-amine via the procedures described in Example 24.
.sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.8 (s, 1H), 9.4 (s, 1H),
8.6 (d, 1H), 8.3 (m, 2H), 7.0 (t, 1H), 6.7 (m, 2H), 5.9 (t, 1H),
4.6 (m, 1H), 4.4 (m, 1H), 2.8 (m, 1H), 2.4 (m, 1H). ##STR74##
[0231]
9-((R)-8-fluorochroman-4-yl)-2-(1H-imidazo[4,5-c]pyridin-1-yl)-7H--
purin-8(9H)-one. The title compound was synthesized from
N-((R)-8-fluorochroman-4-yl)-2-(1H-imidazo[4,5-c]pyridin-1-yl)-5-nitropyr-
imidin-4-amine via the procedures described in Example 24.
.sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.3 (d, 2H), 8.4 (d, 1H),
8.3 (d, 2H), 7.0 (t, 1H), 6.7 (m, 2H), 5.9 (t, 1H), 4.6 (m, 1H),
4.4 (m, 1H), 2.8 (m, 1H), 2.4 (m, 1H).
Synthesis of
2-(5,6-Difluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-7H-
-purin-8(9H)-one
[0232] ##STR75##
[0233] The title compound was synthesized from
5,6-difluoro-1H-benzo[d]imidazole (Example 4) via the procedure
described in Example 25. .sup.1H-NMR (CDCl.sub.3) .delta. 9.2 (s,
1H), 8.8 (s, 1H), 8.3 (s, 1H), 7.8 (t, 1H), 7.6 (t, 1H), 7.1 (t,
1H), 6.8 (m, 1H), 5.9 (t, 1H), 4.7 (m, 1H), 4.4 (m, 1H), 3.6 (s,
3H), 2.9 (m, 1H), 2.4 (m, 1H), ppm.
Synthesis of
9-(R)-Chroman-4-yl-2-(6-methanesulfonyl-benzoimidazol-1-yl)-7,9-dihydro-p-
urin-8-one and
9-(R)-Chroman-4-yl-2-(5-methanesulfonyl-benzoimidazol-1-yl)-7,9-dihydro-p-
urin-8-one
[0234] ##STR76##
[0235] The title compounds were synthesized from
5-methylsulfonylbenzimidazole (prepared as per examples 4 and 5)
via the procedure described in Example 25. Purification by column
chromatography (2% MeOH/DCM) provided
9-(R)-chroman-4-yl-2-(6-methanesulfonyl-benzoimidazol-1-yl)-7,9-dihydro-p-
urin-8-one as the first eluting isomer: .sup.1H-NMR (CDCl.sub.3)
.delta. 9.2 (s, 1H), 8.8 (s, 1H), 8.3 (s, 1H), 7.9 (d, 2H), 7.2 (t,
1H), 7.0 (d, 1H), 6.9 (d, 1H), 6.8 (t, 1H), 5.9 (t, 1H), 4.6 (m,
1H), 4.4 (t, 1H), 3.1 (s, 3H), 2.9 (m, 1H), 2.4 (m, 1H) ppm, and
9-(R)-Chroman-4-yl-2-(5-methanesulfonyl-benzoimidazol-1-yl)-7,9-dihydro-p-
urin-8-one as the second eluting isomer .sup.1H-NMR (CDCl.sub.3)
.delta. 8.9 (s, 1H), 8.4 (s, 1H), 8.3 (s, 1H), 8.0 (d, 1H), 7.8 (d,
1H), 7.2 (m, 1H), 7.1 (d, 1H), 6.9 (d, 1H), 6.8 (t, 1H), 5.9 (t,
1H), 4.5 (m, 1H), 4.4 (t, 1H), 3.1 (s, 3H), 2.9 (m, 1H), 2.4 (m,
1H) ppm.
Synthesis of
9-((R)-8-Fluorochroman-4-yl)-2-(7H-purin-7-yl)-7H-purin-8(9H)-one
[0236] ##STR77##
[0237] The title compound was synthesized from 7H-purine via the
procedure described in Example 25. .sup.1H-NMR (CDCl.sub.3) .delta.
9.4 (s, 1H), 9.2 (s, 1H), 9.1 (s, 1H), 8.3 (s, 1H), 7.8 (s, 1H),
7.0 (m, 1H), 6.8 (d, 2H), 5.9 (t, 1H), 4.6 (m, 1H), 4.4 (m, 1H),
2.9 (m, 1H), 2.4 (m, 1H) ppm.
Synthesis of
2-(1H-Benzo[d][1,2,3]triazol-1-yl)-9-((R)-8-fluorochroman-4yl)-7H-purin-8-
(9H)-one
[0238] ##STR78##
[0239] The title compound was synthesized from
1H-benzo[d][1,2,3]triazole via the procedure described in Example
25. .sup.1H-NMR (5% CD.sub.3OD in CDCl.sub.3) .delta. 8.4 (br s,
1H), 8.0 (d, 1H), 7.5-7.3 (m, 3H), 7.0-6.9 (m, 1H), 6.7 (m, 2H),
5.9 (dd, 1H), 4.5 (dt, 1H), 4.3 (td, 1H), 2.9-2.8 (m, 1H), 2.4-2.2
(m, 1H) ppm.
Example 26
Synthesis of
3-(9-((R)-6,8-difluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-b-
enzo[d]imidazole-5-carbonitrile
[0240] ##STR79##
[0241] 4-(2,4-dimethoxybenzylamino)-3-nitrobenzonitrile. A solution
of 4-fluoro-3-nitrobenzonitrile (5.0 g) in THF (100 mL) was treated
with DIEA (6.3 mL) and 2,4-dimethoxybenzylamine (5.0 mL), and then
stirred for 24 h. The solvent was evaporated and the crude mixture
was dissolved in EtOAc (100 mL). The solution was washed once with
1 M HCl and twice with saturated aqueous NaCl (100 mL each). The
organic layer was separated, dried over Na.sub.2SO.sub.4, filtered,
and concentrated in vacuo. Column chromatography (20% EtOAc/DCM)
provided 9.25 g of the title compound. ##STR80##
[0242] 4-(2,4-dimethoxybenzylamino)-3-aminobenzonitrile. A solution
of 4-(2,4-dimethoxybenzylamino)-3-nitrobenzonitrile (4.54 g) in THF
(400 mL) was treated with a solution of sodium hydrosulfite (20 g)
and sodium bicarbonate (10 g) in distilled water (350 mL). Enough
methanol was immediately added (50 mL) to maintain a homogeneous
solution. After 15 minutes, EtOAc (500 mL) and saturated aqueous
NaCl (500 mL) were added and the organic layer was separated. The
aqueous layer was extracted again with 400 mL EtOAc. The combined
organic layers were washed with saturated aqueous NaCl (500 mL) and
separated. The organic phase was dried over Na.sub.2SO.sub.4,
filtered, and concentrated in vacuo to provide 4.33 g of the title
compound. ##STR81##
[0243]
4-(2,4-dimethoxybenzylamino)-3-(5-nitro-4-thiocyanatopyrimidin-2-y-
lamino)benzonitrile. A solution of
4-(2,4-dimethoxybenzylamino)-3-aminobenzonitrile (3.9 g) in
acetonitrile (100 mL) was cooled to 0.degree. C. and treated with
potassium carbonate (6.3 g) followed by a solution containing 3 g
of 2-chloro-5-nitro-4-thiocyanatopyrimidine (WO 2003/032994) in
acetonitrile (50 mL). The mixture was stirred for 30 minutes at
0.degree. C. and 30 minutes at room temperature resulting in the
formation of a precipitate. The mixture was quenched at 0.degree.
C. by the addition of 4% acetic acid (150 mL) and filtered. The
precipitate was swirled in 100 mL acetonitrile and filtered again.
The precipitate was washed with acetonitrile, which resulted in the
slow dissolution of product into the filtrate. After air-drying,
1.5 g of the title compound remained as the precipitate cake. The
filtrate was extracted with EtOAc, dried over Na.sub.2SO.sub.4,
filtered, and concentrated in vacuo. Column chromatography
(0.fwdarw.20% EtOAc/DCM) and recrystallization from acetonitrile
provided 0.415 g of additional title compound. ##STR82##
[0244]
(R)-4-(2,4-dimethoxybenzylamino)-3-(4-(6,8-difluorochroman-4-ylami-
no)-5-nitropyrimidin-2-ylamino)benzonitrile. A partial suspension
of
4-(2,4-dimethoxybenzylamino)-3-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)-
benzonitrile (415 mg) in 40 mL of acetonitrile was treated with a
solution of (R)-6,8-difluorochroman-4-amine HCl salt (320 mg) in
DMSO (10 mL) followed by potassium carbonate (1.0 g). The mixture
was stirred for 24 hours, and then diluted with EtOAc (200 mL). The
mixture was washed once with saturated aqueous ammonium chloride
(200 mL) and 3 times with saturated aqueous NaCl (200 mL each). The
organic layer was separated, dried over Na.sub.2SO.sub.4, filtered,
and concentrated in vacuo. Column chromatography (20.fwdarw.40%
EtOAc/hexanes) provided 358 mg of the title compound. ##STR83##
[0245]
(R)-4-(2,4-dimethoxybenzylamino)-3-(9-(6,8-difluorochroman-4-yl)-8-
-oxo-8,9-dihydro-7H-purin-2-ylamino)benzonitrile. A solution of
(R)-4-(2,4-dimethoxybenzylamino)-3-(4-(6,8-difluorochroman-4-ylamino)-5-n-
itropyrimidin-2-ylamino)benzonitrile (358 mg) in THF (25 mL) was
treated with a solution of sodium hydrosulfite (1.5 g) and sodium
bicarbonate (1.5 g) in 20 mL of distilled water. Methanol (5 mL)
was added to maintain a homogeneous solution. After 15 minutes, the
mixture was diluted with EtOAc (100 mL) and washed with saturated
aqueous NaCl (2.times.100 mL). The organic layer was separated,
dried over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo to
provide the intermediate
(R)-4-(2,4-dimethoxybenzylamino)-3-(5-amino-4-(6,8-difluorochroman-4-ylam-
ino)pyrimidin-2-ylamino)benzonitrile. The intermediate was
dissolved in THF (5 mL) and treated with carbonyldiimidazole (0.55
g) for 16 hours. The mixture was diluted with EtOAc (100 mL) and
washed twice with saturated aqueous NaCl (2.times.100 mL). The
organic layer was separated, dried over Na.sub.2SO.sub.4, filtered,
and concentrated in vacuo. Column chromatography (2.fwdarw.3%
MeOH/DCM) provided 230 mg of the title compound. ##STR84##
[0246]
3-(9-((R)-6,8-difluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-y-
l)-3H-benzo[d]imidazole-5-carbonitrile. A solution of
(R)-4-(2,4-dimethoxybenzylamino)-3-(9-(6,8-difluorochroman-4-yl)-8-oxo-8,-
9-dihydro-7H-purin-2-ylamino)benzonitrile (230 mg) in DCM (5 mL)
was treated with TFA (5 mL) and triethylsilane (1 mL) for 16 h. The
mixture was concentrated in vacuo to provide the intermediate
(R)-4-amino-3-(9-(6,8-difluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2--
ylamino)benzonitrile. The intermediate was dissolved in 5 mL THF
and treated with 3 mL trimethylorthoformate followed by
p-toluenesulfonic acid (3 mg). After 1 hour, the mixture was
diluted with EtOAc (100 mL) and washed once with saturated aqueous
sodium bicarbonate (100 mL). The organic layer was separated, dried
over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo. Column
chromatography (50.fwdarw.100% EtOAc/hexanes) provided 78 mg of the
title compound. .sup.1H-NMR (300 MHz, 5% CD.sub.3OD in CDCl.sub.3)
.delta. 8.8 (s, 1H), 8.7 (s, 1H), 8.2 (s, 1H), 7.8 (d, 1H), 7.6
(dd, 1H), 6.8 (td, 1H), 6.4 (dd, 1H), 5.8 (dd, 1H), 4.6 (m, 1H),
4.4 (td, 1H), 2.9 (m, 1H), 2.3 (m, 1H). ##STR85##
[0247]
3-(9-((R)-chroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo[-
d]imidazole-5-carbonitrile. The title compound was synthesized from
(R)-chroman-4-amine via the procedures described in Example 26.
.sup.1H-NMR (300 MHz, 5% CD.sub.3OD in CDCl.sub.3) .delta. 8.8 (s,
1H), 8.5 (s, 1H), 8.2 (s, 1H), 7.8 (d, 1H), 7.5 (dd, 1H), 7.1 (m,
2H), 6.8 (d, 1H), 6.7 (td, 1H), 5.8 (dd, 1H), 4.5 (m, 1H), 4.3 (td,
1H), 2.8 (m, 1H), 2.3 (m, 1H). ##STR86##
[0248]
3-[9-(8-Fluoro-chroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl]-3H-b-
enzoimidazole-5-carbonitrile. The title compound was synthesized
from (R)-8-fluorochroman-4-amine via the procedures described in
Example 26. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.8 (s, 1H),
8.6 (s, 1H), 8.2 (s, 1H), 7.8 (d, 1H), 7.6 (d, 1H), 7.0 (t, 1H),
6.6 (m, 2H), 5.8 (t, 1H), 4.6 (m, 1H), 4.4 (m, 1H), 2.8 (m, 1H),
2.4 (m, 1H). ##STR87##
[0249]
3-(9-((R)-6-fluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3-
H-benzo[d]imidazole-5-carbonitrile. The title compound was
synthesized from (R)-6-fluorochroman-4-amine via the procedures
described in Example 26. .sup.1H NMR (300 MHz, CDCl.sub.3+5%
CD.sub.3OD): .delta. 8.86 (s, 1H), 8.41 (s, 1H), 8.18 (s, 1H), 7.72
(d, 1H), 7.51 (d, 1H), 7.0-7.1 (m, 1H), 6.8-6.9 (m, 1H), 6.49 (dd,
1H), 5.76 (br t, 1H), 4.4-4.5 (m, 1H), 4.24 (br t, 1H), 2.7-2.9 (m,
1H), 2.2-2.3 (m, 1H). Conditions for introduction of the chromanyl
amine were improved as described below: ##STR88##
[0250]
(R)-4-(2,4-dimethoxybenzylamino)-3-(4-(6-fluorochroman-4-ylamino)--
5-nitropyrimidin-2-ylamino)benzonitrile. A solution of
4-(2,4-dimethoxybenzylamino)-3-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)-
benzonitrile (139 mg) in anhydrous DMSO (3 mL) was added to
solution of (R)-6-fluorochroman-4-amine hydrochloride (79 mg) in
anhydrous DMSO (3 mL) and DIEA (0.21 mL), the resulting dark red
solution was stirred at RT under an atmosphere of Ar over which
time the solution lighten to yellow. Upon completion of the
reaction, the mixture was cooled to 0.degree. C. with an ice bath,
and water (25 mL) was added (exotherm). The resulting yellow solid
was collected via filtration, washed with additional water, air
dried, then dissolved in CH.sub.2Cl.sub.2, the organic solution was
dried (MgSO.sub.4), filtered and evaporated to yield the titled
compound (quant.), NMR CDCl.sub.3 .sup.1H .delta. 9.0 (s, 1H), 8.6
(d, 1H), 7.7 (br s, 1H), 7.4 (dd, 1H), 7.1 (d, 1H), 7.0-6.8 (m,
4H), 6.5-6.4 (m, 2H), 5.2 (br s, 1H), 4.3 (s, 2H), 4.2 (br s, 2H),
3.8 (s, 6H), 2.2 (br s, 1H), 1.8 (br s, 1H); .sup.19F .delta. -123
ppm; MH.sup.+=572.
[0251] This material was taken on using the same procedures
outlined in Example 26 to give
3-(9-((R)-6-fluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo-
[d]imidazole-5-carbonitrile. ##STR89##
[0252]
3-(9-((R)-7-fluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3-
H-benzo[d]imidazole-5-carbonitrile. The title compound was
synthesized from (R)-7-fluorochroman-4-amine via the procedures
described in Example 26. .sup.1H NMR (300 MHz, CDCl.sub.3+5%
CD.sub.3OD): .delta. 8.86 (s, 1H), 8.58 (s, 1H), 8.19 (s, 1H), 7.79
(d, 1H), 7.56 (d, 1H), 6.7-6.9 (m, 2H), 6.4-6.5 (m, 1H), 5.78 (br
t, 1H), 4.5-4.6 (m, 1H), 4.32 (br t, 1H), 2.7-2.9 (m, 1H), 2.2-2.4
(m, 1H). ##STR90##
[0253]
3-[9-(5,8-Difluoro-chroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl]--
3H-benzoimidazole-5-carbonitrile. The title compound was
synthesized from (R)-5,8-difluorochroman-4-amine via the procedures
described in Example 26. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.
8.8 (s, 1H), 8.7 (s, 1H), 8.2 (s, 1H), 7.8 (d, 1H), 7.6 (d, 1H),
7.0 (m, 1H), 6.4 (m, 1H), 5.9 (t, 1H), 4.6 (m, 1H), 4.4 (m, 1H),
2.5 (m, 2H).
Synthesis of
3-(8-Oxo-9-((R)-5,6,7,8-tetrahydroquinoxalin-5-yl)-8,9-dihydro-7H-purin-2-
-yl)-3H-benzo[d]imidazole-5-carbonitrile
[0254] ##STR91##
[0255] The title compound was synthesized from
(R)-5,6,7,8-tetrahydroquinoxalin-5-amine (example 34) via the
procedure described in Example 26. .sup.1H-NMR (300 MHz,
CDCl.sub.3) .delta. 9.8 (br, 1H), 8.9 (s, 1H), 8.6 (s, 1H), 8.4 (s,
1H), 8.3 (s, 1H), 8.2 (s, 1H), 7.9 (d, 1H), 7.6 (d, 2H), 5.9 (dd,
2H), 3.2-3.5 (m, 2H), 2.8 (q, 1H), 2.3 -2.5 (m, 2H), 2.1 (m,
1H).
Synthesis of
3-(9-Oxepan-4-yl-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzoimidazole-5-car-
bonitrile
[0256] ##STR92##
[0257] The title compound was synthesized from oxepan-4-amine
(obtained from oxepan-4-one (Chemische Berichte, 1958, 91, 1589)
via oxime reduction as per example 29) via the procedure described
in Example 26. .sup.1H-NMR (CDCl.sub.3) .delta. 9.2 (s, 1H), 9.0
(s, 1H), 8.2 (s, 1H), 7.9 (d, 1H), 7.6 (d, 1H), 4.7 (t, 1H), 3.8
(m, 6H), 2.7 (m, 2H), 2.0 (m, 2H) ppm.
Synthesis of
3-(8-Oxo-9-(4,5,6,7-tetrahydrobenzofuran-4-yl)-8,9-dihydro-7H-purin-2-yl)-
-3H-benzo[d]imidazole-5-carbonitrile
[0258] ##STR93##
[0259] The title compound was synthesized from
4,5,6,7-tetrahydrobenzofuran-4-amine (obtained via reductive
amination of 6,7-dihydrobenzofuran-4(5H)-one as per example 33) via
the procedure described in Example 26 .sup.1H-NMR (CDCl.sub.3)
.delta. 9.0 (s, 1H), 8.3 (s, 1H), 8.2 (s, 1H), 7.9 (d, 1H), 7.6 (d,
1H), 7.3 (s, 1H), 6.0 (s, 1H), 5.6 (t, 1H), 3.0 (m, 1H), 2.8 (d,
2H), 2.3 (m, 3H), 2.0 (m, 1H) ppm.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)--
7H-purin-8(9H)-one
[0260] ##STR94##
[0261] The title compound was synthesized from
4,5,6,7-tetrahydrobenzo[b]thiophen-4-amine (obtained via reductive
amination of 6,7-dihydrobenzo[b]thiophen-4(5H)-one as per example
33) via the procedure described in Example 26 .sup.1H-NMR (5%
CD.sub.3OD in CDCl.sub.3) .delta. 9.2 (s, 1H), 8.2 (s, 1H), 7.8-7.7
(m, 2H), 7.4 (m, 2H), 7.0 (d, 1H), 6.6 (d, 1H), 5.7 (dd, 1H), 3.0
(br s, 2H), 2.4-2.0 (m, 4H) ppm.
Synthesis of
9-((R)-8-Fluorochroman-4-yl)-2-(5-methyl-1H-benzo[d]imidazol-1-yl)-7H-pur-
in-8(9H)-one
[0262] ##STR95##
[0263] The title compound was synthesized from
(R)-8-fluorochroman-4-amine and 4-fluoro-3-nitrotoluene via the
procedures described in Example 26. .sup.1H-NMR (CDCl.sub.3)
.delta. 9.0 (s, 1H), 8.2 (s, 1H), 7.6 (d, 1H), 7.5 (s, 1H), 7.1 (d,
1H), 6.9 (m, 2H), 5.8 (t, 1H), 4.6 (m, 1H), 4.4 (m, 1H), 2.8 (m,
1H), 2.4 (s, 3H), 2.3 (m, 1H) ppm.
Example 27
Synthesis of
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluoro-chroman-4-yl)-7H-pu-
rin-8(9H)-one
[0264] ##STR96##
[0265] 4-Fluoro-2-nitro-phenyl di-tert-butyl imidodicarbonate. A
catalytic amount of DMAP was added to a mixture of
4-fluoro-2-nitrobenzenamine (0.78 g) and di-tert-butyl dicarbonate
(2.18 g) in DCM (20 mL) and stirred at room temperature for 15 hr.
The mixture was diluted with H.sub.2O and twice extracted with DCM,
the combined organics were dried, filtered and evaporated to yield
the bis-BOC material (quant). .sup.1H-NMR (300 MHz, CDCl.sub.3)
.delta. 7.8 (dd, 1H), 7.3 (m, 2H), 1.4 (s, 18H).
[0266] tert-Butyl 4-fluoro-2-nitrophenylcarbamate. (procedure:
Connell, R. D.; Rein, T.; Akermark, B.; Helquist, P. J. J. Org.
Chem. 1988, 53, 3845) To a stirred solution of the Bis-BOC material
in DCM (20 mL) was added TFA (0.58 mL). After 3 hr the reaction was
quenched with aq. NaHCO.sub.3 (5 mL), brine was added, the mixture
separated and extracted with additional DCM. The combined organics
were evaporated, purified via column chromatography (eluted with
7.5% EtOAc/Hex) to give the titled product (1.12 g). .sup.1H-NMR
(300 MHz, CDCl.sub.3) .delta. 9.5 (br 1H), 8.5 (dd, 1H), 7.9 (dd,
1H), 7.3 (m, 1H), 1.5 (s, 9H).
[0267] tert-Butyl 2-amino-4-fluorophenylcarbamate. To a solution of
tert-butyl 4-fluoro-2-nitrophenylcarbamate (0.34 g) in THF (30 mL)
was added a premixed solution of sodium hydrosulfite (2 g) and
sodium bicarbonate (1 g) in water (50 mL). MeOH (10 mL) was also
added to aid solution of the mixture, which was stirred at room
temperature for 30 min, when sodium chloride was added to saturate
the solution. The resultant mixture was extracted with EtOAc
(2.times.). The combined organics were dried, filtered and
evaporated to yield the titled compound (quant) that was used as
such for the next step. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.
7.5 (dd, 1H), 6.6 (dd, 1H), 6.5 (m, 1H), 6.4 (br 1H), 4.7 (br 2H),
1.5 (s, 9H); MH.sup.+=227 (minor) 127 (-BOC), 171 (-tBu).
##STR97##
[0268] 2-Chloro-5-nitro-4-thiocyanatopyrimidine. (compound known,
e.g. WO 2003/032994) Potassium thiocyanate (0.97 g, 10 mM) was
added to a solution of 2,4-dichloro-5-nitropyrimidine (1.94 g, 10
mM) in EtOH (40 mL) cooled to 0.degree. C. via an ice bath. The
solution was stirred at 0.degree. C. for 30 min, then the bath was
removed and the resulting suspension allowed to come to RT over 60
min, when water (100 mL) was added. The precipitate was collected
via filtration, washed with ice cold water, dissolved with DCM,
dried (MgSO.sub.4), filtered and evaporated to yield the titled
compound (1.7 g). .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.4 (s,
1H).
[0269] tert-Butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenylcarbamate.
Potassium carbonate (207 mg) was added to a stirred solution of
2-chloro-5-nitro-4-thiocyanatopyrimidine (108 mg) and tert-butyl
4-fluoro-2-nitrophenylcarbamate (113 mg) in ACN (5 mL) and stirred
for 15 hr. The solution was diluted with brine and extracted with
EtOAc (2.times.). The combined organics were evaporated and
purified via column chromatography, elution with 30% EtOAc/Hex gave
the titled compound (144 mg, 71% yield). .sup.1H-NMR (300 MHz,
DMSO-d6) .delta. 10.5 (br s, 1H), 9.3 (br s, 1H), 8.9 (br s, 1H),
7.7-7.4 (m, 2H), 7.1 (br s, 1H), 1.5 (s, 9H), 1.5 (s, 9H);
MH.sup.+=407, 307 (-BOC), 351 (-tBu). ##STR98##
[0270] (R)-tert-Butyl
4-fluoro-2-(4-(8-fluorochroman-4-ylamino)-5-nitropyrimidin-2-ylamino)phen-
ylcarbamate. A solution of the (R)-8-fluorochroman-4-amine
hydrochloride (104 mg) in DMSO (2 mL) and potassium carbonate (141
mg) were added to a stirred solution of tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenylcarbamate
(140 mg) in ACN (10 mL). The mixture was stirred for 15 hr at room
temperature then partitioned between brine and EtOAc and separated.
The aq. layer was washed with additional EtOAc, the combined
organics were evaporated and purified via column chromatography,
elution with 20-30% EtOAc/H gave the titled product in 83% yield.
.sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.1 (s, 1H), 8.7 (m, 1H),
8.2 (br s, 1H), 7.7 (m, 1H), 7.3 (m, 1H), 7.3-6.8 (m, 4H), 6.5 (s,
1H), 5.5 (br s, 1H), 4.4 (m 2H), 2.4 (m, 1H), 2.2 (m, 1H), 1.5 (s,
9H); MH.sup.+=515, 459 (-tBu).
[0271] (R)-tert-Butyl
4-fluoro-2-(9-(8-fluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-ylamino-
)phenylcarbamate. To a solution of (R)-tert-butyl
4-fluoro-2-(4-(8-fluorochroman-4-ylamino)-5-nitropyrimidin-2-ylamino)phen-
ylcarbamate (141 mg) in THF (20 mL) was added a premixed solution
of sodium hydrosulfite (0.6 g) and sodium bicarbonate (0.3 g) in
water (50 mL). MeOH (5 mL) was also added to aid solution of the
mixture, which was stirred at room temperature for 30 min, when
sodium chloride was added to saturate the solution. The resultant
mixture was extracted with EtOAc (2.times.), the combined organics
were dried, filtered and evaporated to yield (R)-tert-butyl
2-(5-amino-4-(8-fluorochroman-4-ylamino)pyrimidin-2-ylamino)-4-fluorophen-
ylcarbamate that was used as such for the next step,
MH.sup.+=485.
[0272] To a stirred solution of the above material in THF (5 mL)
was added CDI (131 mg). After 15 hr brine and EtOAc were added and
the mixture was separated. The aq. layer was washed with additional
EtOAc and the combined organics were evaporated and purified by
column chromatography (eluted 3% MeOH/DCM) to yield titled product
(86 mg, 62% yield for two steps). .sup.1H-NMR (300 MHz, 5%
CD.sub.3OD in CDCl.sub.3) .delta. 7.9 (s, 1H), 7.4 (dd, 1H), 7.3
(m, 1H), 6.9 (dd, 1H), 6.7-6.5 (m, 3H), 5.7 (dd, 1H), 4.6 (m 1H),
4.3 (td, 1H), 2.9 (m, 1H), 2.2 (m, 1H), 1.5 (s, 9H); MH.sup.+=511,
411 (-BOC), 455 (-tBu).
[0273]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-
-7H-purin-8(9H)-one. A freshly prepared solution of 30% TFA/DCM (5
mL) was added to (R)-tert-butyl
4-fluoro-2-(9-(8-fluorochroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-ylamino-
)phenylcarbamate and the solution was stirred at room temperature
for 60 min then the solvents were removed in vacuo to yield
(R)-2-(2-amino-5-fluorophenylamino)-9-(8-fluorochroman-4-yl)-7H-purin-8(9-
H)-one that was used as such MH.sup.+=411.
[0274] To the above di-amine was added MeOH (2 mL),
trimethylorthoformate (2 mL) and p-TsOH (cat). The mixture was
stirred at RT for 60 min then the solvents were reduced and the
resultant material partitioned between DCM and brine and separated.
The crude product was purified via column chromatography (eluted
with 4% MeOH/DCM) to yield the titled compound (46 mg). .sup.1H-NMR
(300 MHz, 5% CD.sub.3OD in CDCl.sub.3) .delta. 8.7 (s, 1H), 8.1 (s,
1H), 7.5 (m, 2H), 6.9 (m, 2H), 6.6 (m, 2H), 5.8 (dd, 1H), 4.6 (m
1H), 4.3 (td, 1H), 2.8 (m, 1H), 2.3 (m, 1H); MH.sup.+=421.
##STR99##
[0275]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-6-fluorochroman-4-yl)-
-purin-8(9H)-one. The title compound was synthesized from
(R)-6-fluorochroman-4-amine via the procedures described in Example
27. .sup.1H NMR (300 MHz, CDCl.sub.3+5% CD.sub.3OD): .delta. 8.72
(s, 1H), 8.16 (s, 1H), 7.5-7.7 (m, 2H), 6.9-7.0 (m, 2H), 6.8-6.9
(m, 1H), 6.54 (dd, 1H), 5.78 (br t, 1H), 4.4-4.5 (m, 1H), 4.26 (m,
1H), 2.7-2.8 (m, 1H), 2.2-2.3 (m, 1H). ##STR100##
[0276]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-
-7H-purin-8(9H)-one. The title compound was synthesized from
4-aminotetrahydropyran via the procedures described in Example 27.
.sup.1H NMR (d.sub.6-DMSO) .delta. 11.65 (s, 1H), 9.13 (s, 1H),
8.34 (s, 1H), 8.28 (m, 1H), 7.82 (m, 1H), 7.25 (td, J=9.0, 2.4 Hz,
1H), 4.56 (m, 1H), 4.03 (dd, J=11.1, 3.9 Hz, 2H), 3.50 (t, J=11.1
Hz, 2H), 2.59 (m, 2H), 1.78 (m, 2H). ##STR101##
[0277]
2-(6-Chloro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-
-7H-purin-8(9H)-one. The title compound was synthesized from
(R)-8-fluorochroman-4-amine and 4-chloro-2-nitrobenzenamine via the
procedures described in Example 27. .sup.1H NMR (300 MHz,
CDCl.sub.3+5% CD.sub.3OD): .delta. 8.7 (s, 1H), 8.2 (s, 1H), 8.1
(s, 1H), 7.6 (d, 1H), 7.2 (dd, 1H), 6.9 (td, 1H), 6.7-6.5 (m, 2H).
5.8 (dd, 1H), 4.6 (m 1H), 4.4 (td, 1H), 2.9 (m, 1H), 2.3 (m,
1H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(pyrazin-2-ylmethyl)-7H-purin-8(9-
H)-one
[0278] ##STR102##
[0279] The title compound was synthesized from
pyrazin-2-ylmethanamine via the procedure described in Example 27.
.sup.1H-NMR (300 MHz, CDCl.sub.3+5% CD.sub.3OD) .delta. 8.9 (br,
1H), 8.7 (s, 1H), 8.5 (s, 1H), 8.5 (s, 1H) 8.2 (s, 1H), 8.2 (dd,
1H), 7.7 (dd, 1H), 7.0 (td, 1H), 5.3 (s, 2H).
Synthesis of
2-(6-Chloro-1H-benzo[d]imidazol-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-7H-pur-
in-8(9H)-one
[0280] ##STR103##
[0281] The title compound was synthesized from
4-aminotetrahydropyran and 4-chloro-2-nitrobenzenamine via the
procedures described in Example 27 .sup.1H NMR
(CD.sub.3OD+CHCl.sub.3) .delta.9.15 (s, 1H), 8.67 (d, 1H), 8.27 (s,
1H), 7.70 (d, 1H), 7.37 (dd, 1H), 4.64 (m, 1H), 4.18 (m, 2H), 3.61
(m, 2H), 2.81 (m, 2H), 1.85 (m, 2H); MS (MH.sup.+371.1.
[0282] Procedure for the synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl)-
-7H-purin-8(9H)-one. ##STR104##
Synthesis of 3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-amine
[0283] ##STR105##
[0284]
3-(tert-Butyldimethylsilyloxy)-1-(2-chloropyridin-3-yl)propan-1-ol-
. (Prepared similarly to literature procedure, Murtiashaw, C. W.,
et. al. J. Org. Chem., 1992, 57, 1930-1933). A solution of
3-(tert-butyldimethylsilyloxy)propanal (2.3 g, prepared from
3-(tert-butyldimethylsilyloxy)propan-1-ol via Swern oxidation as
per Li, X.; Lantrip, D.; Fuchs, P. L. J. Am. Chem. Soc., 2003, 125,
14262-14263, Supporting information) in THF (10 mL) was slowly
added via double ended needle to a solution of
2-chloro-3-lithiopyridine (prepared in turn from freshly prepared
LDA (11.4 mM) and 2-chloropyridine (11.4 mM) (as per Gribble, G.
W.; Saulnier, M. G. Tet. Lett. 1980, 21, 4137-4140) in THF (25 mL)
at -78.degree. C. The resulting mixture was allowed to slowly warm
to RT over 15 hr, quenched via the addition of sat. NH.sub.4Cl (2
mL) and solvents reduced in vacuo. The resultant slurry was taken
up in EtOAc, washed with brine, and purified via column
chromatography (eluted with 15, 20 and 25% EtOAc/Hex) to yield the
titled product (1.0 g), NMR CDCl.sub.3 .sup.1H 5 8.3 (dd, 1H), 8.0
(dd, 1H), 7.3 (dd, 1H), 5.2 (d, 1H), 4.5 (m, 1H), 4.0-3.8 (m, 2H),
2.1 (m, 1H), 1.8 (m, 1H) 0.9 (s, 9H), 0.1 (s, 6H);
MH.sup.+=302/304.
[0285] 1-(2-Chloropyridin-3-yl)propane-1,3-diol. A solution of
tetrabutylammonium fluoride in THF (1M, 3.3 mL) was added to a
solution of
3-(tert-butyldimethylsilyloxy)-1-(2-chloropyridin-3-yl)propan-1-ol
in THF (5 mL) and stirred for 60 min, then silica gel was added and
the solvent were removed under reduced pressure. The entire flask
contents were added to a column, that was prepared and eluted with
75% ETOAC/Hex, to yield that titled product (0.49 g), NMR
CD.sub.3OD .sup.1H .delta. 8.3 (dd, 1H), 8.0 (dd, 1H), 7.4 (dd,
1H), 5.1 (dd, 1H), 3.8 (m, 2H), 2.0 (m, 1H), 1.8 (m, 1H);
MH.sup.+=188/190.
[0286] 3,4-Dihydro-2H-pyrano[2,3-b]pyridin-4-ol. Potassium
tert-butoxide (0.88 g) was added to a solution of
1-(2-chloropyridin-3-yl)propane-1,3-diol (0.49 g) in tert-butanol
and the solution was heated at reflux for 3 hr, allowed to cool to
RT, quenched via the addition al of sat. NH.sub.4Cl (2 mL),
solvents reduced then silica gel added and remaining solvents
removed in vacuo. The material was added to a silica gel column
that was eluted with EtOAc and 1% MeOH/EtOAc to yield the titled
product (0.35 g) NMR CDCl.sub.3 .sup.1H .delta. 8.1 (dd, 1H), 7.7
(dd, 1H), 6.9 (dd, 1H), 4.9 (dd, 1H), 4.5 (m, 2H), 2.1 (m, 2H);
MH.sup.+=152.
[0287] 4-Azido-3,4-dihydro-2H-pyrano[2,3-b]pyridine. (Prep ref:
Phompson, A. S. et. al. J. Org. Chem., 1993, 58, 5886-5888).
Diphenyl phosphoryl azide (0.81 mL) was added to a suspension of
3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol (0.37 g) in dry toluene
(10 mL) then the mixture was cooled to 0.degree. C. under an Ar
atmosphere. Neat DBU (0.56 mL) was added and the resultant biphasic
mixture was stirred at 0.degree. C. for 2 hr and then at RT for 15
hr. The biphasic solution was diluted with sat. NaHCO.sub.3 and
extracted with DCM (2.times.). The combined organics were
concentrated and purified by silica gel chromatography using 10, 25
and 50% EtOAc/Hex elutants to afford the titled product (0.31 g)
NMR CDCl.sub.3 .sup.1H .delta. 8.2 (dd, 1H), 7.6 (dd, 1H), 7.0 (dd,
1H), 4.7 (dd, 1H), 4.4 (m, 2H), 2.2 (m, 1H), 2.1 (m, 1H);
MH.sup.+=177.
[0288] 3,4-Dihydro-2H-pyrano[2,3-b]pyridin-4-amine. A catalytic
amount of Pd/C (9 mg) was added to a solution of
4-azido-3,4-dihydro-2H-pyrano[2,3-b]pyridine (88 mg) in MeOH (5
mL). The flask closed with a septum, evacuated under house vacuum
and hydrogen added via balloon. The resulting suspension was
stirred at RT for 60 min, when the H.sub.2 balloon was removed, the
mixture evacuated and filtered through a plug of celite, that was
thoroughly rinsed with MeOH. Removal of the solvents gave the
titled compound (73 mg), NMR CDCl.sub.3 .sup.1H .delta. 8.1 (dd,
1H), 7.7 (dd, 1H), 6.9 (dd, 1H), 4.5-4.3 (m, 2H), 4.1 (dd, 1H), 2.2
(m, 1H), 1.9 (m, 1H), 1.6 (br s, 2H); MH.sup.+=151.
[0289]
2-(1H-Benzo[d]imidazol-1-yl)-9-(3,4-dihydro-2H-pyrano[2,3-b]pyridi-
n-4-yl)-7H-purin-8(9H)-one. The titled compound was prepared in the
same manner described in Example 19 from
3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-amine. .sup.1H NMR
(CDCl.sub.3+5% CD.sub.3OD) .delta. 8.8 (s, 1H), 8.2 (s, 1H), 8.1
(m, 1H), 7.7 (m, 2H), 7.3 (m, 2H), 6.8 (dd, 2H), 5.9 (dd, 1H), 4.7
(m 1H), 4.5 (td, 1H), 2.9 (m, 1H), 2.3 (m, 1H); MH.sup.+=386.
Example 28
Synthesis of
2-(5-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-7H-pur-
in-8(9H)-one
[0290] ##STR106##
[0291] N-(2,4-Dimethoxybenzyl)-5-fluoro-2-nitrobenzenamine. A
solution of 2,4-difluoro-1-nitrobenzene (1.1 mL), 2,4-dimethoxy
benzylamine (1.5 mL) and DIEA (5.2 mL), in THF (40 mL) was heated
at 60.degree. C. for 60 min, allowed to cool to RT, partitioned
between EtOAc and H.sub.2O, separated, dried (MgSO.sub.4), filtered
and evaporated to yield the titled product as a yellow solid (3.14
g). .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.5 (br s, 1H), 7.2
(dd, 1H), 7.2 (d, 1H), 6.6-6.4 (m, 3H), 6.3 (m, 1H), 4.3 (d, 2H),
3.9 (s, 3H), 3.8 (s, 3H).
[0292] N.sup.1-(2,4-Dimethoxybenzyl)-5-fluorobenzene-1,2-diamine.
Under a flush of Ar, a catalytic amount of a Raney Ni solution in
water was added to a solution of
N-(2,4-dimethoxybenzyl)-5-fluoro-2-nitrobenzenamine (0.5 g) in THF
(20 mL). The flask was closed with a septum, evacuated under house
vacuum and hydrogen added via balloon. The resulting suspension was
stirred at RT for 16 hr, when the H.sub.2 balloon was removed,
mixture evacuated and filtered through a plug of celite, that was
thoroughly rinsed with THF and MeOH, to yield the titled diamine
that was used as such. ##STR107##
[0293]
(R)-2-Chloro-N-(8-fluorochroman-4-yl)-5-nitropyrimidin-4-amine. A
solution of (R)-8-fluorochroman-4-amine hydrochloride (1.02 g) and
DIEA (2.6 mL) in DCM (10 mL) was slowly added to a solution of
2,4-dichloro-5-nitropyrimidine (0.97 g) THF (25 mL) at -78.degree.
C. The reaction mixture was stirred for 30 min at -78.degree. C.
then allowed to warm to RT overnight. The reaction was quenched
with the addition of sat. NH.sub.4Cl (1 mL), the solvent volume was
reduced in vacuo, and the resulting mixture partition between EtOAc
and water then separated. The crude material was purified via
column chromatography, elution with 30% EtOAc/Hex gave the titled
product (1.43 g). .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.1 (s,
1H), 8.6 (br d, 1H), 7.1-6.8 (m, 3H), 5.6 (dd, 1H), 4.4 (m 1H), 4.3
(m, 1H), 2.4 (m, 1H), 2.2 (m, 1H).
[0294]
(R)-N.sup.2-(2-(2,4-Dimethoxybenzylamino)-4-fluorophenyl)-N.sup.4--
(8-fluorochroman-4-yl)-5-nitropyrimidine-2,4-diamine. A mixture of
(R)-2-chloro-N-(8-fluorochroman-4-yl)-5-nitropyrimidin-4-amine (32
mg), N.sup.1-(2,4-dimethoxybenzyl)-5-fluorobenzene-1,2-diamine (28
mg)and KCO.sub.3 (41 mg) in ACN was heated at 65.degree. C. for 3
hr, cooled to RT, diluted with brine and extracted with EtOAc
(2.times.). The combined organics were evaporated, and purified by
column chromatography (eluted with 30% EtOAc/Hex) to yield the
titled product (21 mg). .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.
9.0 (s, 1H), 8.6 (br d, 1H), 7.2-6.8 (m, 6H), 6.5-6.3 (m, 4H),
4.4-4.2 (m, 4H), 3.8 (s, 6H), 2.3-2.2 (m, 2H).
[0295]
(R)-2-(2-(2,4-Dimethoxybenzylamino)-4-fluorophenylamino)-9-(8-fluo-
rochroman-4-yl)-7H-purin-8(9H)-one. Under an Ar atmosphere, a
catalytic amount of a Raney Ni solution in water was added to a
solution of
(R)-N.sup.2-(2-(2,4-dimethoxybenzylamino)-4-fluorophenyl)-N.sup.4-(8-fluo-
rochroman-4-yl)-5-nitropyrimidine-2,4-diamine (21 mg) in THF. The
flask was closed with a septum, evacuated under house vacuum and
hydrogen added via balloon. The resulting suspension was stirred at
RT for 2 hr, when the H.sub.2 balloon was removed, the mixture
evacuated and filtered through a plug of celite, that was
thoroughly rinsed with THF and MeOH, to yield
(R)-N.sup.2-(2-(2,4-dimethoxybenzylamino)-4-fluorophenyl)-N.sup.-
4-(8-fluorochroman-4-yl)pyrimidine-2,4,5-triamine that was used
directly.
[0296] To a stirred solution of the above material in THF (5 mL)
was added CDI (12 mg). After 18 hr brine and EtOAc were added and
the mixture was separated. The organic layer was evaporated and
purified by column chromatography (eluted 4% MeOH/DCM) to yield
titled product (14 mg). .sup.1H NMR (300 MHz, CDCl.sub.3+5%
CD.sub.3OD): .delta. 7.8 (s, 1H), 7.3 (s, 1H), 7.1 (d, 1H), 6.9 (m,
2H), 6.7-6.2 (m, 6H), 5.7 (dd, 1H), 4.5 (m 1H), 4.2 (m, 1H), 4.1
(s, 2H), 3.8 (s, 3H), 3.7 (s, 3H), 2.8 (m, 1H), 2.2 (m, 1H).
2-(5-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-7H-puri-
n-8(9H)-one
[0297] A mixture of
(R)-2-(2-(2,4-dimethoxybenzylamino)-4-fluorophenylamino)-9-(8-fluorochrom-
an-4-yl)-7H-purin-8(9H)-one (14 mg) and TFA (1 mL) was stirred for
60 min when triethyl silane (0.5 mL) was added. The resulting
solution was stirred at RT for 16 hr, then the solvents were
reduced in vacuo to yield
(R)-2-(2-amino-4-fluorophenylamino)-9-(8-fluorochroman-4-yl)-7H-purin-8(9-
H)-one that was used as such.
[0298] A catalytic amount of p-TsOH was added to a solution of the
above amine in trimethylorthoformate (2 mL). The mixture was
stirred at RT for 15 hr then the solvents were reduced and the
resultant material partitioned between DCM and brine and separated.
The crude product was purified via column chromatography (eluted
with 5% MeOH/DCM) to yield the titled compound (9 mg). .sup.1H-NMR
(300 MHz, CDCl.sub.3) .delta. 10.0 (s, 1H), 8.9 (s, 1H), 8.3 (s,
1H), 7.8 (dd, 1H), 7.4 (d, 1H), 7.1 (m, 2H), 6.8 (m, 2H), 5.9 (dd,
1H), 4.7 (m 1H), 4.4 (td, 1H), 2.9 (m, 1H), 2.4 (m, 1H).
Synthesis of
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-7H-pur-
in-8(9H)-one.
[0299] ##STR108##
[0300] (R)-tert-Butyl
4-fluoro-2-(4-(8-fluorochroman-4-ylamino)-5-nitropyrimidin-2-ylamino)phen-
ylcarbamate. tert-Butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenylcarbamate
(2.0 g) was added to a solution of (R)-8-fluorochroman-4-amine
hydrochloride (1.1 gram) and N,N-diisopropylethylamine (2.2 mL) in
THF (anhydrous, 50 mL). The mixture was stirred for 6 hr at room
temperature then partitioned between water and EtOAc and separated.
The aq. layer was washed with additional EtOAc and the combined
organics were dried over Na.sub.2SO.sub.4 and concentrated in vacuo
to give the title product in 94% yield. MH.sup.+=515, 459
(-tBu).
[0301]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-N-((R)-8-fluorochroman-4-yl)-
-5-nitropyrimidin-4-amine. A freshly prepared solution of 30%
TFA/DCM (100 mL) was added to (R)-tert-butyl
4-fluoro-2-(4-(8-fluorochroman-4-ylamino)-5-nitropyrimidin-2-ylamino)phen-
ylcarbamate and the solution was stirred at room temperature for 60
min. The solvents were removed in vacuo to yield
(R)-N2-(2-amino-5-fluorophenyl)-N4-(8-fluorochroman-4-yl)-5-nitropyrimidi-
ne-2,4-diamine that was carried on without further purification.
MH.sup.+=415.
[0302] To the above diamine was added MeOH (50 mL) and
trimethylorthoformate (50 mL). The mixture was stirred for 30
minutes at room temperature, and the solvents were removed in vacuo
to yield crude
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-N-((R)-8-fluorochroman-4-yl)-5-nitr-
opyrimidin-4-amine in 94% yield (2 steps). MH.sup.+=425.
[0303]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-8-fluorochroman-4-yl)-
-7H-purin-8(9H)-one. To a solution of the
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-N-((R)-8-fluorochroman-4-yl)-5-nitr-
opyrimidin-4-amine in EtOAc (20 mL) was added 5 mol % of Platinum,
5% on activated carbon power, sulfide, 0.5% S (as sulfide) (45.6
mg). The mixture was sparged with argon, transferred to the Parr
hydrogenation apparatus, then subjected to a purge/fill sequence
with hydrogen (repeated 5.times.). The mixture was hydrogenated for
18 hr at 40 psi. Filtration through a pad of Celite and
concentration of the filtrate gave crude
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)N.sup.4-((R)-8-fluorochroman-4-
-yl)pyrimidine-4,5-diamine that was carried on without further
purification. MH.sup.+=425.
[0304] To a solution of the above diamine in THF (50 mL) was added
dropwise 20% phosgene solution in toluene at room temperature. A
light brown precipitate formed immediately. Stirring was maintained
for an additional 30 min at room temperature and the solvents were
removed in vacuo to yield the titled compund. The crude product was
crystallized from hot EtOAc to yield 1.10 g (53%, 2 steps) of the
title compound as off white solid. Treatment with 5 mL methanol and
5 mL of HCl (conc. aq) gave 1.25 g of the hydrochloride salt as off
white solid. .sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 10.0 (s,
1H), 8.4 (s, 1H), 7.9-7.8 (m, 2H), 7.5 (td, 1H), 7.0-6.9 (m, 1H),
6.7-6.6 (m, 2H), 5.9 (dd, 1H), 4.6 (dt, 1H), 4.4 (td, 1H), 2.9-2.8
(m, 1H), 2.4-2.3 (m, 1H); MH.sup.+=421.
Example 29
Synthesis and Resolution of 8-Fluorochroman-4-amine
[0305] ##STR109##
[0306] 3-(2-Fluorophenoxy)propanoic acid. A mixture of
2-fluorophenol (15 g), 3-bromopropanoic acid (20 g) and NaOH (11 g)
was refluxed in 50 mL of water. The solution was cooled to room
temperature and acidified to pH 2 with 3 M HCl. The resulting
precipitate was isolated by filtration to yield 9.27 g of title
compound as a white solid. The filtrate was extracted 3 times with
EtOAc to yield 2.5 g of less pure compound.
[0307] 8-Fluorochroman-4-one. Oxalyl chloride (8.79 mL) and 1 drop
of DMF were added to an ice cold solution of
3-(2-fluorophenoxy)propanoic acid (9.27 g) in DCM (50 mL). The
solution was stirred at 0.degree. C. for 2 hours, then aluminum
chloride (7.39 g, 55.42 mM) was added and the solution was stirred
for 16 hours at room temperature. The mixture was poured onto ice
water, and extracted three times with DCM. The combined organics
were washed with 0.5M NaOH and brine, then dried, evaporated, and
purified by column chromatography (eluting with 20% EtOAc/Hex) to
give of the title compound (8.20 g, 98%).
[0308] 8-Fluorochroman-4-amine. A round bottom flask was charged
with 8-fluorochroman-4-one (8.2 g), hydroxylamine hydrochloride
(3.78 g) and sodium acetate (4.46 g). A reflux condenser was added,
the flask was purged with argon, dry EtOH (20 mL) was added, and
the mixture was stirred at reflux for 18 hours. The solution was
cooled to room temperature, diluted with EtOAc, and washed with
water. The organic phase was dried, and evaporated to give the
intermediate 8-fluorochroman-4-one oxime, which was reduced with
Raney Nickel in EtOH at 50 PSI to yield the titled amine (4.69 g,
57%). ##STR110##
[0309] Resolution of 8-fluorochroman-4-amine. (Procedure based on
US published application 2004/0157739). A mixture of
8-fluorochroman-4-amine (3.40 g), methyl 2-methoxyacetate (2.44 g)
and Novozyme 435 (Aldrich, 0.68 g) in anhydrous tert-butyl methyl
ether (75 mL) was heated at reflux under argon for 2 hours (at
which time the ratio of acylated to unacylated product was 1:1 by
HPLC). The solid that formed upon cooling was collected via
filtration and dissolved in EtOAc. The mixture was filtered to
remove the biocatalyst and washed once with 0.5M HCl to remove any
lingering (S)-amine. The solvent was evaporated and the product was
recrystallized from tert-butyl methyl ether to yield
(R)-N-(8-fluorochroman-4-yl)-2-methoxyacetamide (0.78 g). The
reaction solvent and recrystallization mother liquor was washed 3
times with 0.5 M HCl and concentrated to yield additional
(R)-N-(8-fluorochroman-4-yl)-2-methoxyacetamide (0.83 g). The
combined acidic aqueous layers were made basic by NaOH and
extracted with DCM to yield (S)-8-fluorochroman-4-amine (1.6 g). A
solution of (R)-N-(8-fluorochroman-4-yl)-2-methoxyacetamide (0.78
g) in 8M HCl in EtOH (50 mL) was heated at reflux for 4 hours. The
solvents were removed from the cooled reaction mixture, the
resulting solid was taken up in 50 mL of 0.5M NaOH, salted out with
NaCl.sub.(s), and extracted 4 times with DCM to yield
(R)-8-fluorochroman-4-amine (0.48 g (87%)). The % ee was checked
via chiral HPLC: Chiralcel OD-H (0.46.times.25 cm analytical
column, Daicel Chemical Industries) method: isocratic 5% (0.05%
TFA/EtOH) 95% (0.05% TFA/Hex), Rt=7.2 min (S)-enantiomer, Rt=9.2
min (R)-enantiomer.
Example 30
Chroman-4-amine, 5-fluorochroman-4-amine, 6-fluorochroman-4-amine,
6-chlorochroman-4-amine, 6-methylchroman-4-amine,
6-methoxychroman-4-amine, 7-fluorochroman-4-amine,
5,8-difluorochroman-4-amine, and 6,8-difluorochroman-4-amine
[0310] ##STR111##
[0311] These amines were prepared via procedures described in
Example 29 for the synthesis of 8-fluorochroman-4-amine. The
corresponding chroman-4-ones were commercially available as
advanced intermediates for the synthesis of chroman-4-amine,
6-fluorochroman-4-amine, 6-chlorochroman-4-amine,
6-methylchroman-4-amine, and 6-methoxychroman-4-amine. For the
synthesis of 5-fluorochroman-4-amine, the intermediate
5-fluorochroman-4-one was obtained using procedures from GB
2355264, which also provided 7-fluorochroman-4-one.
7-Fluorochroman-4-one could be used in the synthesis of
7-fluorochroman-4-amine. Chroman-4-amine, 5-fluorochroman-4-amine,
6-fluorochroman-4-amine, 7-fluorochroman-4-amine,
5,8-difluorochroman-4-amine, and 6,8-difluorochroman-4-amine were
resolved via the procedure described in Example 29 for the
resolution of 8-fluorochroman-4-amine.
Example 31
1-Methyl-4,5,6,7-tetrahydro-1H-indol-4-amine
[0312] ##STR112##
[0313] The title compound was obtained from
1-methyl-6,7-dihydro-1H-indol-4(5H)-one (Heterocycles (1984), 22,
2313) via the procedure described in Example 29 that were used to
obtain 8-fluorochroman-4-amine from 8-fluorochroman-4-one.
Example 32
Synthesis of 5,6-Difluorochroman-4-amine
[0314] ##STR113##
[0315] 3-(2-Bromo-4,5-difluorophenoxy)propanoic acid. A solution of
1.68 g of NaOH (42 mmol) in 5 mL of water was added slowly to the
suspension of 2.29 mL (20 mmol) 2-bromo-4,5-difluorophenol and 3.07
g (20 mmol) 3-bromopropionic acid. The mixture was heated at
100.degree. C. in an oil bath for 5 hours, and then allowed to cool
to room temperature. Water was added to completely dissolve any
solid material and the reaction mixture was made acidic with
concentrated HCl. The product was extracted into ether (3 times),
and the combined organic layers was dried over Na.sub.2SO.sub.4 and
evaporated to give 3.7 g (66%) of the title compound as a light
brown solid. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 7.4 (t,
1H), 6.8 (q, 1H), 4.3 (t, 2H), 2.9 (t, 2H).
[0316] 8-Bromo-5,6-difluoro-2,3-dihydrochromen-4-one. Oxalyl
chloride (1.7 mL, 20 mmol) was added to the solution of 2.8 g (10
mmol) of 3-(2-bromo-4,5-difluorophenoxy)-propanoic acid in 40 mL of
anhydrous DCM followed by a drop of DMF. After 1.5 hours, a drying
tube was attached and the solution was cooled in an ice-water bath.
AlCl.sub.3 (1.5 g, 11 mmol) was added and the dark red solution was
allowed to slowly reach room temperature while being stirred for 16
hours. The mixture was poured into ice and the organic layer was
separated. The aqueous layer was extracted with DCM twice. The
combined organic layers were washed with 0.5 N NaOH and brine, then
dried over Na.sub.2SO.sub.4 and concentrated. Column chromatography
of this residue with hexane and EtOAc provided 1.9 g of the title
compound as an off-white solid (73%). .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.6 (t, 1H), 4.65 (t, 2H), 2.85 (t, 2H).
[0317] 8-Bromo-5,6-difluoro-2,3-dihydrochromen-4-one oxime. To a
solution of 8-bromo-5,6-difluoro-2,3-dihydrochromen-4-one (7.2
mmol) in 40 mL of ethanol was added hydroxylamine hydrochloride
(0.55 g, 7.9 mmol) and sodium acetate (0.65 g, 7.9 mmol). This
mixture heated at reflux for 20 hrs. The mixture was cooled,
diluted with EtOAc, washed with water and brine, and then dried
over Na.sub.2SO.sub.4 Concentration of the solvent provided the
title compound as a white solid (1.9 g). .sup.1H NMR (300 MHz, 10%
CD.sub.3OD in CDCl.sub.3): .delta. 7.3 (t, 1H), 4.2 (t, 2H), 2.9
(t, 2H).
[0318] 5,6-Difluoro-3,4-dihydro-2H-chromen-4-amine. Raney-Ni (5 mL
slurry in water) was added to a solution of
8-bromo-5,6-difluoro-2,3-dihydrochromen-4-one oxime (1.9 g) in 200
mL MeOH. The mixture was hydrogenated at 50 psi for 24 hrs to
provide 8-bromo-5,6-difluoro-3,4-dihydro-2H-chromen-4-amine. Pd/C
(0.3 g) was added to the mixture and hydrogenation was resumed at
50 psi for 4 hours. The title compound was obtained after
filtration and concentration in vacuo. .sup.1H NMR (300 MHz, 10%
CD.sub.3OD in CDCl.sub.3): .delta. 7.15 (q, 1H), 6.6 (m, 1H), 4.6
(bm, 1H), 4.25 (bm, 2H), 2.2-2.4 (m, 2H).
Example 33
Synthesis of 4-Amino-3,4-dihydro-2H-chromene-8-carbonitrile
[0319] ##STR114##
[0320] 4-Amino-3,4-dihydro-2H-chromene-8-carbonitrile. A mixture of
260 mg of 4-oxo-3,4-dihydro-2H-chromene-8-carbonitrile (made from
2-hydroxybenzonitrile via the procedure described in Example 29),
ammonium acetate (1.2 g), and 3A molecular sieves (1.5 g) in 10 mL
of methanol was stirred for 5 days. The mixture was filtered
through celite and the filtrate concentrated in vacuo. The crude
residue was treated with 100 mL of 1 M HCl and extracted with ethyl
ether (3.times.100 mL). The aqueous layer was made basic to pH 10
with saturated NaOH and extracted with DCM (3.times.100 mL). The
combined DCM layers were washed with brine, dried over magnesium
sulfate, and concentrated in vacuo to provide 150 mg of the title
compound. ##STR115##
[0321] 4-Amino-3,4-dihydro-2H-chromene-6-carbonitrile. The title
compound was made from 6-cyano-4-chromanone (Syntech) via the same
procedure that was described in Example 33. ##STR116##
[0322] 4-Amino-1,2,3,4-tetrahydronaphthalen-1-yl acetate. The title
compound was made from 4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl
acetate (Tetrahedron: Asymmetry 2001, 12, 2283) via the same
procedure that was described in Example 33. ##STR117##
[0323] 6,7-Dihydro-5H-cyclopenta[b]pyridin-5-amine. The title
compound was made as described in WO 03/045924.
Example 34
Synthesis of (R)-5,6,7,8-Tetrahydroquinoxalin-5-amine
[0324] ##STR118##
[0325] (R)-tert-Butyl
acetyl(5,6,7,8-tetrahydroquinoxalin-5-yl)carbamate. A solution
containing 483 mg of
(R)-N-(5,6,7,8-tetrahydroquinoxalin-5-yl)acetamide (J. Org. Chem.
(2003), 68, 3546) in acetonitrile (20 mL) was treated with
Boc.sub.2O (3 g) and DMAP (5 mg). The mixture was heated at
60.degree. C. for 1.5 h and then concentrated in vacuo. Column
chromatography (50% EtOAc/hexanes) provided 293 mg of the title
compound.
[0326] (R)-tert-Butyl 5,6,7,8-tetrahydroquinoxalin-5-ylcarbamate. A
solution of (R)-tert-butyl
acetyl(5,6,7,8-tetrahydroquinoxalin-5-yl)carbamate (293 mg) in
methanol (10 mL) was treated with hydrazine hydrate (0.5 mL) for
1.5 h. The mixture was diluted with EtOAc and washed twice with
saturated aqueous sodium chloride. The organic layer was separated,
dried with sodium sulfate, and concentrated in vacuo to provide 238
mg of the title compound.
[0327] 2,3-dihydrobenzofuran-3-amine. To the solution of
benzofuran-3(2H)-one oxime (1.0 g, obtained from commercially
available benzofuran-3(2H)-one via the procedure outlined for the
synthesis of 4-fluorobenzofuran-3(2H)-one oxime from
4-fluorobenzofuran-3(2H)-one) in 50 mL MeOH, 10% Palladium on
active carbon (0.1 g) was added. The mixture was evacuated then
filled with H.sub.2 three times. Finally the oxime was reduced
under a H.sub.2 balloon for 24 hours. The mixture was filtered
through a pad of celite, and the cake was washed with MeOH twice.
After removing the solvents under vacuum, 0.99 g brown-yellow
residue was obtained as the desired amine. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.32 (d, 1H), 7.19 (t, 1H), 6.94 (t, 1H), 6.82
(d, 1H), 4.5-4.7 (m, 1H), 4.64 (s, 1H), 4.1-4.2 (m, 1H).
[0328] (R)-5,6,7,8-Tetrahydroquinoxalin-5-amine. A solution of
(R)-tert-butyl 5,6,7,8-tetrahydroquinoxalin-5-ylcarbamate (238 mg)
in 10 ml of 1:1 TFA/DCM was stirred for 30 minutes. The mixture was
concentrated in vacuo to provide the title compound as the TFA
salt.
Example 35
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(4,5,6,7-tetrahydro-1H-indol-4-yl)-7H-puri-
n-8(9H)-one
[0329] ##STR119##
[0330] 1-(Phenylsulfonyl)-4-oxo-4,5,6,7-tetrahydroindole. To a
suspension of NaOH (4.44 g) in 1,2-dichloroethane (250 mL) was
added 4-oxo-4,5,6,7-tetrahydroindole (5.0 g). The mixture was then
cooled to 0.degree. C. and stirred for 30 min, following which a
solution of phenylsulfonyl chloride (5.7 mL) in 1,2-dichloroethane
(50 mL) was added dropwise over a period of 30 min. After 30 min of
stirring, the reaction mixture was allowed to come to room
temperature and stirred overnight. The reaction was quenched by
pouring onto distilled water (100 mL). The organic layer was
separated, and the aqueous layer was extracted with dichloromethane
(3.times.50 mL). The combined organic extract was washed with
distilled water to neutrality, dried over MgSO.sub.4, and
concentrated in vacuo to afford 7.0 g of the title compound.
[0331] 1-(Phenylsulfonyl)-4,5,6,7-tetrahydro-1H-indol-4-amine. The
title compound was obtained from
1-(phenylsulfonyl)-4-oxo-4,5,6,7-tetrahydroindole via the procedure
described in Example 29 that was used to obtain
8-fluorochroman-4-amine from 8-fluorochroman-4-one.
[0332]
2-(1H-Benzo[d]imidazol-1-yl)-9-(1-(phenylsulfonyl)-4,5,6,7-tetrahy-
dro-1H-indol-4-yl)-7H-purin-8(9H)-one. The title compound was
obtained from
1-(phenylsulfonyl)-4,5,6,7-tetrahydro-1H-indol-4-amine via the
procedures described in Example 24.
[0333]
2-(1H-benzo[d]imidazol-1-yl)-9-(4,5,6,7-tetrahydro-1H-indol-4-yl)--
7H-purin-8(9H)-one. To a solution of
2-(1H-benzo[d]imidazol-1-yl)-9-(1-(phenylsulfonyl)-4,5,6,7-tetrahydro-1H--
indol-4-yl)-7H-purin-8(9H)-one (50 mg) in MeOH (1 mL) was added 4 N
NaOH (1 mL), and the mixture was refluxed overnight and cooled.
Volatiles were removed under reduced pressure, and the resultant
neutralized with 4 N HCl. The white precipitate was filtered,
washed with a small amount of water, and dried in vacuo to afford
36 mg of the title compound. .sup.1H NMR (d.sub.6-DMSO) .delta.
11.6 (s, 1H), 10.7 (s, 1H), 8.86 (s, 1H), 8.27 (s, 1H), 7.69 (d,
J=7.8 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.33 (m, 2H), 6.53 (t, J=2.4
Hz, 1H), 5.64 (t, J=2.4 Hz, 1H), 5.54 (m, 1H), 2.72 (m, 2H), 2.30
(m, 1H), 2.07 (m, 2H), 1.84 (m, 1H).
Examples 36 and 37
(Dihydrobenzofurans):
2-(1H-benzo[d]imidazol-1-yl)-9-(2,3-dihydrobenzofuran-3-yl)-7H-purin-8(9H-
)-one and
2-(1H-benzo[d]imidazol-1-yl)-9-(4-fluoro-2,3-dihydrobenzofuran-3-
-yl)-7H-purin-8(9H)-one
[0334] ##STR120##
[0335] 2-fluoro-6-methoxybenzoyl chloride. Oxalyl chloride (0.56
mL, 6.4 mmol) was added to the solution of 1.0 g (5.9 mmol)
2-fluoro-6-methoxybenzoic acid in 5 mL anhydrous CH.sub.2Cl.sub.2.
Then a drop of DMF was added. After one hour, when the slow
bubbling was ceased, volatiles were removed under reduced pressure
to afford 1.1 g (95%) acid chloride as pale-yellow liquid. .sup.1H
NMR (300 MHz, CDCl.sub.3): .delta. 7.45 (q, 1H), 6.7-6.8 (m, 2H),
3.9 (s, 3H).
[0336] 4-fluorobenzofuran-3(2H)-one. The yellow
(trimethylsilyl)diazomethane ether solution (2.0 M, 3.7 mL) was
added to 0.57 g (3.0 mmol) above acid chloride with stirring. After
3 hours, solvent was evaporated. The yellow residue was dissolved
in 3 mL acetic acid (strong gas and heat evolution, used a water
bath to cool the flask for a minute), and stirred for 15 min at
room temperature. The solvents were removed under vacuum, and the
red residue was taken into 2 mL CH.sub.2Cl.sub.2, washed with water
twice, then brine, and dried over Na.sub.2SO.sub.4. This crude
product was purified by column chromatography (eluting with 10%
EtOAc in hexanes) to give 0.24 g (53%) 4-fluorobenzofaran-3(2H)-one
as white solid. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 7.58 (m,
1H), 6.92 (br d, 1H), 6.71 (t, 1H), 4.65 (s, 2H).
[0337] (Z)-4-fluorobenzofuran-3(2H)-one oxime. The above ketone
(0.70 g, 4.6 mmol) was dissolved in 5 ml ethyl alcohol, and then
added 0.64 g (9.2 mmol) hydroxylamine hydrochloride and 0.75 g (9.2
mmol) sodium acetate. This suspension was brought to reflux for 1
hr. The mixture was cooled to room temperature and added 4 mL water
to dissolve the excess reagents. Suction filtration, and then wash
the solid cake with small amount of cold water provided 0.48 g
(63%) desired oxime as white needle crystals. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.38 (s, 1H), 7.38 (q, 1H), 6.6-6.8 (m, 2H),
5.21 (s, 2H).
[0338] 4-fluoro-2,3-dihydrobenzofuran-3-amine. The above oxime
(0.48 g) was dissolved in 40 mL anhydrous THF under Argon. Fresh
prepared aluminum amalgam (by dipping 1 g polished aluminum foil
sequentially in 2% HgCl.sub.2 aqueous solution, water, and finally
THF) was added quickly and the mixture was refluxed for 24 hours
under Argon. Shinny mercury beads appeared at the bottom of the
flask. The mixture was allowed to cool to room temperature and
filtered through a pad of celite. Flask and solid cake were washed
with THF three times, then methanol three times. The combined
filtrate was rotary evaporated to give 0.41 g yellow solid as a
mixture of approximately (determined by NMR) 20% desired amine with
80% starting oxime. This mixture was used for next step without
purification. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 7.18 (q,
1H), 6.5-6.7 (m, 2H), 4.8-4.9 (m, 1H), 4.69 (t, 1H), 4.2-4.3 (m,
1H). ##STR121##
[0339] 2,3-dihydrobenzofuran-3-amine. To the solution of
benzofuran-3(2H)-one oxime (1.0 g, obtained from commercially
available benzofuran-3(2H)-one via the procedure outlined for the
synthesis of 4-fluorobenzofuran-3(2H)-one oxime from
4-fluorobenzofuran-3(2H)-one) in 50 mL MeOH, 10% Palladium on
active carbon (0.1 g) was added. The mixture was evacuated then
filled with H.sub.2 three times. Finally the oxime was reduced
under a H.sub.2 balloon for 24 hours. The mixture was filtered
through a pad of celite, and the cake was washed with MeOH twice.
After removing the solvents under vacuum, 0.99 g brown-yellow
residue was obtained as the desired amine. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.32 (d, 1H), 7.19 (t, 1H), 6.94 (t, 1H), 6.82
(d, 1H), 4.5-4.7 (m, 1H), 4.64 (s, 1H), 4.1-4.2 (m, 1H).
##STR122##
[0340] The above racemic
2-(1H-benzo[d]imidazol-1-yl)-9-(2,3-dihydrobenzofuran-3-yl)-7H-purin-8(9H-
)-one can be separated on chiral CHIRALCEL OD-H column (Cellulose
tris(3,5-dimethylphenylcarbamate) on a 5 .mu.M silica-gel
substrate) eluting with 85:15 hexanes:ethanol (both with 0.1%
diethylamine). One enantiomer has a retention time of 25 min, the
other one 33.5 min.
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-purin-8(9H)-
-one
[0341] ##STR123##
[0342] trans-4-(2-Chloro-5nitropyrimidin-4-ylamino)cyclohexanol. A
solution of 2,4-dicloro-5-nitropyrimidine (930 mg) in DCM (40 mL)
was treated with DIEA (0.9 mL) and trans-4-aminocyclohexanol (345
mg) at -78.degree. C. for 6 hours. The mixture was allowed to
slowly warm to room temperature and stirred for 12 more hours. The
solvent was evaporated and the crude mixture was purified by silica
gel chromatography (DCM:EtOAc 70:30) to provide 630 mg of the title
compound. ##STR124##
[0343]
trans-4-(2-(1H-Benzo[d]imidazol-1-yl)-5-nitropyrimidin-4-ylamino)c-
yclohexanol. A mixture of
trans-4-(2-chloro-5nitropyrimidin-4-ylamino)cyclohexanol (310 mg),
benzimidazole (390 mg), and potassium carbonate (0.5 g) was heated
in acetonitrile at 60.degree. C. for 2 hours. The mixture was
concentrated onto silicon gel and purified by column chromatography
(DCM:EtOAc:MeOH 70:22:8) to give 350 mg of the title compound.
##STR125##
[0344]
trans-4-(5-Amino-2-(1H-benzo[d]imidazol-1-yl)pyrimidin-4-ylamino)c-
yclohexanol. A solution of
trans-4-(2-(1H-benzo[d]imidazol-1-yl)-5-nitropyrimidin-4-ylamino)cyclohex-
anol (162 mg) in THF (20 ml) was treated with a solution of sodium
hydrosulfite (500 mg) and NaHCO3 (500 mg) in 20 mL of water and
stirred for 25 minutes. The mixture was diluted with 200 mL EtOAc
and washed twice with saturated sodium chloride. The organic phase
was dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo to provide 150 mg of the title compound.
[0345]
trans-4-(2-(1H-Benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)-
cyclohexyl 1H-imidazole-1-carboxylate. A solution of
trans-4-(5-amino-2-(1H-benzo[d]imidazol-1-yl)pyrimidin-4-ylamino)cyclohex-
anol (150 mg) in DCM (15 mL) was treated with carbonyldiimidazole
(250 mg) overnight. The mixture was diluted with 100 mL of DCM and
washed with brine once, then twice with water. The organic layer
was dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo. Column chromatography purification (DCM:EtOAc;MeOH 70:22:8)
provided 30 mg of the title compound. ##STR126##
[0346]
2-(1H-Benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-puri-
n-8(9H)-one.
trans-4-(2-(1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)cyclohe-
xyl 1H-imidazole-1-carboxylate (30 mg) was dissolved in DMSO (6 mL)
and treated with 1N HCl (5 ml) at 50.degree. C. for 3 hours. The
mixture was diluted with EtOAc and washed with brine three times.
The organic layer was dried over Na.sub.2SO.sub.4, filtered, and
concentrated in vacuo to obtain 16 mg of the title compound.
.sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.10.0 (s, 1H), 8.9 (dd,
1H), 8.2 (s, 1H), 7.9 (dd, 1H), 7.6 (dd, 2H), 4.4 (m, 1H), 4.1 (s,
1H), 2.9 (m, 2H), 2.0 (m, 2H), 1.6 (m, 4H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(4-oxocyclohexyl)-7H-purin-8(9H)-one
[0347] ##STR127##
[0348] tert-Butyl
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-8-oxo-8,9-dihy-
dropurine-7-carboxylate. Crude
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-purin-8(9H)-
-one (16 mg) was dissolved in DCM and treated with Boc.sub.2O (150
mg) and Et.sub.3N (1 ml). The mixture was stirred for 2 hours, then
diluted with DCM and washed 3 times with brine. The organic layer
was dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo. Chromatography column (DCM:EtOAc:MeOH, 70:25:5) provided 17
mg of the title compound. A pure sample of the starting material,
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-purin-8(9H)-
-one, could be obtained by deprotection of the title compound with
1:1 TFA/DCM for one hour, and then treating the resulting material
with 10% methanolic HCl for another hour followed by concentration
in vacuo.
[0349]
2-(1H-Benzo[d]imidazol-1-yl)-9-(4-oxocyclohexyl)-7H-purin-8(9H)-on-
e. A solution of oxalyl chloride (6.4 mg) in DCM (0.5 ml) was
cooled to -60.degree. C. and treated with a solution of DMSO (8 mg)
in DCM (0.5 ml). The reaction mixture was stirred for 2 minutes,
then treated with a solution of tert-butyl
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-8-oxo-8,9-dihy-
dropurine-7-carboxylate (4 mg) in DCM (0.5 ml). After 15 minutes,
triethylamine (0.4 mL) was added and the mixture was stirred at
room temperature for 30 minutes. The mixture was diluted with 10 mL
DCM and washed with 15 mL of water. The organic layer was dried
over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo. The
residue was purified by column chromatography to provide 2.3 mg of
tert-butyl
2-(1H-benzo[d]imidazol-1-yl)-8-oxo-9-(4-oxocyclohexyl)-8,9-dihydropurine--
7-carboxylate, which was deprotected with TFA/DCM (6 ml, 1:1) for 1
h. The mixture was concentrated and the residue was triturated with
ethyl ether to provide 1.8 mg of the title compound. .sup.1H-NMR
(300 MHz, CDCl.sub.3) .delta. 9.0 (s, 1H), 8.5 (dd, 1H), 8.4 (s,
1H), 7.9 (dd, 1H), 7.4 (m, 2H), 4.9 (m, 1H), 3.0 (m, 2H), 2.6 (m,
4H), 2.3 (m, 2H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-pu-
rin-8(9H)-one
[0350] ##STR128##
[0351] tert-Butyl
4-fluoro-2-(4-(trans-4-hydroxycyclohexylamino)-5-nitropyrimidin-2-ylamino-
)phenylcarbamate. Potassium carbonate (105 mg) was added to a
stirred mixture of tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenyl-carbamate
(101 mg) in acetonitrile (5 ml) followed by the addition of
trans-4-hydroxycyclohexylamine (44 mg). The reaction mixture was
stirred for 16 hours, then diluted with DCM and washed with water
and brine. The organic layer was dried over Na.sub.2SO.sub.4,
filtered, and concentrated in vacuo to provide 110 mg of the title
compound. ##STR129##
[0352] tert-Butyl
2-(5-amino-4-(trans-4-hydroxycyclohexylamino)pyrimidin-2-ylamino)-4-fluor-
ophenylcarbamate. A solution of tert-butyl
4-fluoro-2-(4-(trans-4-hydroxycyclohexylamino)-5-nitropyrimidin-2-ylamino-
)phenylcarbamate (110 mg) in THF (30 mL) was treated with a mixture
containing sodium hydrosulfite (600 mg in 20 ml H2O) and sodium
bicarbonate (10 ml, saturated). The resulting mixture was stirred
for 5 minutes during which the color changed from yellow to almost
colorless. Saturated sodium chloride was added and the mixture was
extracted with EtOAc twice. The combined organic layers were washed
with saturated sodium chloride and separated. The organic phase was
dried over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo to
provide 111 mg of the title compound. ##STR130##
[0353]
trans-4-(2-(2-(tert-Butoxycarbonyl)-5-fluorophenylamino)-8-oxo-7,8-
-dihydropurin-9-yl)cyclohexyl 1H-imidazole-1-carboxylate. A
solution of tert-butyl
2-(5-amino-4-(trans-4-hydroxycyclohexylamino)pyrimidin-2-ylamino)-4-fluor-
ophenylcarbamate (111 mg) in DCM (10 mL) was treated with
carbonyldiimidazole overnight. The reaction mixture was diluted
with DCM (10 ml) and washed with water. The organic layer was dried
over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo. Silica
gel chromatography provided 100 mg of the title compound.
##STR131##
[0354]
trans-4-(2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropu-
rin-9-yl)cyclohexyl 1H-imidazole-1-carboxylate. A solution of
trans-4-(2-(2-(tert-butoxycarbonyl)-5-fluorophenylamino)-8-oxo-7,8-dihydr-
opurin-9-yl)cyclohexyl 1H-imidazole-1-carboxylate (100 mg) in
TFA/DCM (18 ml, 1:1) was stirred for 1 hour. The mixture was
concentrated in vacuo to provide 95 mg of material. This material
was dissolved in THF (30 ml) and treated with CH(OCH.sub.3).sub.3
(1 ml) followed by p-toluenesulfonic acid (5 mg). The mixture was
stirred for 3 h, diluted with EtOAc (100 ml) and washed three times
with brine. The organic layer was dried over Na.sub.2SO.sub.4 and
the solvent was concentrated to provide 22 mg of the title
compound. ##STR132##
[0355]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl-
)-7H-purin-8(9H)-one. A solution of
trans-4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)cyclohexyl 1H-imidazole-1-carboxylate (30 mg) in DMSO (5 ml) was
treated with concentrated HCl (1 ml). The mixture was heated at
50.degree. C. for 3 hours. The mixture was diluted with EtOAc and
made basic with 3N NaOH (10 ml) The organic layer was washed three
times with brine, dried over Na.sub.2SO.sub.4, filtered, and
concentrated to provide 20 mg of the title compound. .sup.1H-NMR
(300 MHz, CD.sub.3OD) .delta. 10.5 (s, 1H), 8.8 (dd, 1H), 8.6 (s,
1H), 8.1 (dd, 1H), 7.7 (td, 1H), 4.6 (m, 1H), 4.7 (m, 1H), 4.0 (m,
1H), 2.7 (m, 2H), 2.3 (m, 2H), 2.1 (m, 2H), 1.7 (m, 2H).
Synthesis of
3-(9-(trans-4-Hydroxycyclohexyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benz-
o[d]imidazole-5-carbonitrile
[0356] ##STR133## The title compound could be obtained from
4-(2,4-dimethoxybenzylamino)-3-(4,5-diaminopyrimidin-2-ylamino)benzonitri-
le using the same procedures outlined for the synthesis of
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-pu-
rin-8(9H)-one from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenylcarbamate.
.sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 9.8 (s, 1H), 9.1 (s, 1H),
8.3 (s, 1H), 8.0 (d, 1H), 7.8 (d, 1H), 4.4 (m, 1H), 3.8 (m, 1H),
2.5 (q, 2H), 2.2 (d, 2H), 1.9 (d, 2H), 1.5 (q, 2H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(4-oxocyclohexyl)-7H-purin-8(9H)--
one
[0357] ##STR134##
[0358] The title compound could be obtained from
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-pu-
rin-8(9H)-one using the same procedure outlined for the synthesis
of
2-(1H-benzo[d]imidazol-1-yl)-9-(4-oxocyclohexyl)-7H-purin-8(9H)-one
from
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-purin-8(9H)-
-one. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 8.8 (s, 1H), 9.2
(s, 1H), 9.1 (s, 1H), 7.6 (dd, 1H), 7.8 (dd, 1H), 4.8 (m, 1H), 2.8
(m, 2H), 2.5 (m, 4H), 2.1 (m, 2H).
Synthesis of
3-(8-Oxo-9-(4-oxocyclohexyl)-8,9-dihydro-7H-purin-2-yl)-3H-benzo[d]imidaz-
ole-5-carbonitrile
[0359] ##STR135##
[0360] The title compound could be obtained from
3-(9-(trans-4-hydroxycyclohexyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benz-
o[d]imidazole-5-carbonitrile using the same procedures outlined for
the synthesis of
2-(1H-benzo[d]imidazol-1-yl)-9-(4-oxocyclohexyl)-7H-purin-8(9H)-one
from
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-purin-8(9H)-
-one. .sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 9.3 (s, 1H), 9.2
(s, 1H), 8.5 (s, 1H), 8.1 (d, 1H), 7.8 (d, 1H), 4.6 (m, 1H), 2.9
(m, 2H), 2.6 (m, 4H), 2.2 (m, 2H).
Synthesis of
3-(9-(3-Hydroxycyclohexyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo[d]im-
idazole-5-carbonitrile
[0361] ##STR136## The title compound could be obtained from
4-(2,4-dimethoxybenzylamino)-3-(4,5-diaminopyrimidin-2-ylamino)benzonitri-
le and 3-hydroxycyclohexylamine using the same procedures outlined
for the synthesis of
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-pu-
rin-8(9H)-one from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenylcarbamate.
.sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 9.4 (s, 1H), 9.2 (s, 1H),
8.4 (s, 1H), 8.1 (d, 1H), 7.9 (d, 1H), 4.6 (m, 1H), 3.9 (m, 1H),
2.5 (m, 2H), 2.2 (m, 2H), 2.1 (m, 2H), 1.6 (m, 2H).
Synthesis of
3-(8-Oxo-9-(3-oxocyclohexyl)-8,9-dihydro-7H-purin-2-yl)-3H-benzo[d]imidaz-
ole-5-carbonitrile
[0362] ##STR137## The title compound could be obtained from
3-(9-(3-hydroxycyclohexyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo[d]im-
idazole-5-carbonitrile using the same procedures outlined for the
synthesis of
2-(1H-benzo[d]imidazol-1-yl)-9-(4-oxocyclohexyl)-7H-purin-8(9H)-one
from
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-purin-8(9H)-
-one. .sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 9.2 (s, 1H), 8.6
(s, 1H), 8.5 (s, 1H), 8.1 (d, 1H), 7.9 (d, 1H), 5.0 (m, 1H), 3.8
(m, 1H), 3.7 (m, 1H), 2.9 (m, 2H), 2.6 (m, 2H), 2.3 (m, 2H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-methoxycyclohexyl)-7H-pu-
rin-8(9H)-one
[0363] ##STR138## A solution of
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-7H-pu-
rin-8(9H)-one (112 mg) in DCM was treated with excess Boc.sub.2O
and triethylamine until TLC analysis indicated that the starting
material had been consumed (4 hours). The mixture was washed with
brine, dried over Na.sub.2SO.sub.4, and concentrated. The resulting
residue was dissolved in THF, treated with excess iodomethane, and
then NaH (10 equivalents). The mixture was stirred for 6 hours and
quenched by the addition of saturated ammonium chloride. The
intermediate was extracted with EtOAc, dried, and concentrated.
Silica gel chromatography (70:25:5 DCM:EtOAc:MeOH) provided pure
tert-butyl
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-methoxycyclohexyl)-8-oxo-
-8,9-dihydropurine-7-carboxylate, which was deprotected in 1:1
TFA/DCM for 16 hours and concentrated in vacuo to obtain the title
compound. The HCl salt was obtained by treating a methanolic
solution (10 mL) with 0.5 mL of concentrated HCl followed by
solvent evaporation. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.0
(s, 1H), 8.3 (dd, 1H), 8.1 (s, 1H), 7.6 (dd, 1H), 7.1 (td, 1H), 4.4
(m, 1H), 3.8 (m, 1H), 2.5 (m, 2H), 2.1 (m, 2H), 1.9 (m, 2H), 1.5
(m, 2H).
Synthesis of trans-Methyl
4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)cycl-
ohexanecarboxylate
[0364] ##STR139## The title compound was obtained from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidine-2-ylamino)phenylcarbamate
and methyl trans-4-aminocyclohexanecarboxylate using procedures
outline in Example 27. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta.9.0
(s, 1H), 8.4 (s, 1H), 8.3 (dd, 1H), 7.8 (dd, 1H), 7.2 (td, 1H), 4.5
(m, 1H), 2.6 (m, 3H), 2.3 (m, 2H), 2.0 (m, 2H), 1.7 (m, 2H).
Synthesis of
trans-4-(2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)cyclohexanecarboxylic acid
[0365] ##STR140## A solution of trans-methyl
4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)cycl-
ohexanecarboxylate (5 mg) in THF was treated with an aqueous
solution of KOH (35 mg) in 2 mL of water. The mixture was heated at
50.degree. C. for 12 hours. The mixture was acidified with TFA and
concentrated. Silica gel chromatography (60:30:10 DCM:EtOAc:MeOH)
provided 4.3 mg of the title compound. .sup.1H-NMR (300 MHz,
CDCl.sub.3) .delta. 9.0 (s, 1H), 8.3 (dd, 1H), 8.1 (s, 1H), 7.7
(dd, 1H), 7.1 (td, 1H), 4.3 (m, 1H), 2.4 (m, 3H), 2.2 (m, 2H), 1.9
(m, 2H), 1.6 (m, 2H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-4-(hydroxymethyl)cyclohexy-
l)-7H-purin-8(9H)-one
[0366] ##STR141## A solution of trans-methyl
4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)cycl-
ohexanecarboxylate (6 mg) in DCM was treated with 10 equivalents of
a 1 M THF solution of LiAlH.sub.4 at -10.degree. C. The mixture was
stirred at -10.degree. C. for 12 hours and 0.degree. C. for 2 more
hours. The mixture was quenched with aqueous sodium bicarbonate and
extracted with EtOAc. Silica gel chromatography provided 3.0 mg of
the title compound. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.0
(s, 1H), 8.3 (dd, 1H), 8.1 (s, 1H), 7.7 (dd, 1H), 7.1 (td, 1H), 4.3
(m, 1H), 3.3 (d, 2H), 2.4 (m, 2H), 1.9 (m, 4H), 1.6 (m, 2H).
Synthesis of
trans-4-(2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)cyclohexanecarboxamide
[0367] ##STR142## A suspension of
trans-4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)cyclohexanecarboxylic acid (10 mg) in DCM was treated with 6
drops of DMF followed by 3 equivalents of oxalyl chloride. The
mixture was stirred for 45 minutes, then it was sparged with an
ammonia balloon for 10 minutes. The mixture was concentrated and
purified by HPLC to provide 1.7 mg of the title compound.
.sup.1H-NMR (300 MHz, CD.sub.3OD) .delta. 9.1 (s, 1H), 8.3 (dd,
1H), 8.2 (s, 1H) 7.7 (dd, 1H), 7.1 (td, 1H), 4.4 (m, 1H), 2.5 (m,
2H), 2.4 (m, 1H), 2.1 (m, 2H), 1.9 (m, 1H), 1.7 (m, 2H).
Synthesis of
trans-4-(2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)-N-methylcyclohexanecarboxamide
[0368] ##STR143## The title compound could be obtained from
trans-4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)cyclohexane-carboxylic acid and 2 M methylamine in THF using the
same procedure outlined for the synthesis of
trans-4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-y-
l)cyclohexanecarboxamide. .sup.1H-NMR (300 MHz, CDCl.sub.3 with 5%
CD.sub.3OD) .delta. 9.0 (s, 1H), 8.3 (dd, 1H), 8.2 (s, 1H), 7.7
(dd, 1H), 7.1 (td, 1H), 4.4 (m, 1H), 2.8 (s, 3H), 2.5 (m, 2H), 2.3
(m, 1H), 2.1 (m, 2H), 2.0 (m, 2H), 1.8 (m, 2H).
Synthesis of
9-(8-oxa-bicyclo[3.2.1]octan-3-yl)-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)--
7H-purin-8(9H)-one
[0369] ##STR144## The title compound was obtained from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidine-2-ylamino)phenylcarbamate
and 8-oxa-bicyclo[3.2.1]octan-3-amine (WO 2004/041161) using
procedures outlined in Example 27. .sup.1H-NMR (300 MHz,
CDCl.sub.3) .delta. 9.4 (bs, 1H), 9.0 (s, 1H), 8.4 (dd, 1H), 8.3
(s, 1H), 7.8 (dd, 1H), 7.1 (td, 1H), 4.9 (m, 1H), 4.6 (m, 2H), 2.9
(m, 2H), 2.2 (m, 2H), 2.0 (m, 2H), 1.8 (m, 2H).
Synthesis of
(+/-)-2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-2-phenyl-tetrahydro--
2H-pyran-4-yl)-7H-purin-8(9H)-one
[0370] ##STR145##
[0371] trans-2-Phenyl-tetrahydro-2H-pyran-4-amine. Sulfuric acid
(80%, 16.5 g) was added dropwise at 0.degree. C. to a mixture of
but-3-en-1-ol (13.6 g) and benzaldehyde (10 g). After the addition
the mixture was stirred at room temperature for 16 hours. The
mixture was poured into ice water, made basic (pH 8-10) with 1 N
NaOH, extracted with EtOAc, dried, and concentrated. Silica gel
chromatography provided 9 g of
cis-2-phenyl-tetrahydro-2H-pyran-4-ol.
[0372] A solution of cis-2-phenyltetrahydro-2H-pyran-4-ol (1 g) in
DCM (20 mL) was cooled in an ice-salt water bath and treated with
DIEA (2.2 g) and methanesulfonyl chloride (0.7 g) for 2 hours. The
mixture was diluted with DCM (50 mL) and washed with water and
brine. The organic layer was dried and concentrated. Preparative
TLC provided 0.9 g of cis-2-phenyl-tetrahydro-2H-pyran-4-yl
methanesulfonate.
[0373] A solution of cis-2-phenyl-tetrahydro-2H-pyran-4-yl
methanesulfonate (0.8 g) in DMF (10 mL) was treated with sodium
azide (0.8 g) and heated at 100.degree. C. for 4 hours. The mixture
was diluted with DCM (50 mL) and washed with water and brine. The
organic layer was dried and concentrated. Preparative TLC provided
0.5 g of trans-4-azido-2-phenyl-tetrahydro-2H-pyran.
[0374] The title compound was obtained via catalytic hydrogenation
(Pd--C, H.sub.2) of trans-4-azido-2-phenyl-tetrahydro-2H-pyran.
##STR146##
(+/-)-2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(trans-2-phenyl-tetrahydro--
2H-pyran-4-yl)-7H-purin-8(9H)-one. The title compound was obtained
from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidine-2-ylamino)phenylcarbamate
and trans-2-phenyl-tetrahydro-2H-pyran-4-amine using procedures
outlined in Example 27. .sup.1H-NMR (300 MHz, CDCl.sub.3 with 5%
CD.sub.3OD) .delta. 9.0 (s, 1H), 8.2 (dd, 1H), 8.1 (s, 1H), 7.6
(dd, 1H), 7.4 (d, 2H), 7.3 (t, 2H), 7.2 (t, 1H), 7.0 (td, 1H), 5.2
(br s, 1H), 4.7 (m, 1H), 3.9-3.8 (m, 1H), 3.7 (td, 1H), 3.1-2.8 (m,
2H), 2.4 (br d, 1H), 1.7 (br d, 1H).
Synthesis of
3-(9-(2,2-Dimethylchroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3H-benzo-
[d]imidazole-5-carbonitrile
[0375] ##STR147##
[0376] 2,2-Dimethylchroman-4-amine. A solution of
2'-hydroxyacetophenone (5.0 mL), acetone (4.7 mL), and pyrrolidine
(5.4 mL) in 150 mL of methanol was stirred for 66 hours. The
mixture was concentrated and treated with aqueous HCl (pH<1).
The acidic layer was extracted twice with ethyl ether, which was
dried and concentrated to provide 2,2-dimethylchroman-4-one. The
2,2-dimethylchroman-4-one was dissolved in 300 mL of methanol and
treated with ammonium acetate (65 g) and sodium cyanoborohydride
(2.5 g) for 24 hours. The resulting mixture was concentrated to 100
mL and diluted with 300 mL water. Concentrated HCl was carefully
added until the pH was less than 1 and the acidic mixture was
extracted with ethyl ether. The acidic phase was made basic with
KOH and then extracted twice with ethyl ether. The basic extracts
were dried and concentrated to provide the title compound.
##STR148##
[0377]
3-(9-(2,2-Dimethylchroman-4-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)-3-
Hbenzo[d]imidazole-5-carbonitrile. The title compound was obtained
from
4-(2,4-dimethoxybenzylamino)-3-(4,5-diaminopyrimidin-2-ylamino)benzonitri-
le and 2,2-dimethylchroman-4-amine using procedures outlined in
Example 26. .sup.1H-NMR (300 MHz, CDCl.sub.3) .delta. 9.6 (s, 1H),
9.0 (s, 1H), 8.5 (bs, 1H), 8.3 (s, 1H), 7.8 (d, 1H), 7.6 (dd, 1H),
7.2 (m, 2H), 6.8 (d, 1H), 6.7 (td, 1H), 5.9 (dd, 1H), 2.9 (t, 1H),
2.2 (dd, 1H), 1.6 (s, 3H), 1.5 (s, 3H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(1,2,3,4-tetrahydroquinolin-6-yl)-
-7H-purin-8(9H)-one
[0378] ##STR149## A solution of tert-butyl
4-fluoro-2-(8-oxo-9-(1,2,3,4-tetrahydroquinolin-6-yl)-8,9-dihydro-7H-puri-
n-2-ylamino)phenylcarbamate (obtained from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidine-2-ylamino)phenylcarbamate
and 1,2,3,4-tetrahydroquinolin-6-amine (J. Org. Chem. (2002), 67,
7890) using procedures outlined in Example 27) was stirred for 45
minutes in 1:1 TFA/DCM and concentrated to afford
2-(2-amino-5-fluorophenylamino)-9-(1,2,3,4-tetrahydroquinolin-6-yl)-7H-pu-
rin-8(9H)-one. The
2-(2-amino-5-fluorophenylamino)-9-(1,2,3,4-tetrahydroquinolin-6-yl)-7H-pu-
rin-8(9H)-one was stirred for 15 minutes in trimethylorthoformate
and concentrated to afford
6-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-8-oxo-7,8-dihydropurin-9-yl)-3,4-
-dihydroquinoline-1(2H)-carbaldehyde, which was purified by silica
gel chromatography (2.fwdarw.5% MeOH in DCM). This material was
deformylated by refluxing for 1 hour in 11:2 1 M HCl:MeOH to
provide the title compound as the HCl salt. .sup.1H-NMR (300 MHz,
CD.sub.3OD) .delta. 10.0 (s, 1H), 8.4 (s, 1H), 8.4 (dd, 1H), 7.8
(dd, 1H), 7.8 (s, 1H), 7.8 (d, 1H), 7.5 (d, 1H), 7.4 (td, 1H), 3.6
(dd, 2H), 3.1 (t, 2H), 2.2 (m, 2H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-(5,6,7,8-tetrahydroquinolin-6-yl)-
-7H-purin-8(9H)-one
[0379] ##STR150## The title compound was obtained from tert-butyl
4-fluoro-2-(5-nitro-4-thiocyanatopyrimidine-2-ylamino)phenylcarbamate
and 5,6,7,8-tetrahydroquinolin-6-amine (J. Org. Chem. (2002), 67,
7890) using procedures outlined in Example 27. .sup.1H-NMR (300
MHz, CD.sub.3OD) .delta. 9.3 (s, 1H), 8.6 (d, 1H), 8.5 (dd, 1H),
8.1 (dd, 1H), 7.9 (dd, 1H), 7.4 (td, 1H), 5.2 (m, 1H), 4.2 (dd,
1H), 3.6 (m, 3H), 3.2 (m, 1H), 2.6 (m, 1H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(tetrahydro-1-oxido-2H-thiopyran-4-yl)-7H--
purin-8(9H)-one
[0380] ##STR151##
[0381] A solution oftert-butyl
2-(1H-benzo[d]imidazol-1-yl)-8-oxo-9-(tetrahydro-2H-thiopyran-4-yl)-8,9-d-
ihydropurine-7-carboxylate (8 mg, obtained from
tetrahydro-thiopyran-4-ylamine using procedures outlined in Example
16 followed by protection using the procedure outline for the
synthesis of tert-butyl
2-(1H-benzo[d]imidazol-1-yl)-9-(trans-4-hydroxycyclohexyl)-8-oxo-8,9-dihy-
dropurine-7-carboxylate) in MeOH/H.sub.2O (10 ml, 1:1) was treated
with KIO.sub.4 (50 mg) and stirred for 3 hours. The reaction
mixture was diluted with 10 ml of saturated NaHCO.sub.3 and
extracted 3 times with DCM. The organic layers were dried over
Na.sub.2SO.sub.4, filtered, and concentrated in vacuo.
Chromatography column purification (DCM:EtOAc;MeOH 75:25:5)
provided 5.6 mg of tert-butyl
2-(1H-benzo[d]imidazol-1-yl)-8-oxo-9-(tetrahydro-1-oxido-2H-thiopyran-4-y-
l)-8,9-dihydropurine-7-carboxylate. This material was treated with
TFA/DCM (6 ml, 1:1) for 1 hour and concentrated. Trituration with
Et.sub.2O provided 3.3 mg of the title compound. .sup.1H NMR (300
MHz CDCl.sub.3) .delta. 9.1 (br, 1H), 8.5 (m, 1H), 8.2 (s, 1H), 7.8
(m, 1H), 7.4 (m, 2H), 4.6 (m, 1H), 3.6 (m, 2H), 2.9 (m, 4H), 2.2
(m, 2H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-
-7H-purin-8(9H)-one
[0382] ##STR152## A solution of tert-butyl
2-(1H-benzo[d]imidazol-1-yl)-8-oxo-9-(tetrahydro-2H-thiopyran-4-yl)-8,9-d-
ihydropurine-7-carboxylate (8 mg) in DCM (10 ml) was treated with
MCPBA (13 mg) and stirred for 16 hours. The mixture was washed 3
times with brine. The organic layer was dried over
Na.sub.2SO.sub.4, filtered, and concentrated in vacuo.
Chromatography column purification (DCM:EtOAc;MeOH 75:25:5)
provided 2.2 mg of tert-butyl
2-(1H-benzo[d]imidazol-1-yl)-8-oxo-9-(tetrahydro-1,1-dioxido-2H-thiopyran-
-4-yl)-8,9-dihydropurine-7-carboxylate. This material was treated
with TFA/DCM (6 ml, 1:1) for 1 hour and concentrated. Trituration
with Et.sub.2O provided 1.3 mg of the title compound. .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 9.2 (br, 1H), 8.7 (d, 1H), 7.8 (d,
1H), 7.5 (t, 1H), 7.4 (t, 1H), 4.6 (m, 1H), 3.0-3.5 (m, 6H), 2.2
(m, 2H).
Synthesis of
2-(1H-Benzo[d]imidazol-1-yl)-9-(thiochroman-4-yl)-7H-purin-8(9H)-one
[0383] ##STR153##
[0384] Thiochroman-4-amine. To a solution of thiochroman-4-one (1.6
g) in EtOH (100 ml) was added NH.sub.4OAc (8.2 g), the mixture was
heated at 50.degree. C. for 35 minutes then cooled to room
temperature and treated with Na(CN)BH.sub.4 (0.96 g). The mixture
was stirred at room temperature for 64 hours and the reaction
solvent was removed in vacuo. The residue was dissolved in EtOAc
and washed 4 times with 4N HCl. The combined aqueous washes were
made basic with 3N NaOH, then extracted 5 times with EtOAc. The
combined organic layers were dried over Na.sub.2SO.sub.4 and
concentrated to provide 1.4 g of the title compound. ##STR154##
[0385]
2-(1H-Benzo[d]imidazol-1-yl)-9-(thiochroman-4-yl)-7H-purin-8(9H)-o-
ne. The title compound was synthesized from thiochroman-4-amine
using the procedures outlined in Example 16. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 9.1 (s, 1H), 8.5 (s, 1H), 8.3 (m, 1H), 7.8 (m,
1H), 7.4 (m, 3H), 7.3 (m, 1H), 7.0-7.2 (m, 2H), 6.0 (m, 1H), 3.4
(m, 2H), 3.1 (m, 1H), 2.6 (m, 1H).
Synthesis of
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-4-oxo-1,2,3,4tetrahydronapht-
halen-1-yl)-7H-purin-8(9H)-one,
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrah-
ydronaphthalen-1-yl)-7H-purin-8(9H)-one, and
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4S)-4-hydroxy-1,2,3,4-tetrah-
ydronaphthalen-1-yl)-7H-purin-8(9H)-one
[0386] ##STR155##
[0387]
(R)-2-(1,2,3,4-Tetrahydronaphthalen-1-yl)isoindoline-1,3-dione. To
a solution of (R)-1,2,3,4-tetrahydro-1-naphthylamine (6.0 g) in THF
(150 mL) at 0.degree. C. was added TEA (18.5 mL) and phthaloyl
chloride (8.2 g), and the resultant mixture was stirred at room
temperature overnight and 70.degree. C. for 3 h. The mixture was
diluted with CH.sub.2Cl.sub.2, washed with saturated NaHCO.sub.3,
dried over MgSO.sub.4, and concentrated in vacuo. The resulting
crude was chromatographed on silica gel (EtOAc/hexane, 5/95 to
30/70) to afford 8.2 g of the title compound. ##STR156##
[0388]
(R)-2-(4-Oxo-1,2,3,4-tetrahydronaphthalen-1-yl)isoindoline-1,3-dio-
ne. To a solution of
(R)-2-(1,2,3,4-tetrahydronaphthalen-1-yl)isoindoline-1,3-dione (3.9
g) in acetone (60 mL) at 0.degree. C. was added
MgSO.sub.4.7H.sub.2O (11.5 g) and water (20 mL). Then KMnO.sub.4
(11.5 g) was added portionwise over the period of 2 h and stirring
continued at room temperature overnight. The brown solid was
filtered off and the filtrate treated with saturated sodium
metabisulfite, filtered, and extracted with CH.sub.2Cl.sub.2. The
combined organic layer was washed with distilled water and
saturated brine, dried over MgSO.sub.4, and concentrated in vacuo.
The resultant was chromatographed on silica gel (EtOAc/hexane,
25/75) to afford 0.14 g of the title compound. ##STR157##
[0389] 1,3-Dioxolane of
(R)-2-(4-oxo-1,2,3,4-Tetrahydronaphthalen-1-yl)isoindoline-1,3-dione.
To the mixture of of
(R)-2-(4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)isoindoline-1,3-dione
(138 mg), triethyl orthoformate (0.3 mL), and 1,2-ethanediol (1.5
mL) was added tetrabutylammonium tribromide (12 mg). The reaction
mixture was stirred at room temperature overnight and heated at
90.degree. C. for 3 h. After cooling, the mixture was diluted with
CH.sub.2Cl.sub.2, washed with saturated NaHCO.sub.3, water, and
brine, dried over MgSO.sub.4, and concentrated in vacuo. The
residue was purified by PTLC (EtOAc/hexane, 1/2) to afford 150 mg
of the title compound. ##STR158##
[0390] 1,3-Dioxolane of
(R)-4-amino-3,4-dihydronaphthalen-1(2H)-one. A solution of
1,3-dioxolane of
(R)-2-(4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)isoindoline-1,3-dione
(145 mg) in 0.4 M methanolic hydrazine (40 mL) was stirred at room
temperature overnight. The solvent and excess hydrazine were
evaporated and a small amount of CH.sub.2Cl.sub.2 was added to the
residue. The white solid was filtered off and the filtrate
concentrated in vacuo to afford 85 mg of the title compound.
##STR159##
[0391] 1,3-Dioxolane of (R)-tert-butyl
4-fluoro-2-(5-nitro-4-(4-oxo-1,2,3,4-tetrahydronaphthalen-1-ylamino)pyrim-
idin-2-ylamino)phenylcarbamate. A solution of tert-butyl 4
fluoro-2-(5-nitro-4-thiocyanatopyrimidin-2-ylamino)phenylcarbamate
(170 mg), 1,3-Dioxolane of
(R)-4-amino-3,4-dihydronaphthalen-1(2H)-one (85 mg), and TEA (0.2
mL) in DMF (5 mL) was stirred at room temperature overnight. The
reaction mixture was diluted with EtOAc, washed with saturated
brine, dried over MgSO.sub.4, and concentrated in vacuo. The
residue was purified by PTLC (EtOAc/hexane, 50/50) to afford 150 mg
of the title compound. ##STR160##
[0392]
(R)-4-(2-(2-Amino-5-fluorophenylamino)-5-nitropyrimidin-4-ylamino)-
-3,4-dihydronaphthalen-1(2H)-one. A solution of 1,3-dioxolane of
(R)-tert-butyl
4-fluoro-2-(5-nitro-4-(4-oxo-1,2,3,4-tetrahydronaphthalen-1-ylamino)pyrim-
idin-2-ylamino)phenylcarbamate (145 mg) and TFA (2.5 mL) in
CH.sub.2Cl.sub.2 (5 mL) was stirred at room temperature for 1 h.
Volatiles were removed in vacuo and the crude (120 mg) was
subjected to the next step without further purification.
##STR161##
[0393]
(4R)-4-(2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-5-nitropyrimidin-4-y-
lamino)-3,4-dihydronaphthalen-1(2H)-one. A solution of
(R)-4-(2-(2-amino-5-fluorophenylamino)-5-nitropyrimidin-4-ylamino)-3,4-di-
hydronaphthalen-1(2H)-one (120 mg) and CH(OMe).sub.3 (2.5 mL) in
MeOH/THF (2.5 mL/10 mL) was stirred at room temperature overnight.
Volatiles were removed in vacuo and the residue was purified by
PTLC (EtOAc) to afford 80 mg of the title compound. ##STR162##
[0394]
(4R)-4-(5-Amino-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)pyrimidin-4-y-
lamino)-3,4-dihydronaphthalen-1(2H)-one. To the solution of
(4R)-4-(2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-5-nitropyrimidin-4-ylamino)-
-3,4-dihydronaphthalen-1(2H)-one (80 mg) in THF (10 mL) was added
Na.sub.2S.sub.2O.sub.4 (480 mg) and NaHCO.sub.3 (240 mg) in
H.sub.2O (10 mL), and stirring continued at room temperature for
1.5 h. The reaction mixture was diluted with CH.sub.2Cl.sub.2,
washed with saturated brine, dried over MgSO.sub.4, and
concentrated in vacuo. The crude (32 mg) was subjected to the next
step without further purification. ##STR163##
[0395]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-4-oxo-1,2,3,4-tetrahy-
dronaphthalen-1-yl)-7H-purin-8(9H)-one. A solution of
(4R)-4-(5-amino-2-(6-fluoro-1H-benzo[d]imidazol-1-yl)pyrimidin-4-ylamino)-
-3,4-dihydronaphthalen-1(2H)-one (32 mg) and CDI (100 mg) in THF (6
mL) was stirred at room temperature overnight and refluxed for 2.5
h. Volatiles were removed in vacuo and the residue was purified by
preparative HPLC to afford 9 mg of the title compound as the TFA
salt. .sup.1H NMR (CD.sub.3OD) .delta. 9.20 (s, 1H), 8.36 (s, 1H),
8.20 (m, 1H), 7.68 (m, 1H), 7.58-7.47 (m, 3H), 7.20-7.14 (m, 2H),
6.10 (m, 1H), 3.09-2.93 (m, 3H), 2.49 (m, 1H); MS (MH.sup.+) 415.1.
##STR164##
[0396]
2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-
-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one and
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4S)-4-hydroxy-1,2,3,4-tetrah-
ydronaphthalen-1-yl)-7H-purin-8(9H)-one. To a solution of
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((R)-4-oxo-1,2,3,4-tetrahydronaph-
thalen-1-yl)-7H-purin-8(9H)-one (6 mg) in MeOH (2.5 mL) at
0.degree. C. was added NaBH.sub.4 (4.5 mg), and stirring continued
at 0.degree. C. for 3 h. The reaction was quenched by the addition
of saturated NH.sub.4Cl and extracted with CH.sub.2Cl.sub.2. The
combined organic extracts were dried over MgSO.sub.4 and
concentrated in vacuo. The residue was purified by preparative HPLC
to afford the title compounds as the TFA salts.
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((1
R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one.
3 mg, R.sub.f=0.28 (MeOH/DCM, 5/95); .sup.1H NMR (CD.sub.3OD)
.delta. 8.97 (s, 1H), 8.30 (s, 1H), 7.80 (d, 1H), 7.66 (dd, 1H),
7.56 (dd, 1H), 7.30 (t, 1H), 7.13 (m, 2H), 6.95 (d, 1H), 5.85 (dd,
1H), 5.11 (dd, 1H), 2.63 (m, 1H), 2.43 (m, 1H), 2.32 (m, 1H), 1.94
(m, 1H); MS (MH.sup.+) 417.0.
2-(6-fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4S)-4-hydroxy-1,2,3,4-tetrah-
ydronaphthalen-1-yl)-7H-purin-8(9H)-one. 2 mg, R.sub.f=0.33
(MeOH/DCM, 5/95); .sup.1H NMR (CD.sub.3OD) .delta.9.01 (s, 1H),
8.33 (s, 1H), 8.00 (m, 1H), 7.67-6.94 (m, 6H), 5.72 (m, 1H), 4.91
(m, 1H), 2.99 (m, 1H), 2.42-2.05 (m, 3H); MS (MH.sup.+) 417.0.
Jak3 Kinase Assay
[0397] Human Jak3 cDNA was amplified by PCR. A fragment encoding
the catalytic domain of Jak3 (508aa to 1124aa) was ligated with GST
at 5' end. This fused GST-Jak3 DNA fragment was cloned into the
EcoRI site of the donor plasmid pFastBac 1 (Life Technologies
#10359-016). The transformation, transposition, and transfection of
insect cells (Sf9) were performed according to the manufacture's
instructions. The cell lysate containing recombinant GST-Jak3 was
used in the kinase assay. Anti-GST antibody (10 .mu.g/ml, Sigma
#G1417) was coated onto a 384-well plate at 4.degree. C. overnight.
Cell lysate containing GST-Jak3 (1:100 dilution) was added to the
anti-GST coated plates, and GST-Jak3 was captured by immobilized
anti-GST antibody. Testing compounds and substrate mix (50 mM
HEPES, pH 7, 0.5 mM Na.sub.3VO.sub.4, 25 mM MgCl.sub.2, 1 mM DTT,
0.005% BSA, 1 .mu.M ATP, and 4.5 .mu.g/ml biotinyl
poly-Glu,Ala,Tyr) were added to the plate to initiate the reaction.
After a 60-min incubation, the reaction was stopped by 4 mM EDTA,
and phosphorylation of biotinyl poly-Glu,Ala,Tyr was detected using
17 .mu.g/ml Cy5-streptavidin (Amersham, #PA92005) and 2.7 .mu.g/ml
Europium-conjugated anti-phosphotyrosine antibody (PerkinElmer
#AD0069) using homogeneous time-resolved fluorescence (HTRF)
technology.
Jak3 Cellular Assay
[0398] The mouse F7 pre-B lymphocyte cell line was used for the
cellular Jak3 assay. Human IL-2.beta.c cDNA is stably expressed in
F7 cells (Kawahara et al., 1995). F7 cells were maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum plus IL-3.
Cells (30,000 cells/well) in serum-free medium were seeded in
96-well plates for the cell proliferation assay. Testing compounds
were added to cells, followed by the addition of IL-2 (final 20
ng/ml). After a 24-h incubation, the number of viable cells was
determined by the CellTiter-Glo Luminescent Cell Viability Assay
kit (Promega, #G7573) according to the manufacturer's
instructions.
[0399] The results of testing of representative species are shown
below. The compounds in Table 1 exhibited IC.sub.50 less than 100
nM. The compounds in Table 2 exhibited IC.sub.50 between 101 nM and
1 .mu.M. The compounds in Table 3 exhibited IC.sub.50 between 1
.mu.M and 10 .mu.M. TABLE-US-00002 TABLE 1 Synthesis Reference
Example No. Example 20 101 ##STR165## Example 22 102 ##STR166## 103
##STR167## 104 ##STR168## 105 ##STR169## 106 ##STR170## 107
##STR171## 108 ##STR172## 109 ##STR173## 110 ##STR174## 111
##STR175## 112 ##STR176## 113 ##STR177## Example 16 114 ##STR178##
115 ##STR179## 116 ##STR180## 117 ##STR181## 118 ##STR182## 119
##STR183## 120 ##STR184## 121 ##STR185## 122 ##STR186## 123
##STR187## Example 15 124 ##STR188## 125 ##STR189## 402 ##STR190##
Example 23 126 ##STR191## 127 ##STR192## 128 ##STR193## 129
##STR194## 130 ##STR195## 131 ##STR196## 132 ##STR197## 133
##STR198## Example 21 134 ##STR199## 135 ##STR200## 136 ##STR201##
137 ##STR202## 138 ##STR203## 139 ##STR204## Example 26 140
##STR205## 141 ##STR206## 404 ##STR207## 405 ##STR208## Example 28
142 ##STR209## 143 ##STR210## 144 ##STR211## 145 ##STR212## 146
##STR213## 147 ##STR214## 148 ##STR215## 149 ##STR216## 150
##STR217## 151 ##STR218## 152 ##STR219## Example 27 153 ##STR220##
154 ##STR221## 155 ##STR222## 156 ##STR223## 157 ##STR224## 158
##STR225## 159 ##STR226## 160 ##STR227## 161 ##STR228## 162
##STR229## 163 ##STR230## 164 ##STR231## 165 ##STR232## 166
##STR233## 167 ##STR234## 168 ##STR235## 169 ##STR236## 170
##STR237## 171 ##STR238## 172 ##STR239## 173 ##STR240## 174
##STR241## 175 ##STR242## 176 ##STR243## 177 ##STR244## 178
##STR245## 179 ##STR246## 180 ##STR247## 407 ##STR248## 411
##STR249## 412 ##STR250## 414 ##STR251## 417 ##STR252## 418
##STR253## 420 ##STR254## 426 ##STR255## 425 ##STR256## 427
##STR257## Example 36 181 ##STR258## 182 ##STR259## 183 ##STR260##
406 ##STR261## 428 ##STR262## 429 ##STR263## 430 ##STR264## 431
##STR265## 432 ##STR266##
[0400] TABLE-US-00003 TABLE 2 Synthesis Reference Example No. 201
##STR267## 202 ##STR268## 203 ##STR269## 204 ##STR270## 205
##STR271## 206 ##STR272## 207 ##STR273## 208 ##STR274## 209
##STR275## 210 ##STR276## 211 ##STR277## 212 ##STR278## 213
##STR279## 214 ##STR280## 215 ##STR281## 216 ##STR282## 217
##STR283## 218 ##STR284## 219 ##STR285## 220 ##STR286## 221
##STR287## 222 ##STR288## 223 ##STR289## 224 ##STR290## 225
##STR291## 226 ##STR292## 227 ##STR293## 228 ##STR294## 229
##STR295## 230 ##STR296## 231 ##STR297## 232 ##STR298## 233
##STR299## 234 ##STR300## 235 ##STR301## 236 ##STR302## 237
##STR303## 238 ##STR304## 239 ##STR305## 240 ##STR306## 241
##STR307## 242 ##STR308## 403 ##STR309## 413 ##STR310## 416
##STR311## 421 ##STR312## 422 ##STR313## 423 ##STR314## Example 19
243 ##STR315## Example 17 244 ##STR316## 245 ##STR317## 246
##STR318## 247 ##STR319## 248 ##STR320## 249 ##STR321## 250
##STR322## 251 ##STR323## Example 19 252 ##STR324## 253 ##STR325##
Example 37 254 ##STR326## 255 ##STR327## 256 ##STR328## 257
##STR329## 258 ##STR330## 259 ##STR331## 260 ##STR332## 261
##STR333## 262 ##STR334## 263 ##STR335## Example 24 264 ##STR336##
265 ##STR337## 266 ##STR338## 267 ##STR339## 268 ##STR340## 269
##STR341## 270 ##STR342## 271 ##STR343## 272 ##STR344## 273
##STR345## 274 ##STR346## 275 ##STR347## Example 25 276 ##STR348##
277 ##STR349## 278 ##STR350## 279 ##STR351## 280 ##STR352## 281
##STR353## 282 ##STR354## 283 ##STR355## 400 ##STR356## 401
##STR357## Example 35 284 ##STR358## 285 ##STR359## 286 ##STR360##
287 ##STR361## 288 ##STR362## 289 ##STR363## 290 ##STR364## 291
##STR365## 292 ##STR366## 293 ##STR367## 294 ##STR368## 432
##STR369## 433 ##STR370## 434 ##STR371## 435 ##STR372## 436
##STR373## 437 ##STR374## 438 ##STR375## 439 ##STR376## 440
##STR377##
[0401] TABLE-US-00004 Synthesis Reference Example No. TABLE 3 301
##STR378## 302 ##STR379## ##STR380## 303 ##STR381## 304 ##STR382##
305 ##STR383## 306 ##STR384## ##STR385## 307 ##STR386## 308
##STR387## 309 ##STR388## ##STR389## 310 ##STR390## 311 ##STR391##
312 ##STR392## 313 ##STR393## 314 ##STR394## 315 ##STR395## 316
##STR396## 317 ##STR397## ##STR398## 318 ##STR399## 320 ##STR400##
321 ##STR401## 322 ##STR402## 323 ##STR403## 324 ##STR404## 325
##STR405## 326 ##STR406## 327 ##STR407## 328 ##STR408## 329
##STR409## 330 ##STR410## 331 ##STR411## 332 ##STR412## 333
##STR413## ##STR414## 334 ##STR415## 335 ##STR416## 336 ##STR417##
337 ##STR418## 338 ##STR419## 339 ##STR420## 340 ##STR421## 341
##STR422## 342 ##STR423## 345 ##STR424## 346 ##STR425## 347
##STR426## 348 ##STR427## 349 ##STR428## 350 ##STR429## 351
##STR430## 352 ##STR431## 353 ##STR432## 354 ##STR433## 355
##STR434## 356 ##STR435## 357 ##STR436## 358 ##STR437## 359
##STR438## 360 ##STR439## 361 ##STR440##
IL-2-induced IFN-.gamma. Production in the Mouse
[0402] Administration of IL-2 leads to an increase in serum
IFN-.gamma. in the mouse due to NK secretion of the cytokine
(Thornton S. Kuhn K A, Finkelman F D and Hirsch R. NK cells secrete
high levels of IFN-.gamma. in response to in vivo administration of
IL-2. Eur J Immunol 2001 31:3355-3360). The experiment was carried
out essentially according to the protocol in Thornton et al. and
the test compounds were administered in order to determine the
level of inhibition attained. In summary, female BALB/c mice were
fasted for 12-18 hours before a study but had free access to water
at all times. Test compounds were administered by gavage one hour
before intraperitoneal injection of IL-2 and capture antibody. At
termination of the studies, the mice were sacrificed by carbon
dioxide inhalation, terminal blood samples were collected by
cardiac puncture and serum was generated. Serum was stored frozen
until it was assayed for IFN-.gamma., as described by the kit
manufacturer (BD Pharmingen.TM.M, San Diego, Calif.).
[0403] Using the above method, compounds 114, 120, 135, 137, 138,
139, 142, 143, 151, and 162 from Table 1 were shown to inhibit
IL-2-induced IFN-gamma production by >40% at 30 mg/kg in vivo in
the mouse. A reference compound, CP690550, exhibited 96% inhibition
at 30 mg/kg in this screen.
[0404] Although the foregoing invention has been described in some
detail for purposes of illustration, it will be readily apparent to
one skilled in the art that changes and modifications may be made
without departing from the scope of the invention described
herein.
* * * * *